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CHAPTER I 
 
OVERVIEW 
 
Spontaneous preterm labor leading to delivery (PTB), gestational age less than 37 
weeks, is one of the leading risk factors of neonatal morbidity and mortality.  Multiple 
putative environmental risk factors have been identified, including: infection, stress, 
socioeconomic status, smoking, and nutrition.  The exact causes of PTB, however, are not 
well understood and most cases of PTB cannot be fully explained by any of these 
suspected risk factors.   
Recent studies have found promising associations with candidate genes and PTB 
and/or related phenotypes (preterm premature rupture of the membrane (pPROM) and 
histological chorioamnionitis).  These studies have focused on either maternal or fetal 
genetic information and on the role of single nucleotide polymorphisms (SNPs) singly 
and/or a single gene and PTB.  The goal of the studies presented in the following chapters 
is to both gain greater understanding of the genetic contributions to PTB and identify a 
subset of genes that best predict pregnancies at risk of PTB.  These studies examine 
multiple candidates in both mother and fetus and address a significant deficiency in the 
present understanding of the genetic susceptibility to PTB.  A retrospective case-control 
dataset including African Americans and Caucasians was used.   
The introduction and background are presented in part A of Chapter II, including 
both the clinical aspects and epidemiology of PTB.  Previous work in the field is 
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discussed, as well as the approaches used to analyze this complex phenotype.  Finally, the 
hypothesis and specific aims are presented in part B. 
To begin assessing the genetic contribution to the disparity in prevalence rates 
between African Americans and Caucasians, patterns of genetic variation in two 
established candidate genes, interleukin 6 (IL-6) and its receptor (IL-6R), were analyzed 
in mothers and fetuses.  IL-6 levels in amniotic fluid (AF) samples were determined in a 
subset of these pregnancies.  Chapter III, part A, discusses a small-scale study examining 
the racial disparity between African Americans and Caucasians in both IL-6 gene profile 
and IL-6 protein expression.  Part B follows up on an association found between a marker 
in IL-6 and IL-6 AF levels in part A, expanding on both sample size and the number of 
markers examined.  IL-6 and IL-6R were analyzed for single locus allelic and genotypic 
tests of association, linkage disequilibrium (LD) structure, and haplotype associations.  
Haplotype tests of association were performed with outcome considered as dichotomous 
(PTB/term) and continuous (IL-6 cytokine concentration (pg/ml)).  African American, 
Caucasian, maternal and fetal samples were analyzed separately.  Significant associations 
from both dichotomous and continuous haplotype analyses and across geographic 
populations converged on three regions:  in IL-6 markers (rs1800797, rs1800796, and 
rs1800795); in IL-6R markers (rs4601580, rs4645618, rs6687726, and rs7549338) and 
IL-6R markers (rs4537545, rs4845625, and rs4845374).  
Chapter IV presents the results of a large scale high-throughput candidate gene 
screen on PTB.  Part A discusses the results from the candidate gene screen in Caucasians 
and part B discusses the results from the candidate gene screen in African Americans.  
Chapter V discusses the results from the multi-locus analyses of the high-throughput data 
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presented in Chapter IV.  No strong multi-locus associations were observed.  However, a 
promising result was observed in Caucasian maternal samples in genes from the 
complement and coagulation pathway.  This result suggests that an interaction between 
coagulation factor V (FV) and coagulation factor II (FII) may be functioning in 
conjunction with an independent main effect by tissue plasminogen activator (tPA). 
Previous genetic studies have overlooked the mitochondrial genome/gene(s) as a 
plausible PTB candidate.  Chapter VI discusses a study where we sought to document 
association between nonsynonymous mitochondrial DNA (mtDNA) variants A4917G, 
G10398A, and T4216C and PTB. We performed a case-control analysis of these three 
mtDNA markers and examined their potential interaction with smoking in PTB.  
Caucasian pregnancies were examined; African Americans were excluded due to low 
minor allele frequencies in the African American population.  Marginally significant 
single locus effects were observed for marker A4917G and T4216C after adjusting for an 
interaction with smoking.   
PTB is hypothesized to be a disease mediated by cytokines; however, it is likely 
that no single factor alone adequately explains PTB risk. Rather, it is more probable that 
coordinated networks of cytokines affect risk. Chapter VII presents a study where we 
examined the relationships between cytokines/chemokines and related biomarkers 
associated with PTB in African Americans and Caucasians, separately.  The Th1 and Th2 
cytokines/chemokines and related biomarkers included in the study were:   Th1 cytokines 
interleukin (IL)-1, IL-8, tumor necrosis factor- (TNF)-α, and TNF soluble receptors 1 and 
2 (sTNF-R1 and sTNF-R2); and Th2 cytokines IL-6 and IL-10.  Correlations between 
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biomarkers were calculated; differences between correlations of African Americans and 
Caucasians, and differences between cases and controls were measured.   
Chapter VIII describes the conclusions and future directions. 
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CHAPTER II 
 
INTRODUCTION, BACKGROUND, AND SPECIFIC AIMS 
 
A.  Introduction and Background 
 
Clinical Aspects of Preterm Birth  
Significance and public health impact of preterm birth 
The prevalence of spontaneous preterm labor leading to delivery (PTB), defined 
as gestational age less than 37 weeks, was ~12.3% in the United States (U.S.) in 2005 
(Martin et al., 2005).  500,000 deliveries in the U.S. annually are preterm, resulting in a 
substantial economic and public health burden (Martin et al., 2005).  The cost of care for 
preterm infants in the U.S is ~$26 billion per year for both medical and social expenses 
(Behrman and Butler, 2006).  In addition to the economic costs, 68% of deaths among 
infants without congenital anomalies is related to being born preterm (Goldenberg, 2002). 
Despite these statistics methods for treatment, prediction, and prevention have not been 
clearly established or defined (Martin et al., 2003).   
PTB infants face higher risks of both death and lifelong disability relative to 
infants born at term.  For example, PTB infants are at increased risk of both congenital 
and behavioral anomalies, neuropsychological impairment, chronic lung disease, and 
visual abnormalities (Hack and Fanaroff, 1993;Jacobson and Dutton, 2000).  Preterm 
related diagnoses are the number one cause of neonatal mortality and the number two 
cause of infant mortality in the U.S. (Demissie et al., 2001;Gonik and Creasy, 
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1986;Mathews and MacDorman, 2006).  The effects in African Americans are 
substantially more severe with preterm related disorders being the leading cause of infant 
mortality (Demissie et al., 2001;Gonik and Creasy, 1986;Mathews and MacDorman, 
2006).  
In the U.S. the PTB rate has been slowly increasing over the last decade from 
9.7% in 1990 to 12.7% in 2005 (Hamilton et al., 2007;Martin et al., 2002).  The 
increasing trends in PTB rates are not limited to the U.S.  Similar increasing trends have 
been seen in Europe and across the world including Denmark where a significant increase 
in PTB has been observed over the last decade (Langhoff-Roos et al., 2006).  It is 
apparent from these statistics that PTB has the potential to become a major global public 
health problem if women at risk are not identified and interventions are not developed. 
Preterm birth definitions 
A preterm birth is defined as a delivery completed at a gestational age less than 37 
weeks from last menstrual period.  Preterm birth differs from a “spontaneous abortion” 
by the gestational age cutoff used; for example, a delivery less than 20 weeks gestation is 
termed a “spontaneous abortion” and a delivery greater than 20 but less than 37 weeks 
gestation is termed a preterm birth (Creasy et al., 2004).  Previously newborns born at a 
weight less than or equal to 2500 grams were also termed “premature”, however, this 
definition was not appropriate.  Approximately one-third of neonates less than or equal to 
2500 grams are to due restricted growth and are not due to being born preterm.  Today 
neonates less than or equal to 2500 grams are termed low birth weight infants regardless 
of gestational age.  Preterm birth, in the present context, makes no distinction based on 
gestational weight. 
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Preterm birth features substantial etiological heterogeneity and as a result 
subtypes have been defined in medical literature based on clinical presentation.  Two 
clinical subtypes of preterm birth are:  spontaneous preterm birth (PTB) (spontaneous 
onset of labor leading to delivery or labor following preterm premature rupture of the 
membranes (pPROM)), and medically indicated preterm birth (when maternal and/or 
fetal indications interrupt a pregnancy at preterm gestations) (Ananth and Vintzileos, 
2006).  Medically indicated preterm birth follows a medical or obstetric disorder that puts 
the mother or fetus at risk (i.e. diabetes,  maternal hypertension, and placenta previa or 
abruption) (Creasy et al., 2004).  Spontaneous preterm birth, in contrast to medically 
indicated preterm birth, arises in the absence of maternal or fetal illness.  The studies 
described in the following chapters describe experiments on the spontaneous clinical 
subtype of preterm birth following spontaneous onset of labor. 
The risk of subsequent preterm births following the occurrence of a preterm birth 
varies by clinical subtype, but a predisposition to deliver preterm has been seen in both  
medically indicated and spontaneous preterm birth (Ananth et al., 2006).  Among the 
known risk factors for medically indicated preterm birth (Table 2-1a) proteinuria ranks as 
the most significant with an Odds Ratio (OR) of 5; however, the strongest risk factor for 
spontaneous preterm birth is multiple gestations (OR = 6) (Table 2-1b).  On average, 
however, the risk factors for medically indicated preterm birth incur stronger risk 
(Goldenberg and Rouse, 1998;Meis et al., 1995;Meis et al., 1998).  The etiology 
underlying clinical subtypes varies considerably across both racial and geographic 
populations, and a higher rate of both subtypes has been observed in African Americans 
relative to other racial groups (Ananth and Vintzileos, 2006).   
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Table 2-1.  Risk factors for spontaneous and medically indicated preterm birth 
a. 
Risk Factors 
Spontaneous Preterm Birth Odds Ratio 
Multiple gestation 6 
History of PTB 4 
2nd trimester bleeding 2 or > 
Genitourinary tract infection 2 
African American 2 
Age < 18 2 
Low BMI 2 
Cigarette smoking 1.5 
Frequent contractions 1.5 
b.   
Risk Factors 
Medically Indicated Odds Ratio 
Proteinuria 5 
High blood pressure 4 
History of stillbirth 3.5 
Lung disease 2.5 
Age > 30 2.4 
Bacteriuria 2 
*Data from (Goldenberg and Rouse, 1998;Meis et al., 1995;Meis et al., 1998) 
 
 
 
Diagnosis and treatment 
 Diagnosis.  Upon a pregnant woman’s admission into a hospital, labor is detected 
by digital examination and diagnosed by the presence of persistent uterine contractions 
with dilation and effacement of the cervix (Gonik and Creasy, 1986).  Ultrasound and last 
menstrual period dating are commonly used to determine if a delivery occurs preterm.  
However, recently in efforts to reduce false positive preterm labor diagnoses, fetal 
fibronectin tests from cervicovaginal fluid have also been used to diagnose the onset of 
labor.  Fibronectin is a protein from the extracelullar matrix (ECM) that acts as an 
adhesive between the amnion/chorions and decidua tissues.  It is present in 
cervicovaginal fluids during the first half of pregnancy and also as labor approaches 
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(Feinberg et al., 1991).  Tests of fetal fibronectin levels have been used due to their 
higher sensitivity and negative predictive value when compared to many other clinical 
tests (Creasy et al., 2004).   
Risk factors.  Several risk factors are assessed to identify pregnancies at risk of 
PTB.  Commonly obstetric history, socio-economic status, demographic characteristics 
(i.e. age and race), and premonitory symptoms have been used to predict women at risk; 
these, however, have not been reliable predictors (Creasy et al., 2004;Main et al., 1985).  
Risk factors for PTB include (Table 2-1a): multiple gestations, history of PTB, 2nd 
trimester bleeding, genitourinary tract infection, being African American, age less than 
18 years, low body mass index (BMI), cigarette smoking, and frequent contractions 
(Goldenberg and Rouse, 1998;Meis et al., 1995;Meis et al., 1998).  The risk factors with 
the largest OR are multiple gestations and a history of PTB, with ORs of 6 and 4, 
respectively.    
Clinical markers.  Several clinical markers have been used to assess risk 
including:  cervical change (i.e. early cervical ripening), increasing contraction 
frequency, vaginal bleeding, and several biomarkers including fetal fibronectin, salivary-
estriol, corticotrophin releasing hormone, interleukin 6 (IL-6), C-reactive protein, ferritin, 
and matrix-metalloproteinases among others (Crane et al., 1999;Creasy et al., 
2004;Elovitz et al., 2001;Heine et al., 1999;Hobel, 2004;Holzman et al., 2001;Khan et al., 
1999;Leitich et al., 1999;Lockwood et al., 1991;Main et al., 1985;Meyer et al., 1995;Ozer 
et al., 2005;Vogel et al., 2005).  Among these early cervical ripening has been considered 
an indicator of a high-risk state for PTB.  Cervical ripening induces a pronounced 
remodeling of the cervical ECM.  The process itself is very similar to an inflammatory 
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response as it increases the expression of several cytokine proteins.  However, cervical 
ripening is difficult to detect due to the subjective nature of the assessment.  Biomarkers 
are typically only measured if a woman is suspected of being at risk of PTB; other 
clinical markers are commonly monitored over the course of pregnancy for most women, 
irregardless of PTB risk.  These approaches have also proven to be inconsistent for 
predicting PTB (Copper et al., 1990;Lockwood and Dudenhausen, 1993). 
 
Table 2-2.  Summary of commonly used tocolytic treatments 
Treatment Common Targets Usage 
Magnesium sulfate Myometrium contractions Common 
Prostaglandin synthesis inhibitors Synthesis of prostaglandin G      from arachidonic acid Most common
Calcium antagonists 
Voltage-gated ion channels  
    (to reduce smooth muscle 
    contractions) 
Common 
Beta-adrenergic agonists Myosin light-chain kinase      production Less common 
  
 
Treatment.  PTB is commonly treated with corticosteroids, tocolytic agents, and 
antibiotics (Von Der Pool, 1998)  Of these treatments, tocolytic therapies are most 
commonly used.  Tocolytic approaches act by either inhibiting myometrial contractions 
or targeting prostaglandin synthesis.  Tocolytic therapies often help to delay delivery so 
that corticosteroids can be administered, in efforts to enhance pulmonary maturity and 
reduce the severity of fetal respiratory distress syndrome therapies (deVeciana et al., 
1995).  There are four major established tocolytic pharmacological treatments for preterm 
labor: magnesium sulfate, prostaglandin synthesis inhibitors, calcium antagonists, and 
beta-adrenergic agonists (Creasy et al., 2004) (Table 2-2).   
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Magnesium sulfate has a depressant effect on the contraction of the myometrium, 
the precise mechanism by which the actions of magnesium occur, however, is not well 
understood.  Magnesium sulfate in general does not have severe side effects, when 
administered in combination with other non-tocolytic drugs.  Prostaglandin synthesis 
inhibitors (i.e. indomethacin) inhibit the cycloxygenase enzymes used in the conversion 
of arachidonic acid to prostaglandin G.    Prostaglandin synthesis inhibitors can lead to 
several serious fetal side effects, including constriction of the ductus ateriosus, neonatal 
pulmonary hypertension, and oligohydramnios (Creasy et al., 2004).  Finally, beta-
adrenergic agonists (i.e. isoxsuprine, hexoprenaline, fenoterol, orciprenaline, ritodine, 
salbutamol, and terbutaline) increase beta2-adrenergic activity in the uterus by increasing 
the quantities of cyclic adenosine monophosphate, leading to a decrease in myosin light 
chain kinase production and inhibition of uterine contractions.  The fetal effects of beta-
adrenergic agonists include neonatal hypoglycemia, hypocalcemia, ileus, and 
hypotension (Brazy and Pupkin, 1979).  Often, a physician uses a combination of 
tocolytic treatments, rather than just one, as guidelines for treatment vary.  Tocolytic 
drugs, however, only provide short-term benefits and contribute to increased risks to both 
the mother and fetus that are not necessarily outweighed by their positive effects  
(deVeciana et al., 1995;Simhan and Caritis, 2007).  In conclusion, there are no really 
good treatments for PTB. 
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Table 2-3.  PTB rate (%) by race and Hispanic origin 1990-2005 
Group 1990 1995 2000 2001 2002 2003 2004 2005 
Total, All Races, Origins1       
Fewer than 32 weeks 1.69 1.61 1.58 1.57 1.57 - - - 
32-36 weeks 8.01 8.21 8.54 8.81 8.87 - - - 
Total, fewer than 37 weeks 9.7 9.82 10.12 10.38 10.44 12.30 12.50 12.70 
Non-Hispanic Caucasians       
Fewer than 32 weeks 1.11 1.13 1.14 1.15 1.14 - - - 
32-36 weeks 6.43 6.99 7.55 7.83 7.92 - - - 
Total, fewer than 37 weeks 7.54 8.12 8.69 8.98 9.07 11.30 11.50 11.70 
Non-Hispanic African Americans       
Fewer than 32 weeks 4.22 3.83 3.58 3.52 3.5 - - - 
32-36 weeks 13.63 12.7 12.29 12.49 12.48 - - - 
Total, fewer than 37 weeks 17.85 16.53 15.87 16.01 15.98 17.80 17.9 18.40 
Hispanic2         
Fewer than 32 weeks 1.52 1.48 1.48 1.45 1.48 - - - 
32-36 weeks 8.77 8.64 8.82 9.04 9.14 - - - 
Total, fewer than 37 weeks 10.29 10.12 10.3 10.49 10.63 11.90 12.00 12.10 
*Data from (Hamilton et al., 2006;Hamilton et al., 2007;Martin et al., 2002) 
1Includes all races, including races not presented 
2Includes all Hispanic racial identifications 
*Rate is defined as a percentage 
 
 
Epidemiology of Preterm Birth 
Population disparity in prevalence rates 
In addition to PTB’s lifelong effects on the health of a child, there is a significant 
disparity in the occurrence of PTB among ethnic groups in the U.S.  The prematurity rate 
amongst African Americans, for example, is ~18% compared to ~12% in Caucasians 
(Martin et al., 2003).  Examining the trends of PTB over the last several years (Table 2-3) 
it is clear that rates have been on the rise over the last decade.  When comparing the rates 
in African Americans and Caucasians they clearly have different trends; with the rate in 
African Americans having slowly declined and then increased over the course of the 
decade, while the rate in Caucasians has been gradually increasing.  Interestingly, women 
of African descent born outside of the U.S. have a lower rate of PTB than women born 
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within the U.S. (Martin et al., 2002) and the rate of PTB at all educational levels in 
African American women is still higher than in their Caucasian counterparts (Kogan and 
Alexander, 1998).   
The etiology of PTB seems to be different in African Americans relative to 
Caucasians.  For example, African American women who experience PTB are more 
likely to have future PTBs relative to Caucasian women (Goldenberg et al., 1998; Creasy 
and Resnik 2004) and in African Americans early PTBs (less than 32 weeks gestation) 
occur more often with infection than they do in Caucasians (Creasy et al., 
2004;Goldenberg and Andrews, 1996).  Despite these differences the exact cause of the 
~1.5 fold difference in rate between African Americans and Caucasians remains 
unexplained.   
 
Preterm Birth Pathways 
Mediators of several pathophysiological processes during pregnancy may 
genetically influence risk of PTB.  Four pathogenic mechanisms have been well 
documented in published literature, from studies of both human and animal models (in 
vivo and in vitro), that can influence risk of PTB (Figure 2-1 from (Lockwood and 
Kuczynski, 2001)):  1) activation of maternal or fetal hypothalamic pituitary adrenal 
(HPA) axis; 2) decidual-chorioamniotic or systematic inflammation; 3) decidual 
hemorrhage (abruption) and 4) pathological distention of the uterus (Lockwood and 
Kuczynski, 2001).  All mechanisms lead to a common terminal pathway that leads to the 
release of uterotonins, such as prostaglandins (lipids found in many vertebrate tissues that 
act as messengers in reproduction and inflammatory response).  Increased uterine 
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contractility and cervical changes result due to activation and stimulation of the 
myometrium by increased concentrations of mediators including prostaglandins and 
oxytocin (Lockwood and Kuczynski, 2001). 
 
Figure 2-1.  Four pathophysiological pathways that incur increased risk of PTB 
PTB
Infection/Inflammation
 
Figure 2-1.  Four pathophysiological pathways influence risk of PTB.  Adapted from, 
Lockwood et al (2001) Paediatr. Perinat. Epidemiol. 2, 560-567.  The four proposed 
pathways are presented (activation of the maternal-fetal HPA axis, inflammation, 
decidual hemorrhage, and pathological uterine distension), as well as how they may 
potentially mediate risk of PTB. 
 
 
Below are a few of ways that these four pathophysiological mechanisms can 
contribute to the activation of mediators leading to PTB: 
1) HPA-axis:  The HPA pathway is either stress-induced in the mother and/or 
precociously activated in the fetus.  Increased stress levels increase fetal adrenal 
dehydroepiandrosterone sulfate (DHEAS) production, which is converted to estradiol and 
estrone.  These products interact with the myometrium and cause an increase in gap 
junction formation, oxytocin receptor mRNA levels and prostaglandin activity, resulting 
in contractions (Meis, 2005).   
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2) Infection and/or inflamatory response:  It is well established that 
endogenous host products mediate decidual-chorioamniotic and/or systematic 
inflammation (Belady et al., 1997;Goldenberg and Culhane, 2003).  Inflammatory 
cytokine levels are often elevated in both AF and/or plasma of individuals experiencing 
preterm labor and early delivery suggesting that PTB may be a host inflammatory 
response (Draper et al., 1995;Fortunato et al., 2000;Vadillo-Ortega et al., 1990).  Under 
this model PTB results from inflammatory response in fetal and/or maternal tissues 
generated either against an intrauterine infection or resulting from idiopathic causes.  The 
activation of cytokines by infection induces prostaglandin production and the onset of 
myometrial contraction, labor, and birth.  AF levels of a few cytokines associate with 
PTB including tumor necrosis factor alpha (TNF-α) (a trimeric protein encoded within 
the major histocompatibility complex) (Franchimont et al., 1998), and IL-6 (an important 
mediator in the host response to infection) (Simhan et al., 2003).   
3) Decidual hemorrhage:  Decidual hemorrhage (abruption) leads to a 
proteolytic cascade that can induce damage to the fetal membranes and promote PTB.  
Decidual hemorrhage is found in ~45% of patients with PTB (Salafia et al., 1995).  It 
leads to local generation of increased levels of thrombin.  Thrombin, with its pro-
coagulant properties, binds to cellular receptors in the decidua and enhances the local 
protease and prostaglandin production. This may lead to degradation of laminin, 
fibronectin, and critical components of the decidua.   
4) Distension of the uterus:  Pathological distension of the uterus may be due to 
multiple gestations or polyhydramnios and is known to result in PTB.  Multiple 
gestations or hydroaminos result in 3.3% of all pregnancies in the U.S. and contribute to 
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~15% of all PTBs (http://marchofdimes.com/peristats).  Multiple gestations or 
hydroaminos lead to the stretching of the myometrium and fetal membranes, causing an 
increase in the synthesis of prostaglandins and COX2 expression, cervical maturation, 
membrane rupture, and uterine contractions (Leguizamon et al., 2001).  Multiple 
gestations are becoming increasingly common as a result of artificial reproductive 
technologies which may explain a portion of the rate increase in PTB. 
 
Genetic Studies on Preterm Birth  
Genetic evidence 
Despite the evidence supporting that a large portion of the risk can be explained 
by known non-genetic risk factors there is accumulating evidence supporting the 
hypothesis that PTB is influenced by genetic factors (Khoury et al., 1989;Treloar et al., 
2000;Varner and Esplin, 2005).  These include:  1) previous PTBs are associated with an 
increased risk of future PTBs; 2) an association has been seen between ethnicity/race and 
PTB; 3) mothers who were born preterm or have sisters who had a PTB have a higher 
risk of delivering PTB infants (Carr-Hill and Hall, 1985;Goldenberg and Andrews, 
1996;Porter et al., 1997).  In addition, twin studies estimate a heritability between 20 and 
40% (Clausson et al., 2000;Treloar et al., 2000), this would suggest that despite known 
risk factors (Table 2-1) explaining a large portion of the risk for PTB, 20-40% of risk 
appears to be due to a genetic predisposition.  These data, although not conclusive, 
strongly support a role for genetic variation in the etiology of PTB.   
A factor that distinguishes genetic predisposition to PTB from many other 
phenotypes is that two distinct genomes can affect risk. The maternal-fetal interface has 
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long been thought to play an important role in PTB because both maternal and fetal 
tissues are involved in both maintenance of pregnancy and initiation of labor and 
delivery.  For example, in infection driven PTB there is an immune response mounted by 
both mother and fetus in response to the presence of microorganisms at the decidual-
membrane interface, initiated by microorganisms infecting the genital tract (Creasy et al., 
2004).  Another example is stress, maternal and/or fetal stress can initiate PTB by 
increasing corticotrophin releasing hormone and increasing levels of estrogen (Creasy et 
al., 2004).  Further studies are necessary to determine which genome, mother or fetus, 
contributes most to risk of PTB.   
Overview of established candidate genes 
Several studies have been performed examining genes within all hypothesized 
PTB pathways for association with PTB.  Table 2-4 provides a list of several candidate 
genes that have been associated with preterm birth (included are all clinical subtypes), 
and whether the association was found in maternal or fetal samples.  Among these 
studies, infection and inflammatory response genes have been the focus of most studies 
due to reports documenting elevated cytokine levels in the AF/serum of PTB women.  
Below is an overview of a few established PTB candidate genes: 
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 Table 2-4.  List of candidate genes with positive associations 
 
Gene Gene Name Population Author Year 
ACE angiotensin I converting enzyme isoform 1 Maternal (Valdez et al., 2004) 
ADD1 adducin 1 (alpha) isoform a Fetal (Gibson et al., 2006) 
Maternal (Doh et al., 2004) 
Fetal (Gibson et al., 2007) ADRB2 adrenergic, beta-2, receptor, surface 
Maternal (Landau et al., 2002) 
DHFR dihydrofolate reductase Maternal (Johnson et al., 2005) 
FII coagulation factor II precursor Fetal (Gopel et al., 1999) 
Maternal (Erhardt et al., 2000) FV coagulation factor V precursor 
Fetal (Gopel et al., 1999) 
FAS tumor necrosis factor receptor superfamily, Fetal (Fuks et al., 2005) 
Maternal (Hartel et al., 2005) IL-6 interleukin 6  
Maternal (Simhan et al., 2003) 
Fetal (Ameglio et al., 2007) MBL2 soluble mannose-binding lectin precursor 
Fetal (Bodamer et al., 2006) 
Fetal (Chen et al., 2004b) MTHFR 5,10-methylenetetrahydrofolate reductase 
Maternal (Valdez et al., 2004) 
MTRR methionine synthase reductase isoform 2 Maternal (Engel et al., 2006) 
NOS2A nitric oxide synthase 2A isoform 1 Fetal (Gibson et al., 2007) 
NOS3 nitric oxide synthase 3 (endothelial cell) Fetal (Gibson et al., 2007) 
PON1 paraoxonase 1 Maternal (Lawlor et al., 2006) 
PPARG peroxisome proliferative activated receptor Fetal (Meirhaeghe et al., 2007)
SERPINB2 serine (or cysteine) proteinase inhibitor, clade Fetal (Gibson et al., 2007) 
SHMT1 serine hydroxymethyltransferase 1 (soluble) Maternal (Engel et al., 2006) 
SLC23A2 solute carrier family 23  Maternal (Erichsen et al., 2006) 
THBD thrombomodulin  Fetal (Gibson et al., 2007) 
TLR4 toll-like receptor 4  Fetal (Lorenz et al., 2002) 
Fetal (Aidoo et al., 2001) 
Fetal (Menon et al., 2006c) 
Maternal (Moore et al., 2004) TNF-α tumor necrosis factor alpha 
Maternal (Roberts et al., 1999) 
sTNF-R1 soluble tumor necrosis factor receptor 1  Maternal (Menon et al., 2006c) 
sTNF-R2 soluble tumor necrosis factor receptor 2  Maternal (Menon et al., 2006c) 
VEGF vascular endothelial growth factor isoform a Maternal (Papazoglou et al., 2004)
SERPINB21 serine (or cysteine) proteinase inhibitor Fetal (Gibson et al., 2007) 
TNF-α1 tumor necrosis factor alpha Maternal (Roberts et al., 1999) 
1Results that trended positively toward association while the other studies were positively associated (p < 
0.05) 
 
 
Tumor necrosis factor alpha (TNF-α).  The most extensively studied gene for 
association with PTB is TNF-α.  Increasing evidence suggests that TNF-α levels vary 
greatly among individuals and is under genetic control (Mira et al., 1999).  TNF-α is 
expressed by monocytes in response to microbial infection and in response to other 
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cytokines.  TNF-α is a proinflammatory cytokine that is involved in remodeling of both 
the fetal membranes and the cervix by promoting the production of matrix 
metalloproteinases (MMPs).  Studies reveal that women who have a history of PTB 
produce more TNF-α during pregnancy than women with a history of term delivery, 
suggesting a relationship between increased TNF-α concentrations and PTB (Amory et 
al., 2004a;Amory et al., 2004b).   
One particular SNP in TNF-α at nucleotide G-308A has been extensively studied 
and has been associated with increased risk of PTB, chorioamnionitis, fetal morbidity, 
and pPROM (Louis et al., 1998).  One of the first studies of G-308A observed 
associations of maternal G-308A genotype with pPROM in a small African American 
population (Roberts et al., 1999).  This population contained a small PTB subset that did 
not associate with G-308A, consistent with studies by Dizon-Townson et al. (Dizon-
Townson et al., 1997) but did trend towards positive.  However, once G-308A was 
established as a potential candidate for PTB, a few small case-control studies examined 
this marker and found an association between maternal genotype and PTB in populations 
of mixed ancestry [Moore, 2004 5344 /id]. Studies have also examined G-308A with 
regard to fetal genotype.  Aidoo et al. (2001) observed association of fetal G-308A 
genotype with PTB in a Western Kenyan population.  This study was well powered, 
consisting of 1048 singleton fetal samples, all of the same ancestry.  This association was 
successfully replicated in a Chinese population utilizing a trio study design (54 PTB 
infants and 79 control infants) (Chen et al., 2003).   
A recent meta-analysis examining the associations of maternal G-308A suggests 
that observed associations at this marker may be spurious effects due to poor study design  
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(Menon et al., 2006a).   Each of the studies described utilized a different ascertainment 
criteria, often consisting of pooled and/or mixed racial ancestry and for the most part 
suffered from poor sample sizes.  Further studies will be necessary to determine the 
validity of the associations observed with fetal G-308A genotypes. 
Interleukin 6 (IL-6).  The second most commonly studied cytokine for 
association with PTB has been proinflammatory cytokine IL-6.  IL-6 is an important 
mediator in the host response to infection.  It activates acute phase response, stimulates T 
lymphocytes, and induces C reactive protein production (Simhan et al., 2003).  IL-6 
production influences human disease, especially those related to infection or 
inflammation.  Its concentration in the AF and cervix is elevated in individuals 
experiencing PTB in comparison to other cytokine levels present in the AF (El-
Bastawissi et al., 2000).   
A (C→G) polymorphism at IL-6 C-174G decreases IL-6 promoter activity 
(Simhan et al., 2003).  Homozygote (G/G) and heterozygotes (C/G) display normal 
production of IL-6, while (C/C) homozygotes display reduced concentrations.  Simhan et 
al (2003) suggests that (C/C) homozygote individuals are less likely to have PTB.  This 
study examined 51 PTB and 156 control births with an approximately two to one ratio of 
Caucasians to African Americans.  This polymorphism also has a well documented ethnic 
disparity in both allelic and genotypic distributions between Caucasians and African 
Americans (Cox et al., 2001).  Studies on IL-6 have also failed to replicate.   
 Coagulation factor V (FV).  FV is not a candidate cytokine from the infection 
and inflammatory response pathway, but rather a candidate from the decidual hemorrhage 
pathway.  FV is involved in blood coagulation, and is an integral component of the 
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compliment and coagulation cascade.  Alteration in FV gene expression can result in both 
thrombotic and hemorrhagic diathesis.  It was established as a candidate for PTB due to 
its potential involvement in decidual hemorrhage and due to documented associations 
between a FV marker at nucleotide G1691A, pregnancy complications, and venous 
thromboembolism (Camilleri et al., 2004;Morrison et al., 2002;Wuthrich, 2001).   
FV is the only strong candidate for PTB identified by a high-throughput candidate 
gene screen (Hao et al., 2004).  This study consisted of 300 maternal cases and 348 
maternal controls, and three racial/ethnic groups (African American, Hispanic, and 
Caucasian).  The majority of the samples (193 case and 260 controls) were African 
Americans.  They identified a haplotype in FV, consisting of markers rs2072476, 
rs2072481, and rs2282743, that was statistically significant after a Bonferroni correction.  
The association was documented on pooled racial/ethnic populations; however, they 
noted that the association was stronger in African Americans and Hispanics than in 
Caucasians.  The association in FV has not been replicated. 
The utility of a high-throughput candidate gene association study 
It is not justified at this time to posit any single factor as being critical in the 
initiation and maintenance of PTB.  To date, a comprehensive candidate gene screen has 
not been adequately performed on PTB that encompasses all potential candidate 
pathways.  Previous studies have also failed to address the potential genetic basis of the 
racial disparity in prevalence rates.  Therefore, in the studies presented in the following 
chapters we responded to this deficiency by performing a comprehensive screen of 
established and potential PTB candidate genes from hypothesized PTB pathways and 
examining the relationships between several well-established PTB biomarkers.  In 
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addition to this we also performed all analyses in both African Americans and 
Caucasians, given the established disparity in prevalence rates between the two groups, 
stratifying all analyses in these two groups. 
A large-scale high-throughput candidate gene screen is the best genetic approach 
for identifying genetic factors that increase risk for this clinical phenotype and would 
greatly increase our ability to design a treatment for the prevention of PTB.  Family 
studies have not been well documented in the literature due to the complex relationship 
between maternal and fetal genomes during pregnancy and due to the lack of adequate 
methodology to perform such a study (Wilcox et al., 1998).  The following dissertation 
examines single locus associations with PTB due to individual effects of maternal and 
fetal genetic information, multilocus effects based on epistatic interactions, haplotype 
effects, and effects due to genetic interactions by mother and fetus.  Combining all of 
these approaches and examining multiple SNPs in each of the candidate genes will be the 
first such study in this growing field of PTB research.  This study has multiple lines of 
biological evidence to support the hypothesis that mediators in the hypothesized PTB 
pathways, defined by Lockwood et al (2001), are associated with PTB.  This will also be 
the first study on PTB examining multiple SNPs at each candidate gene extending to a 
multilocus level and examining maternal and fetal contributions.   
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B.  Hypothesis and Specific Aims 
 
Hypothesis:  Variations in multiple genes encoding proteins in four candidate 
pathophysiological pathways (activation of the maternal/fetal HPA 
axis, infection and/or inflammation, decidual hemorrhage, and 
pathological uterine distension) influence susceptibility to PTB.  
Additionally, there is an interactive effect between the genetic 
susceptibility of mother and fetus leading to PTB.   
 
Specific aim I:  Examine the role of maternal and fetal genetic control of biomarkers 
in PTB and term samples.   
            Amniotic fluid (AF) will be examined for protein concentrations of seven PTB 
candidate genes (interleukin (IL) -1, IL-6, IL-8, IL-10, tumor necrosis factor alpha (TNF-
α), soluble TNF-receptor 1 (TNF-R1), and soluble TNF-receptor 2 (TNF-R2)).  These 
cytokines will be examined for the correlated relationships both within African 
Americans and Caucasians.  Finally, a well established candidate gene IL-6 will be 
examined for association between genotype and IL-6 AF protein expression. 
 
Specific aim II:  Select and genotype single nucleotide polymorphisms (SNPs) in 
multiple preterm birth (PTB) candidate genes for maternal and fetal 
PTB and term samples.   
Approximately 130 genes were chosen based on physiological function and 
extensive search of the literature. Upon completion of the gene list, SNPs within each 
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gene were identified and selected based on several databases (i.e. HapMap, NCBI 
dbSNP, and Applied Biosystems) that are amenable to genotyping with an Illumina 
platform.    A total of 1536 SNPs were selected for genotyping.  All samples were 
genotyped for multiple SNPs in each candidate gene using the Illumina GoldenGate 
genotyping system.   
 
Specific aim III:  Test for association between candidate gene SNPs and PTB in 
maternal and fetal samples in a case-control population. 
a. Association analysis of the entire PTB dataset for African American and 
Caucasian maternal and fetal data separately by testing SNPs in the candidate 
genes for allele and genotype association with PTB. 
b. Test for haplotype association with PTB in genes with multiple single locus 
associations in African American and Caucasian maternal and fetal data 
separately. 
c. Perform multi-locus association analyses on the entire PTB dataset and within 
pathways for African American and Caucasian maternal and fetal data 
separately by testing for multi-locus genotype association with PTB. 
To better understand the genetic basis for the established differences in 
prevalence rates between African Americans and Caucasians, all analyses will be 
performed separately for African Americans and Caucasians.  Single locus association 
analyses will be performed by using gestational age as a dichotomous variable.  Tests for 
deviations from Hardy Weinberg equilibrium (HWE) will be performed within PTB and 
term births.  Fisher’s Exact test will be performed for tests of association with disease and 
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single locus alleles/genotypes.  Tests for associations of multilocus genotypes with PTB 
will be performing using Multifactor Dimensionality Reduction (MDR) within the entire 
dataset and within pathway grouping of the data.   
 
Specific aim IV:  Test for association between mitochondrial DNA candidate gene 
SNPs and PTB in Caucasian maternal data. 
a.  Association analysis of Caucasian maternal data by testing mitochondrial 
DNA SNPs for allele association with PTB. 
b. Perform multivariate analyses on mitochondrial DNA SNPs adjusting for 
confounding demographic variables. 
 All analyses will be performed for maternal Caucasian samples.  χ2 tests of 
association of disease with single locus alleles will be performed with gestational age as a 
dichotomous ourcome variable.  Multilocus statistical interactions between markers will 
be evaluated with logistic regression.  Results will be adjusted for effects of confounding 
variables.  
 
Specific aim V:  Test for interactions between genotypes of maternal and fetal 
samples. 
Exploratory multilocus interactions between maternal and fetal samples will be 
examined by application of MDR to allow for the simultaneous analysis of maternal-fetal 
genotype combinations.   
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CHAPTER III 
 
INTERLEUKIN (IL)-6 AND IL-6 RECEPTOR GENES AND SPONTANEOUS 
PRETERM BIRTH 
 
 
Overview Chapter III Part A and B  
PTB is a significant neonatal health problem that is more common in African 
Americans than in Caucasians. Part of this disparity is likely to result from the differing 
genetic architectures of Caucasians and African Americans. To begin assessing the role 
of these differences, patterns of genetic variation in two previously proposed candidate 
genes, in IL-6 (5 markers) and its receptor (IL-6R) (3 markers), were analyzed in mothers 
and fetuses in both Caucasians and African Americans.  IL-6 concentrations in AF were 
determined in a subset of these pregnancies.  Chapter III part A presents a small scale 
study examining these two candidate genes.  No strong single marker effects were 
observed, however, all of the SNPs studied showed significant frequency differences 
between African Americans and Caucasians in at least one comparison; this was in 
significant excess of that expected from general population databases. Higher IL-6 
concentrations associated with the IL-6 SNP -661 (rs1800797) in Caucasian preterm 
samples (p= 6.00x10-3), and this result seems to be driven by MIAC, indicating a gene by 
infection interaction. Chapter III part B expands on the study performed in part A 
examining 8 markers in IL-6 and 22 markers in IL-6R focusing on associations between 
IL-6 AF and patterns of IL-6 genetic variation.  Haplotype tests of association were 
performed by using a sliding window with a dichotomous (PTB/term) outcome and a 
continuous (IL-6 cytokine concentration (pg/ml)) outcome.  In African Americans and 
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Caucasians significant results for both dichotomous and continuous outcomes converged 
on three regions:  in IL-6 markers (rs1800797, rs1800796, and rs1800795); in IL-6R 
markers (rs4601580, rs4645618, rs6687726, and rs7549338); and IL-6R markers 
(rs4537545, rs4845374, and rs4845625).  These findings indicate that, as a function of 
IL-6 genotype, Caucasian and African American women respond differently to infection 
with respect to their expression of IL-6. Our data support complex genetic control of 
levels of IL-6 in AF between Caucasians and African Americans.  
 
(Chapter III part A adapted from Velez et. al. “Ethnic differences in interleukin 6 (IL-6) 
and IL-6 receptor genes in spontaneous preterm birth and effectson amniotic fluid protein 
leveles.”  Ann. Hum. Genet. 71:  586-600.) 
 
 
 
A.  Ethnic Differences in Interleukin (IL)-6 and IL-6 Receptor Genes in 
Spontaneous Preterm Birth and Effects on Amniotic Fluid Protein Levels 
 
 
Introduction 
PTB is a complex disease induced by several etiologic factors from potentially 
interacting pathophysiologic pathways (Lockwood and Kuczynski, 2001). These 
pathways culminate in a terminal biochemical pathway resulting in the activation of 
uterotonins, such as prostaglandins, that induce labor (Lockwood and Kuczynski, 2001). 
Of the different pathways that have been implicated in PTB, infection and the host 
inflammatory response to infection (e.g., cytokine and matrix metalloproteinase 
activation) are among the most commonly found precursors to PTB (Hillier et al., 
1988;Romero et al., 1990;Romero et al., 2006;Romero and Mazor, 1988). Based on these 
data we hypothesize that the response to infection in some women increases their risk of 
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PTB compared to individuals of a different genetic constitution (Macones et al., 
2004;Roberts et al., 1999). 
 In the US a ~2-fold difference in rates of PTB exists between African Americans 
and Caucasians.  The rates of PTB in Caucasians and African Americans have converged; 
from 1989 to 1997 there was a 15.6% increase in the rate of PTB among Caucasians to 
10.2% while African Americans experienced a 7.6% decrease to 17.5% over the same 
period (Demissie et al., 2001). This convergence of rates has continued with Caucasian 
PTB rate being 11.1% in 2002 and the African American rate being 17.5% (Martin et al., 
2003).  The causes of these changes in disparity are also not well understood, although it 
is possible that the disparity can be used to identify candidate risk factors that are 
significantly different between ethnic groups, thereby helping to define the underlying 
etiology of the phenotype.   
One plausible candidate associated with infection that may affect the risk of PTB 
is IL-6.  Increased concentration of this proinflammatory cytokine, in cervical and AF has 
been associated with MIAC in women delivering preterm (El-Bastawissi et al., 
2000;Romero et al., 1990). Increased IL-6 concentration in cord plasma is also associated 
with fetal inflammatory response to maternal infection (Yoon et al., 2000). For these 
reasons IL-6 is considered a “marker” of high risk status for PTB (Romero et al., 1993). 
In addition, genetic association studies demonstrated that a single nucleotide 
polymorphism (SNP) in the promoter region of the IL-6 gene (C-174G) decreases 
promoter activity, and the (G/G) homozygote associates with increased risk of PTB 
(Hartel et al., 2004). IL-6 as well as its receptor (IL-6R), through which IL-6 mediates its 
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biological function, are therefore strong candidates for PTB and perhaps for the ethnic 
disparity in PTB.   
The present association study was undertaken to better understand the patterns of 
variation of SNPs in the IL-6 and IL-6R genes. In this study, we compare the maternal 
and fetal allelic, genotypic, haplotypic patterns between African Americans and 
Caucasians and between cases (PTB) and controls (normal term deliveries) within 
African Americans and Caucasians. In addition, we assessed the effects of genetic 
variation on AF IL-6 concentration in cases and controls in both African Americans and 
Caucasians in efforts to understand ethnic disparity. 
 
Materials and Methods 
Study population  
  Caucasian and African American subjects were recruited at the Centennial 
Medical Center, Nashville, TN and Magee Women’s Hospital, Pittsburgh, PA. 
Institutional Review Boards at Tri-Star Nashville, TN, Vanderbilt University, Nashville, 
TN and Magee Women’s Hospital, Pittsburgh, PA approved this study. All subjects were 
recruited sequentially based on the availability of recruiters.  All included pregnancies 
were singleton live births. Ethnicity was identified by self-report and a questionnaire that 
traces ethnicity back one generation from the mother and father.  Individuals who had 
more than one racial group in their ancestry (one generation from mother and father) 
were excluded from the study. We recruited mothers between the ages of 18 and 40. 
Gestational age was determined by last menstrual period dating and corroborated by 
ultrasound dating.  In our study, cases (PTB) were defined as presence of regular uterine 
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contractions at a minimum frequency of 2-contractions/10 minutes followed by delivery 
at <36 weeks gestation. We excluded subjects with multiple gestations, preeclampsia, 
preterm premature rupture of the membranes (pPROM), placental previa, fetal anomalies, 
gestational diabetes, poly- and oligohydramnios, and other complications such as 
surgeries during pregnancies. The controls consisted of women having normal labor and 
delivery at term (≥ 37 weeks) with no medical or obstetrical complications during 
pregnancy.  A summary of the data recruitment and ascertainment for Centennial 
Women’s Hospital data is described in detail on Figure 3-1.  (Magee Women’s hospital 
data recruitment is not presented, as it is not used in the studies presented in the following 
Chapters). 
 
Recruitment-September 2003-December 2006
Total deliveries-11126
Preterm birth -1562 Term-9564
PTB-682 Other/indicated 
Preterm birth-880
PTB with pPROM-169 PTB without pPROM-513
C-308 AA-134 Other-71 Other-1417 AA-2486 C-5661
Consent eligible
Maternal DNA
Fetal DNA
191 194
183 179
145 75
140 65
1887 3328251 88
Exclusion
Consented     
Successfully genotyped 
Survived quality control 
 
 
Figure 3-1.  Data recruitment and ascertainment. 
Data ascertainment procedure between September 2003 through December of 2006 is 
documented.  The samples collected are outlined at each stage in ascertainment and are 
distributed by race.  C refers to Caucasians and AA refers to African Americans. 
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Demographic and clinical characteristics 
Our genetic study included a total of 496 birth events in Caucasians (149 cases 
and 347 controls) and 397 in African Americans (76 cases and 321 controls).  Placental 
pathology was performed in all cases to document histologic chorioamnionitis and 
funisitis. The means and standard deviations of demographic and clinical characteristics 
for cases and controls are listed in Table 3-1.  Significant differences between cases and 
controls were observed in Caucasians and African Americans for APGAR 1 (a method to 
assess a newborn infant, the score is a number calculated based on scoring heart rate, 
respiratory effort, muscle tone, skin color, and response to a catheter in the nostril 1 
minute after birth (APGAR 1) and 5 minutes after birth (APGAR 5)), birth weight (kg) 
and gestational age at delivery (weeks) with p<0.0001. 
 
Table 3-1.  Clinical and demographic characteristics 
Caucasian African American 
Mean Mean Variable 
Cases Controls 
P-Value1 
Cases Controls 
P-Value1
Age(yrs) 26.74 (6.43) 
26.96 
(5.90) 0.71 
25.39 
(5.91) 24.534 (5.572) 0.26 
APGAR 1 7 (2.02) 
8 
(1.25) <0.0001 
6 
(2.70) 
8 
(1.11) <0.0001 
Birth Weight (kg) 1.80  (0.70) 
3.36  
(0.50) <0.0001 
1.83 
(0.79) 
3.26 
(0.52) <0.0001 
Gestation Age at 
Delivery(wks) 
32.19 
(3.16) 
39.30 
(1.21) <0.0001 
31.62 
(4.29) 
39.11 
(1.13) <0.0001 
Gravidity 2.17 (1.29) 
2.13  
(1.45) 0.77 
2.41 
(1.46) 
2.46 
(1.60) 0.43 
Means are reported with standard deviations reported in parentheses 
1P-values compare cases to controls 
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DNA sampling and genotyping 
DNA was isolated from maternal and fetal blood samples using the Autopure 
automated system (Gentra Systems (Minneapolis, MN)).   
            A total of eight SNPs were screened in IL-6 and IL-6R genes (5 in IL-6 and 3 in 
IL-6R). We used the reported minor allele frequencies of the SNPs (from National 
Institute of Health (NIH) dbSNPs database) and their relative distance on the gene as 
criteria for SNP selection. The rs numbers of SNPs from the NIH database, SNP 
locations, and relative distances are shown in Table 3-2. We did not use functional 
significance of SNPs as selection criteria with the exception of IL-6 -237 (rs1800795 also 
reported as -174) that was previously shown to associate with PTB (Simhan et al., 2003). 
Genotyping was done using the TaqMan assay on an ABI 7900 (Applied Biosystems of 
Foster City, CA).   
 
Table 3-2.  Positional information of SNPs 
 
Gene rs# Location1 Position (bp) Genic Region 
1880243 -7227 22532895 Promoter 
1800797 -661 22539461 Promoter 
1800796 -636 22539486 Promoter 
1800795 -237 22539885 Promoter 
IL-6 
(Chromosome 7) 
1554606 1826 22541947 Intron 
6687726 22215 151213393 Intron 
4845622 33314 151224492 Intron IL-6R (Chromosome 1) 
4845623 37672 151228850 Intron 
1Location refers to position from translational start site 
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Cytokine measurements 
AF samples were collected during active labor (either preterm or term) by 
transvaginal amniocentesis before rupture of the membranes and delivery. Amniotic fluid 
samples were only collected in Nashville. Samples were collected before preterm or term 
vaginal deliveries by puncture of intact membrane using a 22 gauge needle prior to 
artificial rupture of the membranes. A few samples were also collected at the time of 
cesareans. AF was centrifuged immediately for 10 minutes at 2500 RPM to remove 
cellular and particulate matter. Aliquots of AF were stored at –70oC until analysis.  
IL-6 concentration in the AF was measured using multiple solid phase sandwich 
immunoassays utilizing antibody coated beads (Biosource International, Camarillo, CA) 
and analyzed with a LuminexTM (Austin, TX). Standard curves were developed using 
duplicate samples of known quantities of recombinant proteins provided by the 
manufacturer. Sample concentrations were determined by relating the absorbance 
obtained to the standard curve by linear regression analysis. When necessary, samples 
were diluted in assay buffer provided by the manufacturer in addition to the doubling 
dilution required to perform the assay. The sensitivity of the assay was 1 pg/ml. 
Both maternal genetic data and AF IL-6 concentrations were available on 54 
Caucasian cases and 37 Caucasian controls, while both fetal genetic data and AF data 
were available from 57 Caucasian cases and 42 controls. In African Americans, 30 cases 
and 67 controls had both maternal genetic data and AF data, while 26 cases and 68 
controls had both fetal genetic data and AF data.  
MIAC was defined either by polymerase chain reaction (PCR) testing and/or 
clinical evidence. Presence of bacteria in the AF was detected by PCR amplification of 
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microbial 16s ribosomal DNA (TaqMan Assay, CA).  Microbial cultures were not 
attempted since the PCR based detection of microbes is much more sensitive than 
traditional cultures (Gardella et al., 2004;Hitti et al., 1997). Microbial species 
identification using PCR was not performed in this study.  Preterm cases with clinical 
evidence of MIAC were those individuals having three or more of the following criteria:  
abdominal tenderness, temperature > 38oC, foul smelling vaginal discharge, an elevated 
C-reactive protein (CRP) or histologic chorioamnionitis. 
 
Statistical methods 
Single locus allele and genotype analysis.  Shapiro-Walks tests of normality 
were performed to test for normality and as a result Mann-Whitney two sample rank sum 
tests were performed to compare demographic and clinical measurements between cases 
and controls.  Single locus allele frequencies were analyzed, using the software Tools for 
Population Genetic Analysis, TFPGA, version 1.3 (available at 
http://www.marksgeneticsoftware.net/)(Raymond and Rousset, 1995). Genotype 
distributions at single sites were compared between ethnic groups using the program R X 
C at the same website, and are based on the Metropolitan algorithms.  Single site Hardy-
Weinberg Equilibrium (HWE) analyses were also performed using TFPGA (Raymond 
and Rousset, 1995). Statistical significance for the above was determined using Fisher’s 
Exact Tests.  All analyses were done on pooled Nashville and Pittsburgh samples because 
preliminary analyses showed that the two samples did not differ significantly within cases 
or within controls with regards to allele or genotype frequencies.   
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Haplotype analysis.  Pairwise linkage disequilibrium (LD) was characterized and 
haplotype frequencies were calculated for Caucasians and African Americans, using 
Powermarker (Liu and Muse, 2005;Zaykin et al., 2002) and/or HaploView statistical 
software (Barrett et al., 2005). Results from the two software packages did not differ.  
Haplotype blocks were assigned using the algorithm created by Gabriel (Gabriel et al., 
2002).  Both Powermarker and HaploView use an EM algorithm to determine haplotype 
frequency distributions when phase is unknown.  The Powermarker haplotype trend 
analysis was performed to test for haplotype frequency differences between groups.  This 
approach can be applied to both quantitative traits and dichotomous traits.  This analysis 
uses a regression approach to test haplotype-trait association.  The test for association 
then uses an F test for a specialized additive model (Zaykin et al., 2002). This method 
was used to test for differences between African Americans and Caucasians and between 
phenotype classes within an ethnic group. 
IL-6 AF concentration analysis.  One and two-way analysis of variances 
(ANOVA) were used to examine AF IL-6 associations with IL-6 genotypes and 
pregnancy outcome and within Caucasians and African Americans. Both fetal and 
maternal genotypes were analyzed for association.  STATA was used for ANOVA 
analyses (StataCorp, 2007).  A log transformation was performed on IL-6 concentrations 
to normalize data because the Shapiro-Wilks test for normality demonstrated that 
cytokine concentrations deviated from normality.  One-way ANOVA was performed 
with IL-6 markers to determine if the cytokine concentration differs with regards to an 
individual’s genotype within a status groups.  A two-way ANOVA was also performed 
with phenotype status and individual IL-6 markers as covariates, to determine if cytokine 
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concentration associates with status and individual markers.  A two-way ANOVA was 
also used to assess association between marker and MIAC status within cases. 
Correction for multiple testing 
False discovery rate (FDR) was used to correct for multiple testing.  FDR is used 
to measure global error, that is, the expected number of false rejections of the null 
hypothesis among the total number of rejections (Sabatti et al., 2003).  FDR measures the 
proportion of false positives among all SNPs called significant.  The FDR adjusted p-
values are defined in a step-down fashion.  The false discovery rate used was 0.20. 
 
Results 
Analysis of differential distribution IL-6 and IL-6R SNPs in African Americans 
and Caucasians   
Significant differences between African Americans and Caucasians were 
observed at both the genotype and allele frequencies in IL-6 and IL-6R for maternal and 
fetal samples (Table 3-3). Of the 20 comparisons for allele frequency differences between 
Caucasians and African Americans in the IL-6 gene (maternal, fetal, cases and controls x 
5 SNPs) , 13 were significant at the 0.05 level (3 in fetal cases, 3 in fetal controls, 3 in 
maternal cases, and 4 in maternal controls,) and 8 were significant with p values below 
0.0001. Similarly, genotype frequency comparisons between the ethnic groups were 
different in 13 of 20 comparisons at the 0.05 level (3 in fetal cases, 3 in fetal controls, 3 
in maternal cases, and 4 in maternal controls,) and 8 at the 0.0001 level.  Comparisons of 
the IL-6R SNPs between racial groups were even more striking with 11 of 12 
comparisons being significant at the 0.05 level for allele frequencies (2 in fetal cases, 3 in 
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fetal controls, and 3 each in maternal cases and controls). The only value not significant 
at the 0.05 level was fetal allele frequency at position 37672 in cases with a marginal p 
value (p = 0.09).  The genotype comparisons for IL-6R were comparably different with 
10 of 12 SNPs showing significant differences (2 in fetal cases, 3 in fetal controls, 2 in 
maternal cases, and 3 in maternal controls). It is clear from these data that most SNPs 
differed between ethnic groups within a phenotypic class in both maternal and fetal 
samples. 
As might be expected from the patterns of single SNP differences in both fetal 
and maternal samples, haplotypes displayed strong differences in frequencies when 
comparing African Americans and Caucasians in both cases and controls.  Highly 
significant differences (p <0.0001) were observed in IL-6 and IL-6R haplotypes in all 
comparisons (Table 3-4).   
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Table 3-3.  Single locus analysis of Caucasians and African Americans 
 
a. Fetal 
C C AA AA C v AA Alleles C v AA Genotypes 
Allele Frequency HWE P-Value1 Case-Control P-Value Allele Frequency HWE P-Value1 Case-Control P-Value P-Value P-Value Marker 
Allele 
Case Control Case Control Allele2 Genotype3 Case Control Case Control Allele2 Genotype3 Case Control Case Control 
-7227 A 0.25 0.23 0.08 0.25 0.54 0.10 0.15 0.20 1.00 0.84 0.34 0.64 0.05 0.16 0.19 0.29 
-661 A 0.38 0.36 0.07 0.01 0.64 0.91 0.09 0.11 0.35 0.21 0.6 0.86 <0.0001 <0.0001 <0.0001 <0.0001 
-636 C 0.09 0.05 0.12 0.01 0.67 0.49 0.07 0.08 0.22 0.22 1.00 0.47 0.64 0.05 0.64 0.13 
-237 C 0.40 0.37 0.01 0.01 0.37 0.61 0.08 0.11 0.29 0.22 0.47 0.54 <0.0001 <0.0001 <0.0001 <0.0001 
1826 T 0.44 0.39 0.03 0.05 0.25 0.38 0.35 0.34 0.11 0.78 0.91 0.34 0.16 0.08 0.01 0.02 
22215* A 0.43 0.46 0.38 0.23 0.42 0.68 0.59 0.42 0.39 0.51 1.00 0.65 0.0075 <0.0001 0.04 <0.001 
33314 C 0.43 0.39 0.52 0.89 0.40 0.53 0.18 0.14 0.62 0.18 0.19 0.15 <0.0001 <0.0001 <0.0001 <0.0001 
37672* G 0.47 0.42 0.18 0.49 0.34 0.15 0.57 0.44 1.00 0.82 0.91 1.00 0.09 <0.0001 0.18 <0.001 
b. Maternal 
C C AA AA C v AA Alleles C v AA Genotypes 
Allele Frequency HWE P-Value1 Case-Control P-Value Allele Frequency HWE P-Value1 Case-Control P-Value P-Value P-Value Marker 
Allele 
Case Control Case Control Allele2 Genotype3 Case Control Case Control Allele2 Genotype3 Case Control Case Control 
-7227 A 0.21 0.22 0.13 0.59 0.75 0.51 0.20 0.15 1.00 0.67 0.30 0.34 0.78 0.002 0.61 0.01 
-661 A 0.34 0.33 0.45 0.35 0.69 0.41 0.08 0.12 1.00 0.03 0.17 0.48 <0.0001 <0.0001 <0.0001 <0.0001 
-636 C 0.07 0.06 1.00 0.33 0.67 0.49 0.09 0.08 1.00 0.14 0.86 0.55 0.56 0.13 0.39 0.31 
-237 C 0.37 0.34 0.85 0.27 0.33 0.46 0.08 0.13 0.32 0.04 0.09 0.34 <0.0001 <0.0001 <0.0001 <0.0001 
1826 T 0.43 0.38 0.38 0.15 0.17 0.13 0.29 0.32 0.12 0.68 0.46 0.48 0.008 0.02 0.01 0.04 
22215* A 0.43 0.44 0.21 0.22 0.89 0.88 0.54 0.42 0.61 0.72 0.42 0.64 0.05 <0.0001 0.12 <0.0001 
33314 C 0.43 0.38 0.61 0.24 0.19 0.25 0.20 0.16 0.10 0.53 0.29 0.36 <0.0001 <0.0001 <0.0001 <0.0001 
37672* G 0.47 0.43 0.40 0.91 0.26 0.36 0.65 0.45 0.27 0.36 0.04 0.05 <0.0001 <0.0001 0.003 <0.001 
1 HWE-p-values testing for deviations from Hardy Weinberg Equilibrium 
2 Indicates comparisons between case and control allele frequencies. 
3 Indicates comparisons between case and control  genotype frequencies 
*Opposite minor alleles for these two markers in African Americans (AA) and Caucasians (C).
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Table 3-4.  Comparisons of Caucasian and African American haplotype 
frequencies 
 
Fetal Sample 
P-Value Status IL-6 IL-6R 
Case <0.0001 <0.0001
Control <0.0001 <0.0001
Maternal Sample 
P-Values Status IL-6 IL-6R 
Case <0.0001 <0.0001
Control <0.0001 <0.0001
 
 
 
Case-control association analyses 
 Deviations from HWE were observed in Caucasians at -661, -636 and -237 in 
fetal control samples (p= 0.01), 1826 in fetal controls (p= 0.05), -237 in fetal cases (p= 
0.01), and 1826 in fetal cases (p= 0.03) in IL-6 (Tables 3-3a).  Significant deviations 
from HWE were also observed in African Americans at -661 in maternal controls (p= 
0.03), and -237 in maternal controls (p= 0.04; Table 3-3b). None of these p-values are 
corrected for multiple testing.   
 Single locus association analyses (allelic and genotypic) of Caucasian maternal 
and fetal samples found no significant associations between SNPs in IL-6 or in IL-6R and 
PTB (Table 3-3a and 3-3b) including the -237 SNP (commonly referred to as -174 from 
the transcription start site) that was previously shown to be associated with PTB. Allelic 
and genotypic analyses in African Americans found one significant association between 
the SNP at 37672 for IL-6R maternal samples (allele p= 0.04, genotype p= 0.05) with 
PTB (Table 3-3b). A marginally significant allele frequency difference between cases and 
controls was found at -237 for maternal samples (p= 0.09; Table 3-3b).  
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LD patterns were characterized for all populations examined, using r2 as the 
metric (Figure 3-2).  Caucasian controls had strong to moderate LD in both IL-6 and IL-
6R in both fetal cases and controls. Fetal case and fetal control haplotype structure were 
similar to each other in Caucasians, as were Caucasian maternal case and Caucasian 
maternal control patterns (Figure 3-2a-d). IL-6 markers -237 and 1826 formed a block in 
all Caucasians samples.  IL-6R markers 22215 and 33314 formed a block in all control 
samples as well as in Caucasian cases (Figure 3-2b, d, f, and h).  As expected there was 
generally weaker LD present in African American samples as compared to Caucasians 
(Figure 3-2e-h).  However, in African Americans LD appeared to be stronger in the 
control group as compared to the African Americans cases. 
Haplotype regression analyses were also performed by treating PTB as a 
dichotomous variable (Table 3-5a and b). No significant associations were observed 
between haplotype frequencies and PTB in fetal or maternal samples in either ethnic 
group or either gene. Only haplotype frequencies present in 5.0% or more in at least one 
of the groups were included in the tables presented. 
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a.  Caucasian fetal cases    b.  Caucasian fetal controls 
   
c. Caucasian maternal cases   d.  Caucasian maternal controls 
   
e. African American fetal cases    f.  African American fetal controls 
   
g. African American maternal cases   h.  African American maternal controls 
   
 
Figure 3-2. Fetal and maternal interleukin 6 and interleukin 6 receptor linkage 
disequilibrium structure. 
Haplotype block structure and LD across IL-6 and IL-6R.The left hand side of each panel 
is IL-6 and the right and side is IL-6R. Numbers in the diamonds are r2 values with darker 
shades of gray indicating higher values.  Blocks are denoted as described in the text. 
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Table 3-5.  Haplotype frequencies and trend regression results 
a.  IL-6 
Fetal Samples 
Frequency 
C AA P-Value -7227 -661 -636 -237 1826 
Case Control Case Control C AA 
A G G G G 0.20 0.21 0.15 0.16 0.19 0.85 
C G C G G 0.09 0.05 0.07 0.08   
C G G G G 0.26 0.34 0.43 0.42   
C G G G T 0.05 0.03 0.26 0.21   
C A G C T 0.33 0.34 0.09 0.10   
Maternal Samples 
Frequency 
C AA P-Value -7227 -661 -636 -237 1826 
Case Control Case Control C AA 
A G G G G 0.17 0.20 0.17 0.11 0.46 0.53 
C G C G G 0.07 0.06 0.07 0.06   
C G G G G 0.33 0.35 0.47 0.48   
C G G G T 0.06 0.05 0.19 0.19   
C A G C T 0.30 0.31 0.07 0.11   
b. IL-6R 
Fetal Samples 
Frequency 
C AA 
P-Value 
22215 33314 37672 
Case Control Case Control C AA 
A A A 0.42 0.43 0.32 0.38 0.75 0.09 
A A G 0.02 0.03 0.27 0.2   
G A A 0.11 0.15 0.11 0.06   
G A G 0.03 <0.01 0.12 0.22   
G C G 0.43 0.38 0.18 0.14   
Maternal Samples 
Frequency 
C AA 
P-Value 
22215 33314 37672 
Case Control Case Control C AA 
A A A 0.41 0.40 0.32 0.38 0.52 0.39 
G A A 0.12 0.16 0.04 0.08   
G C G 0.42 0.37 0.20 0.16   
A A G 0.03 0.03 0.22 0.20   
G A G 0.03 0.02 0.22 0.18   
*Caucasian-C; African American-AA 
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IL-6 amniotic fluid cytokine analysis 
 Overall, cytokine concentrations were higher in Caucasian cases than Caucasian 
controls, but this was not evident in African Americans (p values for all comparisons 
presented in Table 3-6).  In Caucasian cases there is a significant association between 
maternal genotype at variant -661 and log IL-6 concentration (AA = 8.94±1.01 pg/ml, 
AG = 7.70±1.33 pg/ml, GG 8.92±1.39 pg/ml, p = 6.00x10-3, Table 3-6 and Figure 3-3a). 
In comparison, there was no association in Caucasian controls (AA = 7.95± 0.98 pg/ml, 
AG = 7.37±1.27 pg/ml and GG = 7.54±1.13 pg/ml, p=0.59, Table 3-6 and Figure 3-3a).  
The two-way ANOVA also revealed a significant association for phenotype and -661 
genotype in Caucasian mothers (p = 8.00x10-3, Table 3-6b and Figure 3-3a).  The African 
American samples did not show any differences in IL-6 concentration as a function of the 
genotype at -661 (Table 3-6c-d, Figure 3-3b).  However, in African Americans there were 
only two significant associations between genotype and phenotype, and they were for -
7227 for fetal genotype in control samples (p=0.04, Table 3-6c) and -636 maternal 
genotype in control samples (p=0.04; Table 3-6d).  
Cases were also analyzed for the presence and absence of MIAC and for 
association between genotype and MIAC (Table 3-6a-d).  In Caucasian cases a two-way 
ANOVA analysis for cytokine concentration, assessing maternal genotypes and MIAC, 
two SNPs were found to have significant associations, -661 (p= 9.00x10-4) and -237 (p= 
0.04) (Table 3-6b and Figure 3-3c) with MIAC.  These markers were not statistically 
significantly associated with MIAC in African American cases.  These results indicate a 
significant genotype by MIAC interaction in Caucasian cases.  After performing an FDR 
correction, with a false discovery rate of 0.2, all statistically significant p values (original 
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cutoff p< 0.05) remain statistically significant, with the exception of the association of -
237 and MIAC (p= 0.04) in Caucasian cases.  In African Americans neither of the p-
values remains significant after FDR correction. 
 
Table 3-6.  IL-6 cytokine concentration analysis 
a. 
Caucasian Fetal  
P-Value Mean Cytokine Concentrations 
Marker 
Marker 
& Status1 
Marker 
& MIAC3 
Case 
(N=57)2 
Control 
(N=42)2
Case 
(pg/ml) 
Control 
(pg/ml) 
-7227 0.95 0.86 0.68 0.55 8526.93 3294.96 
-661 0.32 0.62 0.65 0.45   
-636 0.79 0.86 0.87 0.68   
-237 0.49 0.25 0.32 0.94   
1826 0.97 0.95 0.96 0.71   
Status2 3.00x10-3      
MIAC 0.30      
b. 
Caucasian Maternal  
P-Value Mean Cytokine  Concentrations Marker 
Marker 
& Status1 
Marker 
& MIAC3 
Case 
(N=54)2 
Control 
(N=37)2
Case 
(pg/ml) 
Control 
(pg/ml) 
-7227 0.96 0.62 0.74 0.82 8557.30 3235.10 
-661 8.00x10-3 9.00x10-4 6.00x10-3 0.59   
-636 0.81 0.56 0.49 0.92   
-237 0.25 0.04 0.13 0.64   
1826 0.24 0.06 0.06 0.98   
Status2 0.01      
MIAC 0.41      
c. 
African American Fetal  
P-Value Mean Cytokine Concentrations Marker Marker 
& Status1 
Marker 
& MIAC3 
Case 
(N=26)2 
Control 
(N=68)2
Case 
(pg/ml) 
Control 
(pg/ml) 
-7227 0.30 0.43 0.36 0.04 5055.61 4129.07  
-661 0.59 0.67 0.46 0.40 
-636 0.74 0.40 0.60 0.35 
-237 0.59 0.70 0.47 0.40 
1826 0.55 0.56 0.72 0.71 
 
Status2 0.38     
MIAC 0.19       
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d. 
African American Maternal  
P-Value  Mean Cytokine  Concentrations Marker 
Marker 
& Status1
Marker 
& MIAC3
Case 
(N=30)2
Control 
(N=67)2
Case 
(pg/ml) 
Control 
(pg/ml) 
-7227 0.79 0.41 0.62 0.50 4591.77 4256.86 
-661 0.89 0.46 0.56 0.68   
-636 0.13 0.72 0.96 0.04   
-237 0.89 0.45 0.55 0.68   
1826 0.26 0.88 0.84 0.15   
Status2 0.27      
MIAC 0.34      
1Two way ANOVA with marker and status as covariates 
2One way ANOVA 
3Two way ANOVA with marker and infection as covariates within preterm cases only 
*Caucasians-fetal with genotype and MIAC information = 15, without genotype and MIAC information = 
39; Caucasians-maternal with genotype and MIAC information = 17, without genotype and MIAC 
information = 35; AA-fetal with genotype and MIAC information = 6, without genotype and MIAC 
information = 18; African American-maternal with genotype and MIAC information = 8, without genotype 
and MIAC information = 20 
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*Median cytokine concentrations indicated by a white line in box, lines indicates range of values 
 
Figure 3-3.  Median cytokine concentrations by genotype for IL-6 -661 in Caucasian and African American maternal samples. 
Median shown in the box plots for Caucasians by genotype (a) and African Americans by genotype (b). Caucasians by genotype and 
MIAC status is shown in (c) and African Americans by genotype and MIAC status is shown in (d).   
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Discussion 
 A case-control association study was performed to examine genetic variations in 
the IL-6 and IL-6R genes in efforts to explain ethnic disparity in the PTB rate between 
African Americans and Caucasians. Our data demonstrate that African Americans and 
Caucasians differ in allele, genotype, and haplotype frequencies.  Additionally one IL-6R 
marker (37672) was found to statistically associate between cases and control within 
African American maternal samples. Our data also provide preliminary evidence that IL-
6 AF concentration differs according to promoter variants in the IL-6 gene in Caucasian 
cases and that there is evidence for an interaction between maternal genotype and case-
control and MIAC status in Caucasians, but not in African Americans.  
With respect to patterns of genetic variation our results are very similar to 
previously published findings that found allele and genotype differences between 
Caucasians and African Americans for one of the SNPs we analyzed (rs1800795, which 
is typically referred to by its location to the transcriptional start site C-174G) (Cox et al., 
2001;Hassan et al., 2003;Hoffmann et al., 2002). For example, in Cox et al the C allele 
frequency was reported as 0.35 in Caucasians and 0.09 in African Americans. We found 
that the C allele frequency was 0.37 in cases and 0.34 in control Caucasians and 0.08 in 
African American cases and 0.11 in African American controls (Cox et al., 2001), 
indicating that ethnicity correlates with differences in IL-6 gene variation. Our study, 
however, is more comprehensive than previously published ones in that we examined 
more markers and include both maternal and fetal samples.  We, therefore, extended the 
findings to demonstrate that in both IL-6 and IL-6R there are many significant 
differences between African Americans and Caucasians. In addition, we identified 
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significant differences in haplotype frequencies in both maternal and fetal samples in 
both cases and controls between the two groups.  Our data provide substantial evidence 
of ethnic differences in these genes. 
To assess whether the differences we found are in line with overall genetic 
differences between Caucasians and African Americans, a χ2 test comparing allele 
frequencies between African Americans and Caucasians was performed on all SNPs 
available on the Perlegen SNP genotype database (Hinds et al., 2005).  Analyses of allele 
frequency differences between African Americans and Caucasians, using SNP genotype 
data available from the Perlegen database, demonstrate that 41.98% (p < 0.05) of SNPs 
differ between these groups.  These p-values were not corrected for multiple testing. In 
our data, all of the SNPs examined demonstrated significant differences in allele 
frequencies between these two ethnic groups, and 7 of 8 did so at the genotype level, in at 
least one comparison. This is more than double the expected number of allele differences, 
indicating that the loci we analyzed differ between the ethnic groups more than expected 
from the genomic background. 
The results from the single locus case-control analyses identified a single SNP at 
37672 associated with PTB in IL-6R for both allelic and genotypic frequencies in African 
American mothers, although this result was not corrected for multiple comparisons.  No 
significant haplotype associations were observed. These results are suggestive of the 
limitations of single locus associations in a complex phenotype such as PTB. It is 
possible that even though the genetic variants we studied affect PTB, they do so only in 
the context of other variants or other endogenous or exogenous risk factors. For example, 
we have already indicated that a multilocus interaction between TNF-α, IL-6 and IL-6R 
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genes are predictive of ~65% PTB in Caucasian women (Menon et al., 2006b). Other 
studies have documented that the effect of single promoter SNPs in IL-1β have different 
effects depending on what other SNPs are present elsewhere in the promoter region 
(Chen et al., 2006).  
In addition to examining allele, genotype, and haplotype frequencies for 
association with PTB, we looked at the relationship between genotype, case status, and 
IL-6 AF concentration. We identified a significant association between IL-6 
concentration and marker -661 in Caucasian maternal cases; this association is still 
significant after an FDR correction for multiple testing.  This finding has several potential 
implications for the role of IL-6 on PTB.  It suggests that AF IL-6 concentration is more 
closely associated with maternal than fetal genotype. However, the association with 
cytokine phenotype is not universal but differs by ethnicity and case status, indicating 
that other factors interact with these parameters to affect AF IL-6 concentration.  
Cytokine analyses examining the effect of marker and MIAC status within case 
samples also revealed an association at IL-6 marker -661.  This result remained 
statistically significant after an FDR correction, and is consistent with the interpretation 
that the IL-6 AF association between -661 and Caucasian cases is due primarily to MIAC 
status.  Interestingly, a marginally significant association was also found at C-237G in 
Caucasians that was previously found to associate with PTB (Simhan et al., 2003).  In our 
study, we found that C-237G and -661 are in strong LD. It is therefore likely that the 
previous association with C-237G may have actually been due to the effects of -661 or 
another SNP in very strong LD with it because -661, but not C-237G, significantly 
associates with AF concentrations.   
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The association of cytokine concentration with -661 genotype and MIAC and 
cytokine concentration differences seen between term and PTB individuals at -661 
suggests that an interaction between maternal genotype and environment (MIAC) may in 
fact be important in PTB. These results have several implications for the understanding of 
the mechanism of PTB.  First, our findings are supportive of a maternal genetic 
contribution to AF IL-6. This may be because maternal inflammatory cells (such as 
macrophages and NK cells) present in AF may function as major contributors of AF IL-6. 
Second, it suggests that IL-6 genotype may affect pregnancy outcome as indicated by 
previous studies (El-Bastawissi et al., 2000;Romero et al., 1990), but that the effects are 
not strong independent predictors of clinical phenotype, especially in the absence of an 
environmental factor such as MIAC.  Instead, IL-6 concentration is more directly 
associated with SNP genotype as a product of gene by environment interaction, and that 
the genotype explains IL-6 concentration only as part of an interaction network with 
either other unstudied SNPs in this or other genes and/or environmental factors. 
Moreover, this association and interaction is limited to Caucasians making this finding a 
potentially important basis for ethnic disparity studies in PTB.  
It is clear from our data that the distribution of genetic variation at the IL-6 and 
IL-6R genes differs significantly between Caucasians and African Americans. Given 
these findings and those of previous researchers it is reasonable to hypothesize a potential 
role for these genes in the disparity in PTB between Caucasians and African Americans. 
Such a conclusion is also supported by the relationship that we documented between 
genotype at an IL-6 promoter and AF IL-6 concentration in some but not all of our 
comparisons. Evidence for ethnic specific association with concentration provides even 
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more support for this hypothesis.  However, although these data alone do not support a 
role for these genes in PTB, in conjunction with other genetic and physiological data the 
results strongly suggest a plausible functional role for them. In addition, our data provide 
a good baseline for understanding the patterns of variation in these populations that will 
be useful in future genetic epidemiological studies of this important phenotype.  
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B.  Haplotypes in Interleukin-6 (IL-6) and Receptor (IL6-R) Spontaneous Preterm 
Birth (PTB) Candidate Genes Associate with Amniotic Fluid Protein Levels 
 
 
Introduction 
In a previous study, we examined a small subset of SNPs in IL-6 and IL-6R and 
found an association between AF IL-6 protein levels and a marker in the promoter region 
of IL-6, rs1800797 (G-661A), but only in Caucasian PTB (Velez et al., 2007a).  The 
association between AF IL-6 concentrations and genotype at G-661A also differed 
between PTB with and without MIAC, showing evidence of a gene-environment 
interaction. This marker was also in LD with the previously described C-174G variant 
(described in Chapter II), indicating that a haplotype effect may account for the observed 
association with AF IL-6 concentrations.  Support for this hypothesis was further 
provided by a report that haplotypes in the promoter region of IL-6, and not individual 
SNPs, control IL-6 gene expression (Terry et al., 2000).  In the present study we analyzed 
tag SNPs in the IL-6 and IL-6R genes to better assess the relationship between AF IL-6 
concentrations and genetic variation in the context of PTB. We focus on haplotype 
variation, as haplotype analyses may be able to better detect variants of etiological 
significance (Johnson et al., 2001).  Given the disparity in PTB rates, we analyzed 
African American and Caucasian samples separately to provide insight into haplotype 
diversity and association across different ethnic groups. Specifically, we examined 
maternal and fetal DNA from PTB (cases) and term (controls) for single locus and 
haplotype associations within the IL-6 and IL-6R genes, using both dichotomous (case 
vs. control) and continuous outcome (AF IL-6 concentration).    
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Materials and Methods 
Study population 
 African American and Caucasian subjects from Centennial Women’s Hospital in 
Nashville, TN were used in the present study.  Please refer to Chapter III part A for a 
complete description of subject recruitment and ascertainment. 
Demographic and clinical characteristics 
The total number of DNA samples included maternal and fetal samples from 
Caucasians (145 case and 194 control maternal; 140 case and 179 control fetal) and 
African Americans (75 case and 191 control maternal; 65 case and 183 control fetal).   
DNA sampling and genotyping 
DNA was isolated from maternal and fetal blood samples using the Autopure 
automated system (Gentra Systems (Minneapolis, MN)).   
           A total of 30 SNPs were screened in IL-6 and IL-6R genes (8 in IL-6 and 22 in IL-
6R). We selected SNPs from a previously published publication (Velez et al., 2007a) 
(Chapter III part A) and additional SNPs based on their ability to tag surrounding variants 
from the HapMap (http://www.hapmap.org). The criteria for Caucasian tag SNPs were a 
minor allele frequency (MAF) of 0.07 and for African Americans a MAF of 0.20.  For 
both we used an LD cutoff of r2 ≥ 0.80.  The rs numbers of SNPs from the National 
Institute of Health (NIH) dbSNP database, chromosome, base pair (bp) position on 
chromosome, and SNP functions are shown in Table 3-7. We did not use functional 
significance of SNPs as selection criteria with the exception of IL-6 C-237G (rs1800795 
also reported as C-174G) that was previously shown to associate with PTB and IL-6 
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expression (Simhan et al., 2003). Genotyping was performed using the Illumina 
GoldenGate genotyping system (Illumina, San Diego, CA)   
Cytokine measurements 
IL-6 concentrations in the AF were measured by multiplex assay (Biosource 
International, Camarillo, CA), using LuminexTM (Austin, TX).  The details of the assay 
procedure and details about the AF sample collection can be found in Chapter III part A.   
AF samples were measured from Caucasian (105 cases and 100 controls) and African 
American mothers (41 cases and 91 controls).  Among these the following had genetic 
data:  Caucasians (82 maternal cases and 40 maternal controls; 78 fetal cases and 36 fetal 
controls); African Americans (33 maternal cases and 57 maternal controls; 33 fetal cases 
and 57 fetal controls). 
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Table 3-7.  SNP positions and functions 
Gene rs# Position (bp) Relative position1 Function 
rs1880243 22532895 -7227 Promoter 
rs12700386 22536249 -3873 Promoter 
rs1800797 22539461 -661 Promoter 
rs1800796 22539486 -636 Promoter 
rs1800795 22539885 -237 Promoter 
rs2069840 22541812 1690 Intron 
rs1554606 22541947 1825 Intron 
IL-6 
(Chromosome 7) 
rs11766273 22548903 8781 3' UTR 
rs952146 151182001 -9178 Promoter 
rs1552481 151189426 -1753 Promoter 
rs6427641 151193559 2380 Intron 
rs11265610 151193857 2678 Intron 
rs1386821 151195122 3943 Intron 
rs4075015 151202269 11090 Intron 
rs4601580 151207490 16311 Intron 
rs4845618 151213088 21909 Intron 
rs6687726 151213393 22214 Intron 
rs7549338 151217453 26274 Intron 
rs4553185 151224028 32849 Intron 
rs4845622 151224492 33313 Intron 
rs4845623 151228850 37671 Intron 
rs4537545 151231952 40773 Intron 
rs4845625 151235140 43961 Intron 
rs4845374 151240020 48841 Intron 
rs11265618 151243165 51986 Intron 
rs10752641 151245115 53936 Intron 
rs4329505 151245493 54314 Intron 
rs2229238 151250969 59790 Exon 
rs4072391 151251953 60774 Exon 
IL-6R 
 (Chromosome 1) 
rs7526293 151257282 66103 3' UTR 
1Position relative to translation start site 
 
 
Statistical analysis 
Shapiro-Wilks tests of normality were performed on gestational age, gestational 
weight, APGAR 1 (1 minute after birth), APGAR 5 (5 minutes after birth), maternal age, 
and IL-6 cytokine concentration.  All measurements deviated significantly from 
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normality with the exception of maternal age; as a result Mann-Whitney two-sample rank 
sum tests (Hollander and Wolfe, 1999) were used to test for statistical differences 
between medians of cases and controls of these variables; t-tests were used to test for 
statistical differences between case and control means for maternal age. STATA 9.0 
statistical software (StataCorp, 2007) (College Station, TX) was used for all analyses.   
Statistical tests for differences in single locus allele and genotype frequencies 
between ethnic groups and deviations from HWE were performed by the use of 
Powermarker statistical software (Liu and Muse, 2005;Zaykin et al., 2002).  Statistical 
significance for these analyses was determined using Fishers Exact tests.    
Pairwise LD was characterized and haplotype frequencies were calculated using 
Powermarker (Liu and Muse, 2005;Zaykin et al., 2002)  and HaploView (Barrett et al., 
2005) statistical software.  Standard summary statistics D’ and r2 were calculated using 
HaploView (Devlin and Risch, 1995).  Haplotype blocks were assigned using the D’ 
confidence interval algorithm created by Gabriel et al (2002) (Gabriel et al., 2002).  Both 
Powermarker and HaploView use an EM algorithm to determine haplotype frequency 
distributions when phase is unknown.  The Powermarker haplotype trend analysis was 
performed with outcome as both dichotomous and continuous with 2, 3, and 4 marker 
sliding windows.  A log transformed cytokine concentration was used for these analyses 
because the untransformed data were not normally distributed as assessed by a Shapiro-
Wilks test and examination of distribution.  This analysis is a regression approach to test 
haplotype-trait association.  Haplotype trend analyses produce global p values for tests of 
haplotype associations (whether there is a different trend in haplotype frequency 
distributions between cases and controls for a dichotomous outcome or between different 
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strata of continuous outcomes).  We performed analyses for cytokine concentrations 
initially on pooled cases and controls in order to narrow down the regions of interest for 
follow up with haplotype analyses, stratified by status. This was done under the 
presumption that pooled analysis would reveal most haplotype associations.  For 
continuous outcomes, within each race p values were calculated within pooled cytokine-
genotype data, then within each status group, and finally within cases with and without 
MIAC.   
For case-control analyses the haplotypes with the most significant global 
associations were analyzed for haplotype specific effects.  This included the calculation 
of OR for each haplotype, as well as determination of case and control haplotype 
frequencies.  The highest frequency haplotype was used as the reference haplotype 
 
Table 3-8.  Clinical and demographic characteristics 
African American Caucasian 
Variable Case 
Mean(SD) or 
Median[IQR] 
Control 
Mean(SD) or 
Median[IQR] 
P-
Value 
Case 
Mean(SD) or 
Median[IQR] 
Control 
Mean(SD) or 
Median[IQR] 
P-
Value 
       
Gravidity  
(number of births) 
2  
[1-6] 
2 
[1-13] 0.96 
2 
[1-9] 
2 
[1-8] 0.02 
Gestational Age 
 (days) 
242 
[154-255] 
273 
[257-290] <0.001 
239 
[166-255] 
274 
[257-296] <0.001 
Gestational Weight 
(grams) 
2240 
[462-3782] 
3190 
[1952-4517] <0.001 
2150 
[370-3790] 
3446 
[2100-4661] <0.001 
APGAR 1 8 [1-9] 
8 
[3-9] <0.001 
8 
[1-9] 
8 
[4-9] <0.001 
APGAR 5 9 [6-10] 
9 
[7-10] <0.001 
9 
[1-9] 
9 
[7-10] <0.001 
Maternal Age 
(years) 
25.32 
(5.53) 
25.22 
(5.29) 0.88 
27.33 
(6.30) 
28.39 
(5.80) 0.10 
Smoking (%) 36.67% 21.25% 0.08 31.77% 14.74% <0.001 
       
*Means are reported with standard deviations reported in parentheses and medians are reported with 
interquartile ranges in brackets 
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Results 
Baseline characteristics 
As expected by the case status, significant differences between cases and controls 
were observed in both Caucasians and African Americans for gestation age (days) 
(Caucasians p < 0.001; African Americans p < 0.001), birth weight (grams) (Caucasians 
p < 0.001; African Americans p < 0.001), APGAR 1 (1 minute after birth)(Caucasians p 
< 0.001; African Americans p < 0.001), APGAR 5 (5 minutes after birth)(Caucasians 
p<0.001; African Americans p < 0.001).  Caucasians also had significant differences for 
gravidity (p = 0.02) and smoking (p < 0.001) (Table 3-8).   
Single locus associations 
 Tests for HWE were performed for all SNPs in case and control samples 
separately in each population (Table 3-9). Among the 120 tests for deviations from HWE 
8 deviated in cases (p < 0.05). In controls, of the 120 HWE tests, 17 deviated from HWE 
(p < 0.05), and one had a p <0.01. It is of note that for most situations where control p < 
0.05 for HWE tests there is evidence that the inbreeding coefficients (F) were in opposite 
directions in cases and controls.  For example, examining the ‘F’ in Caucasian maternal 
controls revealed that four of the markers that deviated from HWE in IL-6R showed that 
the directions of deviations from HWE was opposite to that of cases (rs4845622 - PTB F 
= -0.07 term F = 0.16; rs4845623 - PTB F = -0.06, term F = 0.18; rs5437545 – PTB F = 
0.19, term F = -0.002; rs4329505 - PTB F = 0.04, term F = -0.13).  These results suggest 
that the deviations are not likely due to genotyping error, as cases and controls were 
mixed in the same plates for genotyping.       
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In Caucasian maternal samples 4 marginally significant allelic associations were 
observed in IL6-R at rs7549338 (p = 0.04), rs4845625 (p = 0.04), rs11265618 (p = 0.05), 
and rs4072391 (p = 0.04) (Table 3-9c).  No statistically significant single locus 
associations were observed in Caucasian fetal samples (Table 3-9c).  African American 
maternal samples had one statistically significant association in IL-6 at rs2069840 (allelic 
association p = 0.03), but in IL-6R there were 8 SNPs with significant associations (either 
for allelic or genotypic association): rs4845618, rs6687726, rs4553185, rs4845622, 
rs4845623, rs4537545, and rs4845625 (Table 3-9d).  African American fetal samples had 
two associated markers in IL-6 (rs1880243 and rs12700386), but none in IL-6R (Table 3-
9d).  
Linkage disequilibrium characterization 
 In Caucasian maternal and fetal DNA samples there is evidence for substantial 
LD in IL-6 in both cases and controls (Appendix Figure 1a-d).  Two IL-6 SNPs in the 5’ 
part of the gene had D’ values of 1.0 in all Caucasian samples (rs1880243-rs12700386), 
although the pattern may be slightly different for other variants between cases and 
controls. As expected African American maternal and fetal samples showed less evidence 
of LD in IL-6. In fact, in the African American samples there was little evidence of LD in 
IL-6. Of particular note, the two most 5’ markers that demonstrated complete LD in 
Caucasians showed no sign of LD in African Americans. 
 IL-6R had strong regions of LD in Caucasians; however, no blocks were 
identified according to the Gabriel et al. (2002) definition (Appendix Figure 2 a-d).  The 
strongest regions of LD were in the 3’ part of the gene between markers rs4845618 and 
rs7526293; weaker pairwise LD was observed in the 5’ region between markers rs952146 
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and rs4075015. Again African American samples had weaker LD in comparison to 
Caucasians; however, several small blocks were identified (Appendix Figure 2 e-h).  
None of the blocks were consistent across status groups.   
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Table 3-9.  Single locus association analysis of maternal and fetal samples 
a. Caucasian IL-6 
Maternal Fetal 
Allele Freq. 1HWE Allele Freq. 1HWE Case-Control 
Association P-value P-Value 
Case-Control 
Association P-value P-Value 
 
IL-6rs# 
 
Allele 
Control Case 
Allele Genotype Control Case 
Control Case 
Allele Genotype Control Case 
rs1880243 A 0.23 0.18 0.10 0.31 0.42 1.00 0.25 0.24 0.79 0.37 0.12 0.49 
rs12700386 G 0.24 0.19 0.18 0.35 0.35 0.80 0.26 0.23 0.52 0.30 0.05 0.62 
rs1800797 A 0.37 0.40 0.52 0.43 0.11 0.86 0.38 0.38 0.87 0.71 0.01 0.19 
rs1800796 C 0.05 0.08 0.11 0.08 0.40 0.21 0.04 0.05 0.46 0.70 0.02 0.32 
rs1800795 C 0.39 0.42 0.30 0.33 0.09 0.87 0.39 0.39 0.93 0.98 0.04 0.08 
rs2069840 G 0.38 0.34 0.26 0.54 0.87 0.72 0.39 0.40 0.87 0.95 0.27 0.16 
rs1554606 T 0.41 0.44 0.39 0.27 0.07 0.62 0.41 0.41 0.93 0.98 0.04 0.09 
rs11766273 A 0.06 0.08 0.55 0.42 0.03 0.58 0.07 0.07 0.76 0.35 0.01 0.15 
b. African American IL-6 
Maternal Fetal 
Allele Freq. 1HWE Allele Freq. 1HWE Case-Control 
Association P-value P-Value 
Case-Control 
Association P-value P-Value 
IL-6 rs# Allele 
Control Case 
Allele Genotype Control Case
Control Case 
Allele Genotype Control Case 
rs1880243 A 0.14 0.16 0.51 0.66 0.22 0.40 0.21 0.11 0.01 0.03 0.37 0.59 
rs12700386 G 0.15 0.18 0.34 0.49 0.77 0.69 0.22 0.13 0.03 0.10 1.00 1.00 
rs1800797 A 0.09 0.07 0.73 0.79 0.63 1.00 0.09 0.07 0.47 0.44 0.37 0.25 
rs1800796 C 0.08 0.09 0.60 0.24 0.01 1.00 0.09 0.07 0.58 0.79 0.04 0.25 
rs1800795 C 0.09 0.08 0.74 0.71 1.00 1.00 0.10 0.08 0.62 0.69 0.38 0.05 
rs2069840 G 0.21 0.13 0.03 0.07 0.02 0.34 0.20 0.16 0.29 0.57 0.82 0.64 
rs1554606 T 0.33 0.33 0.99 0.94 0.52 0.80 0.34 0.36 0.58 0.26 0.87 0.03 
rs11766273 A 0.02 0.02 0.73 0.74 1.00 1.00 0.02 0.02 0.71 0.70 1.00 1.00 
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c. Caucasian IL-6R 
Maternal Fetal 
Allele Freq. 1HWE Allele Freq. 1HWE Case-Control 
Association P-value P-Value 
Case-Control 
Association P-Value P-Value 
IL-6R rs# Allele 
Control Case 
Allele Genotype Control Case
Control Case 
Allele Genotype Control Case 
rs952146 G 0.38 0.37 0.87 0.97 0.44 0.48 0.40 0.38 0.59 0.64 0.53 0.11 
rs1552481 G 0.00 0.01 - - - - 0.00 0.00 - - - - 
rs6427641 G 0.45 0.45 0.94 0.35 0.24 0.31 0.44 0.43 0.72 0.79 0.48 1.00 
rs11265610 C 0.01 0.01 - - - - 0.01 0.00 - - - - 
rs1386821 C 0.20 0.23 0.24 0.55 0.82 0.82 0.18 0.20 0.45 0.48 0.80 0.19 
rs4075015 A 0.42 0.43 0.79 0.23 0.23 0.23 0.41 0.40 0.81 0.45 0.34 0.49 
rs4601580 A 0.40 0.42 0.63 0.24 0.14 0.40 0.47 0.45 0.65 0.92 0.09 0.18 
rs4845618 T 0.39 0.45 0.10 0.21 0.53 0.23 0.44 0.47 0.46 0.68 0.47 0.24 
rs6687726 A 0.39 0.45 0.12 0.24 0.66 0.25 0.46 0.48 0.55 0.87 0.47 0.61 
rs7549338 C 0.36 0.44 0.04 0.06 0.76 0.22 0.44 0.46 0.51 0.70 0.88 0.40 
rs4553185 C 0.38 0.45 0.08 0.15 1.00 0.39 0.45 0.47 0.59 0.85 0.45 0.61 
rs4845622 C 0.45 0.42 0.48 0.09 0.03 0.40 0.40 0.39 0.80 0.51 0.54 0.21 
rs4845623 G 0.47 0.43 0.31 0.07 0.02 0.50 0.42 0.41 0.87 0.23 0.36 0.11 
rs4537545 T 0.46 0.43 0.43 0.17 0.01 1.00 0.41 0.39 0.59 0.18 0.22 0.21 
rs4845625 C 0.37 0.45 0.04 0.10 1.00 0.74 0.44 0.49 0.24 0.45 0.77 0.86 
rs4845374 A 0.18 0.13 0.14 0.11 0.45 0.13 0.15 0.14 0.50 0.68 2.29x10-3 0.27 
rs11265618 T 0.19 0.13 0.05 0.12 0.82 0.48 0.17 0.14 0.38 0.61 0.03 0.14 
rs10752641 G 0.21 0.26 0.08 0.24 0.66 1.00 0.26 0.26 0.92 0.11 0.70 0.03 
rs4329505 C 0.17 0.13 0.12 0.06 0.04 0.53 0.14 0.14 1.00 0.97 0.76 0.47 
rs2229238 T 0.17 0.23 0.06 0.13 0.62 1.00 0.21 0.22 0.69 0.40 0.50 0.22 
rs4072391 T 0.17 0.23 0.04 0.13 0.61 0.83 0.21 0.22 0.66 0.24 0.36 0.31 
rs7526293 T 0.19 0.24 0.09 0.21 0.63 0.82 0.22 0.22 0.86 0.39 0.65 0.32 
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d. African American IL-6R 
Maternal Fetal 
Allele Freq. 1HWE Allele Freq. 1HWE Case-Control 
Association P-value P-Value 
Case-Control 
Association P-value P-Value 
IL-6R rs# Allele 
Control Case 
Allele Genotype Control Case
Control Case 
Allele Genotype Control Case 
rs952146 G 0.40 0.41 0.84 0.71 0.29 0.10 0.38 0.43 0.37 0.52 0.88 0.33 
rs1552481 G 0.19 0.18 1.00 0.79 0.48 0.71 0.17 0.18 0.79 0.92 1.00 1.00 
rs6427641 A 0.31 0.39 0.07 0.14 1.00 0.63 0.34 0.38 0.41 0.55 0.31 0.80 
rs11265610 C 0.28 0.25 0.55 0.24 0.47 0.13 0.25 0.23 0.67 0.55 0.43 0.15 
rs1386821 C 0.10 0.12 0.53 0.10 0.70 0.06 0.11 0.10 0.75 0.64 0.12 0.51 
rs4075015 A 0.11 0.14 0.34 0.12 0.48 0.14 0.12 0.12 1.00 0.64 0.28 0.58 
rs4601580 T 0.43 0.41 0.78 0.42 0.31 0.23 0.41 0.42 0.92 0.60 0.28 0.04 
rs4845618 G 0.46 0.58 0.02 0.03 0.19 0.23 0.44 0.51 0.19 0.30 0.56 0.13 
rs6687726 G 0.38 0.48 0.04 0.09 1.00 0.49 0.38 0.40 0.58 0.78 0.64 0.30 
rs7549338 C 0.38 0.26 0.01 0.02 0.54 0.13 0.40 0.35 0.35 0.27 0.47 0.18 
rs4553185 T 0.39 0.52 4.49x10-3 0.01 0.43 0.27 0.40 0.44 0.42 0.38 0.51 0.46 
rs4845622 C 0.12 0.18 0.08 0.02 0.32 0.06 0.12 0.16 0.19 0.18 0.16 0.68 
rs4845623 A 0.44 0.33 0.02 0.02 0.88 0.12 0.47 0.43 0.54 0.82 0.19 0.44 
rs4537545 C 0.40 0.31 0.05 0.14 1.00 0.61 0.42 0.38 0.54 0.78 1.00 0.80 
rs4845625 T 0.34 0.24 0.03 0.08 0.48 0.35 0.34 0.29 0.34 0.07 0.62 0.02 
rs4845374 A 0.23 0.27 0.29 0.35 0.31 0.56 0.25 0.24 0.91 0.87 0.16 0.75 
rs11265618 T 0.34 0.32 0.63 0.14 0.51 0.03 0.34 0.34 1.00 1.00 0.74 1.00 
rs10752641 G 0.36 0.30 0.21 0.39 0.26 1.00 0.37 0.40 0.56 0.79 0.87 0.60 
rs4329505 C 0.34 0.35 0.75 0.91 0.11 0.31 0.33 0.30 0.59 0.25 0.40 0.04 
rs2229238 T 0.22 0.18 0.23 0.25 0.15 0.69 0.22 0.22 0.90 0.22 0.39 0.07 
rs4072391 T 0.33 0.31 0.70 0.32 0.20 0.41 0.31 0.28 0.51 0.10 0.29 0.07 
rs7526293 T 0.42 0.42 1.00 0.88 0.77 0.33 0.42 0.41 0.84 0.98 0.75 0.63 
1HWE-Hardy-Weinberg equilibrium deviation p-values 
*All significant p values (p <0.05) are labeled in bold 
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Table 3-10.  IL-6 sliding window haplotype analysis results 
a. Dichotomous outcome 
Frequencies 
Population Markers Haplotype 
Cases Controls 
OR 95% CI p Global p 
rs12700386-rs1800797-rs1800796-rs1800795 C-G-G-G 0.35 0.34 1.00 - - 0.05 
 C-A-G-C 0.35 0.35 0.97 0.66-1.42 0.87  
 G-G-G-G 0.15 0.22 0.65 0.33-1.29 0.07  
 C-G-C-G 0.08 0.05 1.57 0.77-3.22 0.18  
Caucasian 
Maternal 
 G-A-G-C 0.05 0.02 2.42 0.92-6.85 0.06  
rs2069840-rs1554606-rs11766273 G-G-G 0.40 0.39 1.00 - - 0.01 
 C-T-G 0.34 0.33 1.01 0.69-1.48 0.97  
 C-G-G 0.18 0.20 0.86 0.56-1.38 0.53  
Caucasians 
Fetal 
 C-T-A 0.07 0.06 1.19 0.58-2.43 0.60  
rs1800795-rs2069840 G-C 0.79 0.72 1.00 - - 0.05 
 G-G 0.13 0.18 0.67 0.37-1.17 0.14  
African American  
Maternal 
 C-C 0.08 0.07 1.01 0.45-2.17 0.97  
rs1880243-rs12700386 C-C 0.80 0.72 1.00 - - 0.02 
 C-G 0.09 0.07 1.15 0.51-2.46 0.70  
 A-G 0.05 0.15 0.32 0.12-0.73 4.00x10-3  
African American  
Fetal 
 A-C 0.07 0.05 1.24 0.48-3.03 0.60  
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b. Cytokine concentration outcome  
Mean Log(pg/ml) Cytokine p 
Population Markers Haplotype 
Case Control (Global(Case/control))1 
rs12700386-rs1800797 G-G 3.58 3.24 0.04 (0.36/0.34) 
 G-A 3.47 2.90  
 C-G 3.41 3.23  
Caucasian  
Maternal 
 C-A 3.44 3.31  
rs1554606-rs11766273 G-G 3.60 3.28 0.05 (0.14/0.51) 
 T-A 3.23 3.06  
Caucasian  
Fetal 
 T-G 3.39 3.26  
rs1554606-rs11766273 G-G 3.46 3.39 0.05 (0.68/0.03) 
 T-A 3.37 2.91  
African American 
Maternal 
 T-G 3.29 3.13  
rs1800797-rs1800796 G-G 3.40 3.19 0.02 (0.58/0.02) 
 G-C 3.30 2.95  
African American  
Fetal 
 A-G 2.99 3.34  
rs1800796-rs1800795 G-G 3.40 3.19 0.02 (0.58/0.16) 
 G-C 2.99 3.34  
African American  
Fetal 
 C-G 3.30 2.95  
1Cytokine p values are presented by global p for the pooled data, followed by p for analyses within cases and within controls 
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Table 3-11.  IL-6R sliding window haplotype analysis results 
a. Dichotomous outcome 
Frequencies Global Population Markers Haplotype 
Cases Controls 
OR 95% CI p 
p 
rs4845625-rs4845374 T-T 0.41 0.45 1.00 - - 0.02 
 C-T 0.45 0.37 1.34 0.95-1.89 0.08  
Caucasian 
Maternal 
 T-A 0.13 0.18 0.80 0.49-1.29 0.34  
rs4075015-rs4601580-rs4845618 T-A-T 0.30 0.31 1.00 - - 0.01 
 T-T-G 0.26 0.25 1.07 0.63-1.82 0.79  
 T-A-G 0.20 0.18 1.12 0.62-1.99 0.70  
 T-T-T 0.10 0.15 0.68 0.32-1.36 0.24  
 A-A-G 0.07 <0.001 - - 1.00x10-3  
 A-A-T 0.02 0.08 0.17 0.02-0.71 0.01  
African American 
Maternal 
 A-T-G 0.06 0.02 2.89 1.00-9.12 0.05  
rs4845625-rs4845374 C-T 0.47 0.42 1.00 - - 0.04 
 T-T 0.29 0.34 0.76 0.46-1.25 0.25  
African American 
Fetal 
 C-A 0.24 0.25 0.86 0.51-1.46 0.56  
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b. Continuous cytokine concentration outcome 
Mean Log(pg/ml)   Cytokine p 
Population Markers Haplotype 
Case Control (Global(Case/control))1 
rs4601580-rs4845618 A-G 3.67 3.22 1.60x10-3 (0.04/0.63) 
 A-T 3.50 3.19  
 T-G 3.43 3.24  
Caucasian  
Fetal 
  
  T-T 3.30 3.43  
A-G-G-G 3.77 3.13 2.30x10-3(0.03/0.05) 
A-G-A-G 3.45 3.04  
A-T-G-G 3.59 3.29  
A-T-G-C 3.50 3.20  
T-G-A-G 3.10 3.30  
T-T-G-G 2.65 2.86  
African American 
Maternal 
  
rs4601580-rs4845618-
rs6687726-rs7549338 
  
  
T-T-G-C 3.84 3.49  
rs4537545-rs4845625 T-T 3.40 3.23 0.02 (0.33/0.08) 
 T-C 3.27 3.17  
African American 
Fetal 
    C-C 3.55 2.91  
1Cytokine p values are presented by global p for the pooled data, followed by p for analyses within cases and within controls 
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Table 3-12.  MIAC analyses of haplotypes identified with continuous outcome 
a.  IL 6 
Mean Log (pg/ml) P-Values 
Population Markers Haplotype 
MIAC1 No MIAC2 MIAC1 No MIAC2 
rs12700386-rs1800797 G-G 3.60 3.55 0.64 0.29 
 C-G 3.69 3.35   
 C-A 3.53 3.39   
Caucasian  
Maternal 
 G-A - 3.48   
rs1554606-rs11766273 G-G 3.82 3.51 0.11 0.44 
 T-A 3.44 3.11   
Caucasian  
Fetal 
 T-G 3.51 3.38   
T-G 3.65 3.39 0.29 0.84 African American 
Maternal 
rs1554606-rs11766273 
G-A 3.44 3.24   
rs1800797-rs1800796 A-G - 2.99 <1.00x10-3 0.72 
 G-C - 3.30   
African American  
Fetal 
 G-G 3.50 3.35   
rs1800796-rs1800795 C-G - 3.30 <1.00x10-3 0.72 
 G-C - 2.99   
African American  
Fetal 
 G-G 3.50 3.35   
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b.   IL6-R 
Mean Log (pg/ml) P-Values 
Population Markers Haplotype 
MIAC1 No MIAC2 MIAC1 No MIAC2 
rs4601580-rs4845618 A-G 3.56 3.72 0.66 0.16 
 A-T 3.69 3.45   
 T-G 3.59 3.40   
Caucasian   
Fetal 
 T-T 3.75 3.15   
rs4601580-rs4845618-rs6687726-rs7549338 A-G-G-G 4.16 3.63 0.69 0.17 
 A-T-G-G 3.30 3.50   
 T-G-A-G 3.85 3.44   
 T-T-G-C 3.49 3.50   
 A-G-A-G 3.07 3.11   
African American  
Maternal 
 A-T-G-C 3.29 2.54   
rs4537545-rs4845625 T-T 3.45 3.43 0.06 0.31 
 T-C 3.61 3.19   
African American  
Fetal 
 C-C - 3.00   
1MIAC-8 African American maternal, 7 African American fetal, 22 Caucasian maternal, 19 Caucasian fetal 
2No MIAC- 25 African American maternal, 26 African American fetal, 59 Caucasian maternal, 57 Caucasian fetal 
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IL-6 haplotype and case-control status 
Sliding window haplotype analyses in Caucasian maternal samples found that 
haplotypes defined by SNPs rs12700386-rs1800797-rs1800796-rs1800795 associated 
with pregnancy outcome (global p = 0.05). The G-G-G-G (OR 0.65 [CI 0.33-1.29], p = 
0.07) and the G-A-G-C haplotype (OR 2.42 [CI 0.92-6.85], p = 0.06) showed the 
strongest associations (Table 3-10a).  Caucasian fetal sample analyses found association 
with haplotypes defined by rs2069840-rs1554606-rs11766273 (global p = 0.01) (Table 3-
10a), but no single haplotype showed significant association. 
In African American maternal samples an association for a two SNP haplotype 
defined by rs1800795-rs2069840 (global p = 0.05) was found, but no single haplotype 
significantly associated (Table 3-10a).  African American fetal analyses found an 
association with SNPs rs1880243-rs12700386 (global p = 0.02).  This result is due to the 
A-G (OR = 0.32 [CI 0.12-0.73], p = 4.00x10-3) haplotype that confers a significant 
protective effect relative to the most common haplotype, C-C.   
IL-6 haplotype and IL-6 concentration 
In Caucasian maternal samples haplotypes defined by rs12700386-rs1800797 
associated with AF log transformed cytokine concentrations in pooled analyses of cases 
and controls (p = 0.04) but showed no significant association when stratified by status 
(cases p = 0.36; controls p = 0.34) (Table 3-10b).  Of interest is the observation that 
rs12700386-1800797 haplotypes have apparently different patterns of association 
depending on clinical status. The G-A haplotype associated with a higher concentration 
in cases [3.47 log(pg/ml)] compared to controls [2.90 log(pg/ml)]). These two markers 
also have different LD structure in cases and controls with D’ = 0.75 in controls and D’ = 
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0.36 in cases (Appendix Figure 1a and b).  Caucasian fetal sample haplotype analyses 
found that rs1554606-rs11766273 associated with IL-6 concentrations (pooled p = 0.05) 
however this is probably due to the fact that the haplotype associations trended in the 
same direction in cases and controls even though they were not significant (cases p = 
0.14; controls p = 0.51) (Table 3-10b).   
Haplotype analyses in African Americans revealed associations in both maternal 
and fetal samples with two site haplotypes (Table 3-10b). In maternal samples 
rs1554606-rs11766273 haplotypes associated with IL-6 concentration in controls 
(p=0.03) but not in cases (p = 0.68).  Haplotypes for rs1554606-rs11766273 had different 
trends in IL-6 concentrations in cases and controls, with T-A having the lowest IL-6 
concentration in controls [2.91 log(pg/ml)]) but T-G having the lowest concentration in 
cases [3.29 log(pg/ml)]).  These two SNPs are in high LD in both cases and controls (D’ 
= 1.00), but rs11766273 has low MAF (0.02) in both cases and controls in African 
Americans.  For African American fetal sample haplotype analyses the rs1800797-
rs1800796 haplotype associated with IL-6 concentrations (pooled cases and controls p = 
0.02; cases p = 0.58; controls p = 0.02) as did rs1800796-rs1800795 (pooled cases and 
controls p = 0.02; cases p = 0.58; controls p = 0.16) (Table 4b).  In both the rs1800797-
rs1800796 and rs1800796-rs1800795 IL-6 haplotype mean concentrations trended in 
opposite directions with respect to case status. For example, for rs1800796-rs1800795 the 
G-G haplotype has the lowest concentration in cases [2.99 log(pg/ml)]) but the highest in 
term [3.34 log(pg/ml)]).  The three marker haplotype including rs1800797-rs1800796-
rs1800795 did not associate with AF IL-6. 
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IL-6R haplotype analyses and case-control status 
In Caucasian maternal samples IL-6R haplotype rs4845625-rs4845374 showed 
significant association with PTB (global p = 0.02) (Table 3-11a).  The C-T haplotype had 
the strongest association (OR = 1.34 [CI = 0.95-1.89 [, p = 0.08).  No fetal haplotype 
associated with pregnancy outcome.   
In African American mothers a three SNP haplotype associated with cases, 
rs4075015-rs4601580-rs4845618 (global p = 0.01) (Table 3-10a).  In addition to there 
being global significance, three individual haplotypes associated:  A-A-G (frequency 0.07 
in cases, undetected in controls, OR uncalculated, p < 0.001), A-A-T (OR = 0.17 [CI 
0.02-0.71]; p = 0.01), and A-T-G (OR = 2.89 [CI 1.00-9.12], p = 0.05). These differences 
appear to be driven by rs4845618 as indicated in the single SNP association (Table 3-8c). 
In African American fetal samples rs4845625-rs4845374 haplotypes associated with PTB 
(global p = 0.04), but no haplotype associated individually.   
IL-6R haplotype and IL-6 concentration 
Haplotype analyses of IL-6R found several haplotypes associated with IL-6 
concentration, although none for Caucasian maternal haplotypes. A two SNP Caucasian 
fetal haplotype at rs460158-rs4845618 associated significantly with IL-6 concentration 
(pooled p = 1.60x10-3; case p = 0.04; control p = 0.63) (Table 3-11b).  As in some 
situations above trends differed between cases and controls; in cases the A-G haplotype 
had higher IL-6 concentration (3.67 log(pg/ml)) compared to controls (3.22 log (pg/ml)).  
 In African American maternal samples haplotypes defined by rs4601580-
4845618-rs6687726-rs7549338 significantly associated with IL-6 concentration (pooled 
p = 2.30x10-3; case p = 0.03; control p = 0.05). The analysis provided evidence for 
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similar trends in mean cytokine concentrations between cases and controls (Table 3-11b).   
In African American fetal sample haplotypes there was an association with rs4537545-
rs4845625 and IL-6 concentration (pooled p = 0.02; case p = 0.33; control p = 0.08).  
Case and control mean cytokine concentrations trended in different directions.   
Haplotype-MIAC analyses 
Cases stratified by MIAC were examined for IL-6 and IL-6R haplotype 
association (Table 3-12) in IL-6 and IL-6R.  Only African American fetal samples 
showed evidence for differences in haplotype associations between cases with and 
without MIAC for IL-6 rs1800797-rs1800796 (MIAC p = < 1.00x10-3; no MIAC p = 
0.72) and rs1800796-rs1800795 (MIAC p = < 1.00x10-3; no MIAC p = 0.72) and in IL-
6R rs4537545-rs4845625 (MIAC p = 0.06; no MIAC p = 0.31). 
 
Discussion 
 This study examined 30 polymorphisms in IL-6 and IL-6R for association with 
PTB as an extension of our previous study of many fewer SNPs in these genes with the 
intent of assessing haplotype association (Velez et al., 2007a) (Chapter III part A).  This 
analysis was performed with the intention of identifying common regions in both IL-6 
and IL-6R across African Americans and Caucasians that influences risk of PTB.  Several 
statistically significant haplotypes were found in both Caucasians and African Americans 
with both dichotomous and continuous cytokine outcome; however, three regions in the 
two genes appear to be shared in several of the comparisons (Figure3- 4a and b).   
In the IL-6 gene one small region in the promoter region including markers 
rs1800797-rs1800796-rs1800795 showed significance in both Caucasian and African 
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American maternal and African American fetal samples; two significant associations 
were observed with IL-6 concentration and two with PTB.  In our previous report one 
SNP in this region showed evidence for association with IL-6 concentration (rs1800797) 
(Velez et al., 2007a).  African American fetal samples had two independent overlapping 
haplotypes and Caucasian maternal samples had one overlapping haplotype in this region.  
In Caucasians SNPs in this region are in very strong LD (pairwise D’ 0.96-1.00).  In 
African American maternal and fetal samples only two of these markers have strong 
pairwise LD (rs1800797-rs1800795, D’ = 1.00), with stronger overall LD in this region 
in controls relative to cases in both maternal and fetal samples.  This indicates that there 
may be an effect caused by either an ungenotyped variant in the region or a haplotype 
effect. 
Our results are in agreement with a previously published report of IL-6 promoter 
haplotypes (Terry et al., 2000).  This study examined rs1800797, rs1800796 and 
rs1800795 in Caucasians in which haplotypes within the IL-6 promoter region (including 
rs1800797, rs1800796, rs1800795 and -373AnTn) were shown to influence IL-6 
transcription.  The results demonstrated that upon IL-1 stimulation IL-6 expression is 
greatest with the G-G-G (rs1800797-rs1800796-rs1800795) haplotype but this same 
haplotype shows lowest IL-6 concentration in the absence of stimulation (Terry et al., 
2000).  In our study this haplotype did not associate with IL-6 concentration; however, in 
Caucasian maternal samples markers rs12700386-rs1800797-rs1800796-rs1800795 
associated with PTB status with the G-G-G-G haplotype being protective. African 
American fetal data also associated with IL-6 concentration with two overlapping 
haplotypes (rs1800797-rs1800796; rs1800796-rs1800795).  The fact that African 
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American fetal samples have two haplotypes rather than one may suggest a 
recombination event split a single functional haplotype into two independent functional 
haplotypes. Across the analyses, three markers in this haplotype (rs1800797-rs1800796-
rs1800795) were found to have the most overlapping associations, suggesting that a 
variant tagged by this haplotype may be playing an important regulatory in AF IL-6 
production in cases, regardless of ethnicity. 
In IL-6R two regions (rs4601580-rs4845618-rs6687726 and rs4537545-
rs4845625-rs4845374) associated with a phenotype in more than one analysis. Both 
regions contain intronic and exonic markers (Figure 3-4b).  These two regions had the 
strongest overall haplotype associations and also had more associations in African 
Americans than Caucasians, especially with IL-6 concentration as outcome.  Of note, two 
haplotypes in maternal Caucasian samples (rs4845618-rs6687726-rs7549338, p = 0.06 
and rs4537545-rs4845625, p = 0.04 both for PTB) and one in fetal Caucasian samples 
(rs453745-rs4845625, p = 0.02 IL-6) that are not represented in the figures also had some 
evidence for association in these two regions. Although these were not the most strongly 
associating haplotypes, they were significant or of borderline significance, and these data 
further support the likelihood that these regions of the IL-6R gene affect phenotype. 
Comparing the strength of the results in the IL-6 gene to that of IL-6R indicates 
that IL-6R rather than IL-6 has more influence on AF IL-6 concentration.  This may be 
because these SNPs are in close proximity and in LD with functional/coding parts of the 
gene. For example, markers rs4845618 and rs6687726 are in close proximity to several 
exons and rs4537545-rs4845625-rs4845374 have exons between them.  The CEU LD 
structure from the HapMap for IL-6R markers shows that both of the interesting regions 
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in IL-6R are all in LD and in close proximity to several coding variants.  The part of the 
IL-6R gene from rs4537545-rs4845625-rs4845374 was found to associate with increased 
IL-6 concentration (Rafiq et al., 2007). This study found that a variant in IL-6R 
(rs4537545) associated with both IL-6 and IL-6R serum concentrations; this variant did 
not associate with inflammatory status. It was observed that these markers associate with 
several metabolic traits, e.g. diabetes, and marginally associates with cardio-vascular 
disease and asthma.  Another recent study found that IL-6 concentrations are more 
associated with IL-6R variants than IL-6 gene variants (Reich et al., 2007).  This study 
identified a variant (rs8192284 – between markers rs4845374 and rs11265618) in 
Caucasians and African Americans that associated with IL-6 concentrations; this marker 
is located downstream of in the 3’ most region in IL-6R that we identified (Reich et al., 
2007). 
In our haplotype/AF analyses opposite trends in AF IL-6 concentrations were 
observed between cases and controls for some of the same haplotypes.  This indicates 
that the same haplotypes can affect IL-6 concentrations as a function of status and 
ethnicity.  Haplotype trend regression analyses within cases and controls for AF 
concentrations revealed different trends in AF haplotype levels between ethnic groups in 
cases with MIAC further supporting this conclusion. 
We were underpowered to detect an association with our MIAC subset; however, 
we observed association between IL-6R haplotypes, MIAC, and IL-6 concentrations in 
African Ameircan cases with MIAC, but not in those without MIAC.  No differences 
were seen for cases with and without MIAC for any of the haplotypes associated with 
cytokine concentration as outcome.  This is indicative of environmental influence (i.e. 
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infection) on IL-6 production in African American fetal samples but not in the others.  
However, in previous studies we observed that at the single SNP level MIAC plays a 
strong regulatory role on IL-6 production within Caucasian maternal samples (Velez et 
al., 2007a) especially at rs1800797.  Interestingly, rs1800797 overlaps with the 
haplotypes found to associate with MIAC in African American fetal data.  These data 
further support the hypothesis that a gene-environment interaction is occurring in PTB in 
both African American fetal and Caucasian maternal genes; the mechanism, however, is 
unclear but is consistent with a strong regulatory role by the markers within the region 
including rs1800797 in the IL-6 gene and this result is consistent across ethnic groups. 
Previous results and our present study indicate that both IL-6 and IL-6R haplotype 
variation contribute to variations in AF IL-6 concentrations in both ethnic groups.  
Different maternal and fetal associations were observed in the two groups.  Our 
dichotomous and continuous analyses were consistent for variants in IL-6 and/or elevated 
IL-6 levels being a risk factor for PTB.  Results also suggest that some haplotype effects 
may be common across African Americans and Caucasians, although our analyses were 
designed to increase chances to detect commonalities. Our data also support the 
hypothesis that the regulation by genetic variation is dependent on a variety of other 
factors such as infection, but others may be operating, including patterns of variation at 
other genes related to inflammatory processes. Demonstrating the role of other factors 
will however require further investigation. Although we identified interesting statistical 
associations, the interpretation of their biological relevance is currently unclear.  
Functional studies will need to be performed to assess the biological implications of these 
associations and these gene regions in IL-6 and IL-6R.  In conclusion, haplotype 
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association analyses revealed three regions in IL-6 and IL-6R that associate with AF IL-6 
in PTB.   
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Figure 3-4.  Haplotype summary 
Dark lines with bounded vertical lines indicate haplotypes that were associated with 
dichotomous outcome and dashed lines indicate haplotype that were associated with 
continuous outcome, dark bounded lines on the x-axis indicate regions of overlapping 
haplotype associations.   Introns are labeled with light grey, promoter with dashed lines, 
exons with solid black, and 3’UTR with dark grey.  a) Results for haplotype analyses for 
IL-6; b) results for haplotype analyses for IL-6R. 
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 CHATPER IV 
 
A LARGE SCALE HIGH-THROUGHPUT CANDIDATE GENE ASSOCIATION 
STUDY OF PRETERM BIRTH IN CAUCASIANS AND AFRICAN-AMERICANS 
 
 
Overview Chapter IV Part A and B 
A large-scale candidate gene association study was performed examining 1536 
SNPs in 130 novel and previously tested candidate genes from established PTB 
pathways. Maternal and fetal DNA from 370 Caucasian birth-events (172 cases and 198 
controls) and 279 African American birth-events (82 cases and 197 controls) were 
examined. Single locus, haplotype, and multi-locus association analyses were performed 
on maternal and fetal data separately.  These analyses will be presented in two sections, 
Chapter IV part A presents the results from our Caucasian samples and part B presents 
the results from our African American samples.  Multilocus analyses were also 
performed and an overview of those analyses is presented in Chapter V.  In the Caucasian 
maternal data the strongest associations were found in genes in the complement-
coagulation pathway related to decidual hemorrhage in PTB. The single strongest effect 
was observed in tissue plasminogen activator (tPA) marker rs879293 with a significant 
allelic (p = 2.00x10-3) and genotypic association (p=2.0x10-6) with PTB. The best model 
had an OR of 2.80 [CI 1.77 - 4.44] for GG v AG&AA. The single strongest effect in fetal 
samples was observed in the inflammatory pathway at rs17121510 in the interleukin 10 
receptor antagonist (IL-10RA) gene for allele (p = 0.01) and genotype (p = 3.34x10-4).  
The best model had an OR 1.92 [CI 1.15-3.19] (p = 2.00x10-3) for the additive model.  
Finally, multi-locus analyses in the compliment and coagulation pathway were performed 
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and revealed a significant interaction between a marker in coagulation factor V (FV) 
(rs2187952) and coagulation factor VII (FVII) (rs3211719) (p <10-3).  In both African 
American maternal and fetal data the strongest associations were found in genes related 
to infection and inflammatory response pathways. The strongest associations were in 
interleukin 15 (IL-15) (rs10833, allele p = 2.91x10-4, genotype p = 2.00x10-3) in maternal 
data and interleukin 2 receptor beta (IL-2RB) (rs84460, allele p = 1.37x10-4, genotype p = 
6.29x10-4) in fetal data.  The ORs for the best models in maternal and fetal data were 
additive (rs10833 OR = 0.54[CI 0.37-0.78], p = 1.0x10-3; rs84460 OR = 2.36[CI 1.49-
3.73], p <1.0x10-3).  Finally, multi-locus analyses identified tumor necrosis factor alpha 
(TNF-α) (rs1800683) and interleukin 10 (IL-10) (rs3024498) (p = 0.03) from the T cell 
receptor signaling pathway from fetal samples as being a potentially interesting 
interaction.  These results support a strong role for complement and coagulation 
pathways in Caucasian maternal data, infection and inflammation pathways genes in 
African American PTB, and suggest that there may be different maternal and fetal genetic 
risks for PTB in African Americans. 
 
A. A Large Scale High-throughput Preterm Birth Candidate Gene Association 
Study in Caucasians  
 
 
 
Introduction 
It has become well established that PTB has a genetic component (Adams et al., 
2000;Carlini et al., 2002;Goldenberg and Andrews, 1996;Varner and Esplin, 2005).  
Supporting this is the fact that among the known risk factors of PTB the most significant 
is a family history of PTB (Adams et al., 2000;Carlini et al., 2002;Goldenberg and 
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Andrews, 1996;Varner and Esplin, 2005). Twin studies also estimate ranges for the 
heritability of PTB between 20-40%, suggesting that as many as 40% of PTB can be 
attributed to genetic causes (Clausson et al., 2000;Treloar et al., 2000).  Associations 
have also been seen between ethnicity/race and PTB (Goldenberg and Andrews, 
1996;Zhang and Savitz, 1992).  Although, these data are not conclusive they do suggest 
that genetic variation may increase or decrease PTB susceptibility.   
Data from previously published studies in both in vivo and in vitro human and 
animal models suggests that four primary pathogenic pathways either independently or 
through interactions lead to PTB (Lockwood and Kuczynski, 2001).  The four proposed 
pathways are:  1) activation of maternal or fetal hypothalamic-pituitary-adrenal (HPA) 
axis; 2) decidual-chorioamniotic or systematic inflammation; 3) decidual hemorrhage 
(abruption) and 4) pathological distention of the uterus (Lockwood and Kuczynski, 
2001).  All pathways culminate in a common terminal pathway that causes the release of 
uterotonins, such as prostaglandins, leading to labor, and eventually PTB (Lockwood and 
Kuczynski, 2001) (Figure 2-1).   
Given the complex and poorly understood etiology underlying PTB and the 
increasing trends of PTB rates in Caucasians, we chose to perform a large-scale PTB 
candidate gene association study focusing on a Caucasian population.  We examined 
1536 SNPs and given the complex exchange of genetic information at the maternal-fetal 
unit during pregnancy, we analyzed maternal and fetal data from 130 new and previously 
assayed candidate genes in the hypothesized pathways.  Single locus, haplotype, and 
multi-locus tests of association (PTB – case; term birth – control) were performed, genes 
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were grouped into pathways according to biological process and analyzed according to 
these pathways.   
 
Materials and Methods 
Study population  
Caucasian subjects from Centennial Women’s Hospital in Nashville, TN were 
used in the present study.  Please refer to Chapter III part A for a complete description of 
subject recruitment and ascertainment. 
Demographic and clinical characteristics 
The present study included Caucasian maternal and fetal samples (145 case and 
194 control maternal; 140 case and 179 control fetal).  Placental pathology was 
performed in all cases to document histologic chorioamnionitis and funisitis. Smoking 
status was determined from a questionnaire.   
DNA sampling and genotyping  
DNA was isolated from maternal and fetal blood samples using the Autopure 
automated system (Gentra Systems (Minneapolis, MN)).  A total of 1536 SNPs were 
screened in 130 candidate genes (4 genes were within 5000 kb of candidate genes and 
were analyzed as members of the established candidate). We chose SNPs based on their 
ability to tag surrounding variants in the CEPH and Yoruba population of the HapMap 
database (http://www.hapmap.org) using a minimum minor allele frequency (MAF) of 
0.07 in CEPH and 0.20 in Yoruba and r2 0.80, given that our genotyping was performed 
in conjunction with an African American sample.  1432 markers remained after removing 
monomorphic markers (markers with MAF < 0.05) and markers that were not genotyped 
  83
successfully from Illumina (please refer to Appendix Tables 1 and 2 for a complete list of 
genes and SNPs).  As a quality control step all matched mother-baby pairs were analyzed 
for Mendelian inconsistency, all samples with over 1% of their markers having 
inconsistencies were removed from analyses (24 samples dropped due to Mendelian 
inconsistencies).  We also included functional SNPs and SNPs that previously associated 
in assays. Genotyping was performed by Illumina’s GoldenGate genotyping system 
(http://www.illumina.com/General/pdf/LinkageIV/GOLDENGATE_ASSAY_FINAL.pdf
).   
Bioinformatics tools  
SNPper (http://snpper.chip.org) using the National Center for Biotechnology 
Information (NCBI) Build 35.1 was used to determine marker positions (base pair (bp)), 
marker function, and identify amino acid changes.  Kyoto encyclopedia of genes and 
genomes (KEGG) (http://www.genome.ad.jp/kegg/pathway.html) was used to examine 
gene ontology and to group genes into biological process pathways. 
Statistical methods  
Clinical and demographic characteristics between cases and controls were 
compared using Shapiro-Wilks tests of normality for gravidity (number of births), 
gestational age (days), gestational weight (grams (g)), APGAR 1, and APGAR 5.  All 
measurements deviated significantly from normality; as a result Mann-Whitney two-
sample rank sum tests were used to compare case and control groups (Hollander and 
Wolfe, 1999).  Standard t-tests were used to test whether maternal age differed between 
cases and controls.  χ2 tests were used to test for differences in the counts of smokers and 
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non-smokers between cases and controls.  STATA 9.0 statistical software (StataCorp, 
2007) (College Station, TX, U.S.A) was used for all analyses.   
Statistical tests for differences in single locus allele and genotype frequencies, 
deviations from Hardy Weinberg equilibrium (HWE), and measurements of inbreeding 
coefficients (F) were calculated using Powermarker statistical software (Liu and Muse, 
2005) .  Statistical significance for these analyses was determined using Fishers Exact 
tests.     Measurements of population attributanle risk (proportion of cases in the study 
population that is attributable to the exposure) were calculated using Stata statistical 
software (StataCorp, 2007) (College Station, TX, U.S.A). 
Pairwise LD was characterized and haplotype frequencies were calculated using 
Powermarker (Liu and Muse, 2005) and HaploView (Barrett et al., 2005) statistical 
software.  Standard summary statistics D’ and r2 were calculated using HaploView 
(Zaykin et al., 2002).  Haplotype blocks were assigned using the D’ confidence interval 
algorithm created by Gabriel et al. (2002) (Gabriel et al., 2002).  Both Powermarker and 
HaploView use an EM algorithm to determine haplotype frequency distributions when 
phase is unknown.  The Powermarker haplotype trend analysis was performed for 
dichotomous outcome with 2, 3, and 4 marker sliding windows, using 10,000 
permutations in order to determine p - values.  This analysis is a regression approach to 
test haplotype-trait association.  The test for association then uses an F test for a 
specialized additive model.  The strongest associated sliding window was then analyzed 
for haplotype specific effects.  This included the calculation of ORs for each haplotype, 
as well as determination of case and control haplotype frequencies.  The highest 
frequency haplotype was used as the baseline haplotype frequency.  Only haplotypes with 
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a frequency of 5% or more were considered for haplotype analyses and only significant 
haplotypes are reported. 
Genes were grouped into KEGG biological process pathways and Z tests were 
used to determine if the total number of significant single locus allele and genotype 
associations within genes of a pathway statistically deviated from expected number of 
significant results given the number of tests and the dataset sample size.  These analyses 
used only tag SNPs (r2 ≥ 0.6) to correct for lack of independence between markers within 
a gene due to LD. 
Results are only presented for the following: 1) single locus tests of association 
with p values ≤ 10-3 for either allele or genotype tests of association; 2) haplotype tests 
for genes with at least 1 marker with a p values ≤ 10-3, genes with 3 or more markers; 3) 
Z-tests within KEGG pathways testing for deviations from expected number of 
significant tests (either allele or genotype) given the number of tests performed. 
Exploratory multi-locus analyses were performed.  Analyses were performed 
using Multifactor Dimensionality Reduction (MDR) which has been previously described 
in Ritchie et al. 2001 and is available as open source software at www.epistasis.org 
(Ritchie et al., 2001).  First, all SNPs within the dataset, both for maternal and fetal data, 
were analyzed for two and three way interactions.  The second analysis was conducted 
only on markers with statistically significant (p ≤ 0.05) single locus effects within single 
KEGG pathways.  In the context of this analysis MDR is being used as a search tool to 
identify interactions among loci with single locus associations.  Markers were 
systematically removed if they were observed in one through three loci analyses and had 
a poor cross validation consistency (CVC) in all models; this was performed as a filtering 
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step to remove models due to strong single locus effects.  All MDR analyses with 
statistically significant permutation tests were followed up with logistic regression 
analyses modeling the interaction.  This was finally followed up with a likelihood ratio 
(LR) test modeling the interaction in logistic regression.  Models were only considered 
significant if they were confirmed with logistic regression analyses.  10 fold cross 
validation was implemented with average balanced accuracy as the function for 
evaluating a model (Velez et al., 2007b). 
 
Results 
Baseline characteristics 
Clinical and demographic characteristics are summarized in Chapter III part B on 
Table 3-8.   Significant differences between cases and controls were observed for 
gestation age (days) (p<0.001), birth weight (grams) (p<0.001), APGAR 1 (1 minute 
after birth) (p<0.001), APGAR 5 (5 minutes after birth) (p<0.001), gravidity (number of 
births) (p = 0.02), and smoking (p <0.001). 
Single locus associations 
Table 4-1 presents the results for the single locus allele and genotype associations 
and ORs for the best model at each marker.  The single strongest association in maternal 
data was seen at tPA rs879293 (allele p = 2.30x10-3; genotype p = 2.00x10-6) with a case 
minor allele frequency (MAF) = 0.35 and a control MAF = 0.46.  The strongest model for 
the effects of this marker was GG v AG&AA (Table 4-1) with an OR = 2.80 [CI 1.77-
4.44] and a p = < 1.00x10-6.  Upon examining maternal genotypic associations, tPA at 
rs879293 remains significant after a Bonferroni correction.   
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In fetal samples the most significant association was (Table 4-1) seen in 
interleukin 10 receptor alpha (IL10RA) rs17121510 (allele p = 0.01; genotype p = 
3.34x10-4) with case MAF = 0.15 and control MAF = 0.09.   The most significant model 
for rs17121510 was AA v AG&GG with a protective OR = 0.43 [CI 0.25-0.74] (p = 
2.00x10-3).  In the fetal data the most significant ORs were for IL10RA rs17121510, 
klotho isoform a (KL) rs522796 (OR = 1.52 [CI 1.17-1.96]), and triggring receptor 
expressed on myeloid cells 1 (TREM1) rs6910730 (OR = 2.30 [CI 1.34-3.95]) all had 
equally significant results with p = 2.00x10-3; both KL rs522796 and TREM1 rs6910730 
were additive models.   
 Model p-values for associated markers were adjusted for demographic variables 
that had baseline differences between cases and controls (Appendix Table 3).  Both 
smoking and gravidity were used; however, gestation age, birth weight, APGAR 1, and 
APGAR 5 were not used as they are expected to differ between cases and controls.  In 
maternal data all markers remained statistically significant after an adjustment, with the 
exception of coagulation factor V (FV) rs9332624, interleukin 5 (IL-5) rs739718, and 
prostaglandin E receptor 3 subtype EP3 isoform (PTGER3) rs977214.  In fetal data all 
significance was lost with the exception of KL marker rs522796. 
 Given that the presence of MIAC in cases may influence associations we 
examined markers for allele and genotype difference between cases with and without 
MIAC (Appendix Table 4).  There were no differences for any of the markers we 
examined in maternal or fetal data at either the allele or genotype level except fetal 
marker TREM1 rs6910730 that differed between MIAC and no MIAC at both the allele 
(p = 0.02) and genotype level (p = 0.05). 
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Among the markers with p ≤ 10-3 (this cutoff was chosen for presentation 
purposes and in order to focus on the strongest associations) seven deviated from HWE 
for either cases or controls (Table 4-1).  Five were from maternal data, one in cases at 
tPA rs879293 (p = 0.01) and PTGER3 rs977214 (p = 0.02) and one in controls at IL-5 
rs739718 (p = 0.02), tPA rs879293 (p = 0.01), and PTGER3 (p = 0.05).  One was from 
fetal case data at IL-10RA marker rs17121510 (p = 0.02) and one was in fetal control 
data at cytathionine beta synthase (CBS) marker rs12329764 (p = 0.01).  It is of note that 
for most situations where control p < 0.05 for HWE tests there is evidence that the 
inbreeding coefficients were in opposite directions in cases and controls. This suggests 
that the deviations are not likely due to genotyping error, as cases and controls were 
mixed in the same plates for genotyping.       
Details regarding the associated markers are on Table 4-2a for maternal and Table 
4-2b for fetal data.  Among these markers, only one was a coding exon in fetal data (KL 
rs9527025, nonsynonymous amino acid change 370 S/C).  The remaining markers were 
in promoters, introns, exons (synonymous), and exon/intron boundary regions.   
Haplotype associations 
Among the genes identified in single locus analyses, haplotypes in those genes 
were examined in five genes from maternal data (corticotrophin releaseing hormone 
binding protein (CRHBP), FV, IL-5, tPA, and PTGER3) and three from fetal data (CBS, 
IL-10RA, and TREM1).  Detailed LD structure for maternal and fetal genes for cases and 
controls are available in Appendix Figure 3 a-p.  Table 4-3 has the results of the 
haplotype association analyses with only the significant haplotypes and their ORs 
reported.   
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Table 4-1.  Single locus association results and genotypic ORs 
 
Case v Control P Population Gene(s) SNP rs# Allele Case Freq. 
Control 
Freq. Allele Genotype 
Model OR 95% CI Model P 
rs1875999 G 0.29 0.40 3.00x10-3 0.02 Additive 1.37 1.08-1.72 8.00x10-3 
rs32897 G 0.13 0.21 4.00x10-3 0.02 Additive 1.68 1.14-2.49 9.00x10-3 CRHBP 
rs10055255 T 0.33 0.45 5.90x10-4 0.01 AAvAT&TT 1.95 1.25-3.05 3.00x10-3 
FV rs9332624 C 0.03 0.01 3.00x10-3 0.01 Additive 9.79 1.19-80.48 0.03 
IL-5 rs739718 G 0.09 0.04 4.10x10-3 0.01 AAvAG&GG 0.38 0.19-0.79 9.00x10-3 
tPA rs879293* A 0.35 0.46 2.30x10-3 2.00x10-6 GGvAG&AA 2.80 1.77-4.44 <1.00x10-6 
rs977214 G 0.09 0.13 0.17 4.08x10-3 AGvAA 0.51 0.29-0.90 0.02 PTGER3 rs594454 G 0.44 0.31 1.00x10-3 4.00x10-3 Additive 1.71 1.24-2.35 1.00x10-3 
Maternal 
SCNN1A/ 
sTNF-R1 rs3764874 G 0.28 0.19 3.00x10
-3 0.01 Additive 1.70 1.19-2.44 4.00x10-3 
CBS rs12329764 A 0.12 0.09 0.16 2.00x10-3 GGvAG&AA 0.86 0.75-0.99 0.04 
IL-10RA rs17121510 G 0.15 0.09 0.01 3.34x10-4 AAvAG&GG 0.43 0.25-0.74 2.00x10-3 
rs9527025 C 0.10 0.18 4.0x10-3 0.02 Additive 1.91 1.15-3.19 0.01 KL rs522796 C 0.50 0.38 3.00x10-3 2.00x10-3 Additive 1.52 1.17-1.96 2.00x10-3 
Fetal 
TREM1 rs6910730 G 0.15 0.07 3.00x10-3 3.00x10-3 Additive 2.30 1.34-3.95 2.00x10-3 
1maternal cases deviated from HWE at rs879293 (p = 0.01) andrs9772114 (p = 0.02) and fetal cases deviated at rs17121510 (p = 0.02) 
2maternal control deviated from HWE at rs739718 (p = 0.02), rs879293 (p = 0.01), and rs977214 (p = 0.05) and fetal control deviated at rs12329764 (p = 0.01) 
*Still significant after Bonferroni correction and FDR correction (false discovery rate = 0.20)
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Table 4-2.  Genes and markers with strongest associations 
a. Maternal 
Gene Name Gene Code Band
1 
# Markers 
Genotyped 
in Gene 
dbSNP rs# Role 
Amino 
Acid 
Change 
KEGG Pathway 
rs1875999 Exon - 
rs32897 Intron - 
Corticotrophin 
releasing hormone 
binding protein 
CRHBP 5q23.3 5 
rs10055255 Intron - 
- 
Coagulation factor 
V FV 1q24.2 26 rs9332624 Intron - Compliment and coagulation cascade 
Interleukin 5 IL-5 5q23.3 5 rs739718 3’UTR - 
T cell receptor signaling pathway/, Fc 
epsilon RI signaling pathway, 
hematopoietic cell lineage, Jak-STAT 
signaling pathway, cytokine-cytokine 
receptor interaction 
Tissue plasminogen 
activator tPA 8p11.21 8 rs879293 Intron - Compliment and coagulation cascade 
rs977214 Intron - Prostaglandin E 
receptor 3, subtype 
EP3 isoform 
PTGER3 1p31.1 53 
rs594454 Intron - 
Calcium signaling pathway, neuroactive 
ligand-receptor interaction 
Sodium channel, 
nonvoltage-gated 1 
alpha/ 
Soluble tumor 
necrosis 
factor receptor 1 
SCNN1A/ 
sTNF-R1 12p13.31 1 rs3764874 
Intron 
(boundary) 
/Promoter 
- Taste transduction, cytokine-cytokine receptor interaction 
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b. Fetal 
Gene Name Gene Code Band
1 
# Markers 
Genotyped 
in Gene 
dbSNP rs# Role 
Amino 
Acid 
Change 
KEGG Pathway 
Cystathionine-beta-
synthase CBS 21q22.3 16 rs12329764 
Intron 
(boundary) - 
Glycine, serine and 
threonine metabolism, 
methionine metabolism, 
Huntington's disease, 
selenoamino acid 
metabolism 
Interleukin 10 
receptor, alpha 
precursor 
IL-
10RA 11q23.3 11 rs17121510 3’UTR - 
Cytokine-cytokine receptor 
interaction, Jak-STAT 
signaling pathway 
rs9527025 Coding exon 370 S/C 
Klotho isoform b KL 13.q13.1 19 
rs522796 Intron - 
- 
Triggering receptor 
expressed on 
myeloid cells 1 
TREM1 6p21.1 11 rs6910730 Intron - - 
1NCBI build 35.1 
2Gene Ontology and KEGG pathway information obtained from SNPper (http://snpper.chip.org) and KEGG gene ontology browser 
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Table 4-3.  Haplotype frequencies and OR for strongest sliding window 
 
Frequency Population Gene(s) Markers Global P1 Haplotype 
Case Control 
OR 95% CI P 
CRHBP rs32897-rs6453267-rs10055255-rs1875999 0.01 A-G-A-A 0.65 0.53 1.00 - - 
   A-G-T-G 0.10 0.18 0.45 0.27-0.74 9.00x10-4 
FV rs12131397-rs9332624-rs9332618 <1.00x10-3 C-A-C 0.43 0.52 1.00 - - 
   A-A-C 0.44 0.34 1.57 1.11-2.21 8.00x10-3 
IL-5 rs739719-rs739718 0.01 G-A 0.90 0.94 1.00 - - 
   T-G 0.09 0.03 2.70 1.30-5.85 4.00x10-3 
tPA rs4471024-rs2020922-rs879293-rs2299609 6.00x10-3 T-T-A-C 0.32 0.42 1 - - 
   C-A-G-G 0.29 0.21 1.82 1.20-2.76 3.00x10-3 
   T-T-G-C 0.21 0.17 1.62 1.03-2.55 0.03 
PTGER3 rs977214-rs6665776-rs594454 3.00x10-3 A-C-T 0.564 0.469 1.00 - - 
   A-C-G 0.309 0.438 0.59 0.42-0.83 2.00x10-3 
PTGER3 rs2050066-rs6424414-rs2300167 3.00x10-3 C-C-C 0.314 0.402 1.00 - - 
   C-T-T 0.297 0.258 1.47 0.98-2.21 0.05 
Maternal 
   C-C-T 0.286 0.209 1.76 1.15-2.67 6.00x10-4 
CBS rs1005584-rs6586282 9.00x10-3 - - - - - - 
CBS rs1005584-rs6586282-rs6586283 9.00x10-3 - - - - - - 
IL-10RA rs4938467-rs11216666 0.02 T-T 0.43 0.51 1.00 - - 
   C-C 0.16 0.08 2.31 1.33-4.04 1.00x10-3 
TREM1 rs1817537-rs3804277-rs4711668 2.00x10-3 G-G-C 0.48 0.48 1.00 - - 
Fetal 
   C-A-C 0.25 0.16 1.61 1.04-2.51 0.02 
1Global P is the p-value for the haplotype sliding window 
*Only haplotypes with frequencies of 5% in at least one status group and with a significant OR are presented. 
*ORs are calculated comparing each haplotype to the highest frequency haplotype. 
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Among the haplotype sliding window analyses (sliding windows were performed 
with windows consisting of 2, 3, and 4 markers and only the strongest (most significant p 
value) window is presented) maternal FV had the most significant global p value 
(<1.00x10-3) (Table 4-3; Appendix Figure 3g and h) associating intronic markers 
rs12131397-rs9332624-rs9332618 with PTB.  The A-A-C haplotype (rs12131397-
rs9332624-rs9332618; OR = 1.57 [CI 1.11-2.21], p 8.00x10-3) was the only significant 
haplotype.  Two of these three markers (rs121313197 and rs9332618) are in tight LD (D` 
= 1) in both cases and controls (Appendix Figure 3c and 1d).  The association does not 
appear to be main effect driven as rs9332624 is the only marker with a main effect but its 
MAF (0.03 in cases and 0.01 in controls) is low and does not appear to be contributing 
greatly to the haplotype association.  tPA (p = 6.00x10-3) and PTGER3 (p = 3.00x10-3) 
both had strong global p values for haplotype sliding windows. The haplotype 
associations observed in tPA at rs4471024-rs2020922-rs879293-rs2299609 appear to be 
main effect driven by rs879293 as the rs879293 G allele was common to both associated 
haplotypes (C-A-G-G, OR = 1.82 [CI 1.20-2.76], p = 3.00x10-3; T-T-G-C, OR = 1.62 [CI 
1.03-2.55], p = 0.03) and the reference haplotype included A.  Two non-overlapping 
haplotypes were associated in PTGER3, rs977214-rs6665776-rs594454 and rs2050066-
6424414-rs2300167 both located in intronic regions.  The pattern of haplotype 
associations suggests that both associations are main effect driven; the first haplotype is 
driven by the effect of rs594454 and the second haplotype by rs2300167. 
Examining the three genes in fetal data (Table 4-3; Appendix Figure 3k-p), the 
associated haplotypes were in CBS (rs1005584-rs6586282 global p = 9.00x10-3), CBS 
(rs1005584-rs6586282-rsrs6586283 global p = 9.00x10-3), IL-10RA (rs4938467-
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rs11216666 global p = 0.02), and TREM1 (rs1817537-rs3804277-rs4711668 global p = 
2.00x10-3).  In CBS only the global haplotype association was significant.  IL-10RA had 
an associated haplotype C-C (rs4938467-rs11216666, OR = 2.31 [CI 1.33-4.04], p = 
1.00x10-3) and this haplotype did not appear to be main effect driven.  The TREM1 C-A-
C (rs1817537-rs3804277-rs4711668, OR = 1.61 [CI 1.04-2.51], p = 0.02) haplotype 
associated with outcome.  The TREM1, C-A-C (rs1817537-rs3804277-rs4711668), 
haplotype association appears to be driven by the effects of two marker C-A (rs1817537-
rs3804277), as the rs4711668 C allele was common to the associated haplotype and the 
reference, suggesting that this marker does not contribute to the haplotype effect. 
 
Table 4-4.  Significant results by KEGG pathway  
 
Population KEGG Pathway  
(tags with r2 ≥ 0.60) # Genes Maternal Fetal 
Apoptosis 12   
Arachidonic acid metabolism 5   
Compliment and coagulation cascade 6 AG  
Cytokine-cytokine receptor interactions 31 A AG 
Focal adhesion 6 A  
Hematopoietic cell lineage 12 A  
Jak-STAT signaling pathway 14   
MAPK signaling pathway 18   
Neuroactive ligand-receptor interaction 12   
T cell receptor signaling pathway 12   
Toll-like receptor signaling 14   
Type I diabetes mellitus 7   
Other (genes not in other pathways) 55  AG 
*A-indicates statistically significant allelic association 
*G-indicates a statistically significant genotypic association 
 
 
Pathway analysis 
In maternal data the complement and coagulation pathway, cytokine-cytokine 
receptor interaction, focal adhesion, and hematopoietic cell lineage pathways had 
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significant excess of associations for either allele or genotype (Table 4-4).  The 
complement and coagulation pathway had a significant excess of association for both 
allele and genotype tests.  The cytokine-cytokine receptor and the other pathways were 
also significant for both allele and genotype tests for fetal data.   None of the remaining 
pathways deviated from expected.  
Multilocus analyses 
 Full data maternal multilocus analyses identified the tPA marker rs879293 as the 
single strongest model with 10/10 CVC with 59.94% average balanced accuracy (results 
not shown).  Fetal full data multilocus analyses identified PTGFR marker rs6424776 and 
MTHFR marker rs1801133 as the best model with 9/10 CVC with 63.72 % (permutation 
p = 0.02); however, this model did not hold up to logistic regression analyses.   
Multilocus analyses on pathways with excess of significant associations for either 
allele or genotype tests (identified by Z test analyses) revealed a statistically significant 
two locus model in the complement and coagulation pathway in maternal data after 
removing the strong main effect of tPA marker rs879293 (Figure 4-1a, b).  This model 
included a marker in FV (rs2187952) and in coagulation factor VII (FVII) (rs3211719) 
and was confirmed with logistic regression analyses.  The testing average balanced 
accuracy was 61.58% and the CVC was 10/10 (permutation p <1.00x10-3).  Logistic 
regression analyses showed that the interaction was statistically significant (p = 9.00x10-
3) and the LR test p value for including the interaction in the logistic regression model 
was 7.20x10-3. 
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a. 
# of 
Loci Model 
Testing Balanced 
Accuracy (%) 
Cross Validation 
Consistency 
(CVC) 
1 rs2299609 (tPA) 53.40 6/10 
2 rs2187952 (FV) x rs3211719 (FVII) 61.58 10/10 
3 rs2187952 (FV) x rs3211719 (FVII) x rs4471024 (tPA) 50.03 3/10 
b. 
A/G
G/G
A/A
rs
32
11
71
9
A/A A/G G/G
rs2187952
 
High-Risk 
Low-Risk 
 
Figure 4-1.  MDR compliment and coagulation two locus model between FV and 
FVII 
Each multifactor cell is labeled as “high risk” or “low risk”.  For each multifactor 
combination, hypothetical distributions of cases (left bar in cell) and controls (right bar 
in cell) are shown.  Each multilocus genotype is labeled on the figure.  The testing 
average balanced accuracy is 61.58% (p-value <1.00x10-3) with a CVC of 10/10.  
Logistic regression analyses showed that the interaction for the additive effects of these 
two markers was statistically significant (p = 9.00x10-3) and the LR test p value for 
including the interaction in the logistic regression model was 7.20x10-3. 
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Factor Xa
TF + Factor VII
Factor IX Factor IXa
Factor X
ThrombinProthrombin
Fibrinogen Fibrin
Plasmin
Fibrin 
Degradation
Ca2+, PL
Factor VIII,
Ca2+, PL
Factor V,
Ca2+, PL
Plasminogen
tPA, PAI1
 
Figure 4-2.  Compliment and coagulation pathway subset 
This branch of the compliment and coagulation cascade had a cluster of three genes with 
significant (α = 0.05) association at allele and/or genotype level, these are labeled in red 
(coagulation factor V (FV), coagulation factor VII (FVII), and tissue plasminogen 
activator (tPA)).  In addition to these genes we also genotyped markers in three other 
genes from other branches of the compliment and coagulation cascade (soluble mannose-
binding lectin 2 (MBL2), plasminogen activator inhibitor 1 (PAI1), coagulation factor II 
(FII) however, no markers in these genes were associated. 
 
 
Discussion 
 In the present study a large-scale candidate gene association analysis was 
performed, in a U.S. Caucasian sample, on new and previously established PTB 
candidate genes in an effort to further understand the etiology underlying PTB.  
Comprehensive single locus, haplotype, and multi-locus analyses were performed and 
revealed several interesting results in both maternal and fetal data.  Pathway analyses 
revealed strong associations in maternal data within the compliment and coagulation 
cascade, particularly in the fibrinolytic branch where three genes associated.  Upon 
examining the compliment and coagulation pathway in more detail (Figure 4-2) it was 
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found that in the fibrinolytic branch of the pathway, three of four genes genotyped in that 
branch had markers that were significantly associated.  These genes include coagulation 
factor VII (FVII), FV, and tPA.  PAI1, also genotyped in that branch, was not 
significantly associated at the single locus allele or genotype level.  Two other genes 
upstream and downstream of this branch did not associate (soluble mannose-binding 
lectin (protein C) 2 (MBL2) and coagulation factor II (FII)).  The only result to stand up 
to a Bonferroni correction was tPA, from the compliment and coagulation cascade.  The 
population attributable risk for this marker was ~0.32, suggesting that 32% of our cases 
can be explained by this variant. A multi-locus search also revealed an interesting 
association between FV and FVII within the compliment and coagulation cascade that 
suggests that there may be both an interaction among genes within the pathway and locus 
heterogeneity.  Interestingly, the cytokine-cytokine receptor pathway revealed the 
strongest association with fetal DNA and it was also significant in maternal samples.    
The majority of previous studies on PTB have focused on pathways contributing 
towards intrauterine infection (Lockwood, 2002) ignoring the potential contribution of 
other pathways such as decidual hemorrhage.  Decidual hemorrhage is found in ~45% of 
patients with PTB (Salafia et al., 1995).  Expression studies of decidual tissues have 
observed that tissue factors and tPA have strong patterns of expression (Bogic et al., 
1999;Lockwood et al., 1993;Lockwood et al., 2001).  To our knowledge there are no 
association studies associating tPA markers with PTB; however, several studies have 
observed that tPA and tissue factors are highly expressed in preterm human decidual 
tissues relative to term decidual tissues (Bogic et al., 1999;Bryant-Greenwood and 
Yamamoto, 1995).  tPA is a serine protease inhibitor in the fibrynolitic cascade (Figure 4-
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2) that converts inactive plasminogen to plasmin.  The generation of plasmin is important 
for the degradation of components of the extra cellular matrix, such as matrix 
metalloproteinases (MMPs), which break down interstitial collagens.  If MMPs are not 
degraded they can compromise the structural integrity of the decidua.  Our association 
with tPA seen in maternal samples supports previous findings observing elevated 
amounts of tPA in maternally derived decidua and not in fetally derived amnion/chorion 
tissues (Bogic et al., 1999;Bryant-Greenwood and Yamamoto, 1995).   
Another strong association was also observed in CRHBP in maternal data.  
Although it has not been directly associated with tPA it plays an important role in binding 
of corticotrophin releasing hormone (CRH).  Studies have also demonstrated that tPA 
plays an important role in the cascade of CRH.  CRH is released from several cell types, 
including but not limited to neuronal cells, the gastrointestinal tracts, placenta, and sites 
of inflammation; tPA is released in response to CRH and acts downstream of CRH 
receptor 1 (CRH-R1), a necessary step for the activation of anxiety-like behavior and 
neuronal activation (Matys et al., 2004).  tPA is released from neurons upon excitation 
and is present in brain tissues such as the hippocampus, amygdala, hypothalamus, and 
cerebellum, functioning in neuronal plasticity (Baranes et al., 1998;Gualandris et al., 
1996;Neuhoff et al., 1999;Parmer et al., 1997;Sappino et al., 1993).  In the amygdala tPA 
has an important role in stress-induced synaptic plasticity and is an integral component 
for stress response (i.e. anxiety-like behavior) (Pawlak et al., 2002).  This relationship is 
of interest as it would also implicate tPA with the maternal-stress PTB pathways in 
addition to decidual hemorrhage pathways.  This may potentially implicate tPA and 
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CRHBP in maternal-stress pathways; however, despite the biological relationship 
between these two genes, no statistical associations were observed between them. 
 Single locus tests of association in fetal data were not as strong as maternal data 
and were not statistically significant after adjusting for the effects of confounders 
(gravidity and smoking) with the exception of KL rs522796.  PTB with and without 
MIAC did not differ with the exception of TREM1 marker rs6910730.  No statistically 
strong multilocus models were observed in any pathway in fetal data; however, a 
marginally significant model encompassing genes in PTGFR and MTHFR was observed 
with an average balanced accuracy of 63.72%.  This result, however, did not hold up to 
logistic regression tests and one of the markers had a very rare genotype.   The two 
largest pathways, the cytokine-cytokine receptor interaction pathway and the “other” 
pathway, were the pathways implicated with fetal data.  The cytokine-cytokine receptor 
interaction pathway was also implicated in maternal data, which may be the result of 
either mother-fetal allele sharing or of independent associations in mother and fetus; 
however, such relationships can only be clarified by assessment of paternal contribution 
by the use of a family-based study design.   
 In conclusion, we conducted a gene-centric association study on PTB and found 
several interesting associations confirming several established PTB candidates, including 
a result that stood up to a Bonferroni correction.  Sample size is a major limitation to our 
study, despite our sample being well phenotyped.  However, given the patterns of 
associations observed within genes and by pathways, it is clear that several of the 
findings are consistent with established literature. We replicated the association found in 
FV, a well established PTB candidate also found using a large-scale high throughput 
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genotyping platform and identified new candidates (Hao et al., 2004).  This association 
was previously observed in an African American population; however, our study suggests 
that it was not necessarily population specific given that we found the association in 
Caucasians.  Our overall strongest association was seen in the decidual hemorrhage 
pathway suggesting that this pathway may be very important for the initiation of PTB and 
should be focused on in future studies.  
 
B.  A Large Scale High-throughput Preterm Birth Candidate Gene Association 
Study in African Americans 
 
 
Introduction 
The prevalence rate of PTB in the U.S. is ~17-18% for African Americans 
(Martin et al., 2005).   Given the complex and poorly understood etiology underlying 
PTB and the high rate in African Americans, we chose to perform a large-scale PTB 
candidate gene association study focusing on an African American population.  Data 
from previously published studies in both in vivo and in vitro human and animal models 
suggests that four primary pathogenic pathways either independently or through 
interactions lead to PTB (Lockwood and Kuczynski, 2001).  All pathways culminate in a 
common terminal pathway that causes the release of uterotonins, such as prostaglandins, 
and eventually PTB (Lockwood and Kuczynski, 2001).  We examined 1536 single 
nucleotide polymorphisms (SNPs) in and around 130 new and previously selected 
candidate genes from the hypothesized pathways described by Lockwood et al. (2001) in 
maternal and fetal samples.  Single locus, haplotype, and multi-locus tests of association 
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were performed and genes were grouped according to known biological pathways (PTB – 
case; term birth – controls).  Pathway grouping was based solely on biological function. 
 
Materials and Methods 
Study population  
  African American subjects from Centennial Women’s Hospital in Nashville, TN 
were used in the present study.  Please refer to Chapter III part A for a complete 
description of subject recruitment and ascertainment. 
Demographic and clinical characteristics 
Our study included African American maternal and fetal samples (75 case and 
191 control maternal; 65 case and 183 control fetal).  Placental pathology was performed 
in all cases to document histologic chorioamnionitis and funisitis. Smoking status 
(current smoker or not current smoker) was determined from a questionnaire.   
Please refer to Chapter IV part A for a complete description of DNA sampling 
and genotyping, statistical analysis, and bioinformatics tools used in these analyses. 
 
Results 
Baseline characteristics 
Clinical and demographic characteristics are summarized in Chapter III part B on 
Table 3-8.   Significant differences between cases and controls were observed for 
gestation age (days) (0.001), birth weight (grams) (p < 0.001), APGAR 1 (1 minute after 
birth) (p < 0.001) and APGAR 5 (5 minutes after birth) (p < 0.001). A marginally 
significant difference was seen between case and control smokers (p = 0.08). 
  103
Single locus associations 
 Markers with the strongest associations (p ≤ 10-3) for either maternal or fetal 
samples are presented.  Four of twenty-one markers with significant associations deviated 
from HWE (Table 4-5).  Two were in maternal samples, one in cases at heat shock 70kDa 
protein 1-like (HSPA1L) rs2075800 (p = 3.60x10-5) and one in controls at interleukin 2 
receptor alpha (IL-2RA) rs6602392 (p = 0.04).  Two were in fetal cases at CD14 antigen 
precursor (CD14) marker rs4914 (p = 0.02) and PON2 (p = 0.01).  The deviations from 
HWE in cases may provide further support of an association at that marker.  The 
inbreeding coefficients for cases and controls for the maternal IL-2RA marker rs6602392 
had opposite signs, suggesting that the deviation from HWE was in opposite direction 
and not likely due to genotyping error.   
 Table 4-5 presents the results for the single locus allele and genotype associations 
and ORs for the best model at each marker.  The single strongest association in maternal 
data was seen at interleukin 15 (IL-15) rs10833 (allele p = 2.91x10-4; genotype p = 
2.0x10-3) with a case MAF = 0.06 and a control MAF = 0.18.  The most significant 
maternal genotypic OR were seen for IL-15 rs10833 (OR = 0.54 [CI = 0.37-0.78] (p = 
1.0x10-3)) and interleukin 1 receptor accessory protein isoform (IL-1RAP) rs9290936 
(OR = 1.99 [CI = 1.30-3.04] (p = 1.0x10-3)), both are for additive models.   
In fetal samples (Table 4-5) the single most significant association was seen in 
interleukin 2 receptor beta (IL-2RB) rs84460 (allele p = 1.37x10-4; genotype p = 6.29x10-
4) with the case MAF = 0.25 and a control MAF = 0.44.   The best model for rs84460 was 
additive with an OR = 2.36 [CI = 1.49-3.73] (p<1.00x10-3). TNF-α  marker rs1800629 
(a.k.a. G-308A) has been previously associated with PTB, therefore, we examined it for 
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association as well and observed a marginally significant association (allele p = 0.01; 
genotype p = 0.02) in fetal data at this marker but not in maternal data, no deviations 
from HWE were seen (data not presented).  Fetal genotypic ORs show the strongest ORs 
for IL-2RB rs84460 additive model (OR = 2.36 [CI 1.49-3.73] (p = <1.0x10-3)), matrix 
metalloproteinase 2 (MMP2) rs243832 model GG v (CG&CC) (OR = 2.97 [CI = 1.60-
5.54] (p = 1.0x10-3)), and TNF-α rs1800683 additive (OR = 0.49 [CI = 0.32-0.76] (p = 
1.0x10-3)).  Of note, this SNP is in strong LD with established PTB candidate -308 
(rs1800629). 
A description of the associated markers and gene functions is on Table 4-6a and 
Table 4-6b for maternal and fetal data.  In maternal data HSPA1L rs2075800 
(nonsynonymous amino acid change 602 E/K) resulted in a synonymous amino acid 
changes.  The remaining markers were promoters, introns, exons (no amino acid 
changes), and exon/intron boundary regions.   
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Table 4-5.  Single locus association results and genotypic ORs 
 
Case v Control P Population Gene(s) SNP rs# Allele Case Freq. 
Control 
Freq. Allele Genotype 
Model OR 95% CI Model P 
HSPA1L rs20758001 A 0.07 0.09 0.61 5.93x10-4 AAvAG&GG 10.7 1.18-97.39 0.04 
IL-15 rs10833 A 0.06 0.18 2.91x10-4 2.00x10-3 additive 0.54 0.37-0.78 1.00x10-3 
IL-1RAP rs9290936 T 0.37 0.23 1.53x10-3 0.01 additive 1.99 1.30-3.04 1.00x10-3 
IL-2RA rs66023922 A 0.13 0.23 4.46x10-3 0.03 additive 0.51 0.30-0.85 0.01 
IL-6R rs4553185 C 0.48 0.61 4.49x10-3 0.01 additive 1.75 1.19-2.59 0.01 
Maternal 
sTNF-R2 rs5746053 A 0.20 0.11 0.01 3.00x10-3 additive 0.51 0.30-0.86 0.01 
CD14 rs49141 G 0.10 0.03 2.51x10-3 0.02 additive 2.69 1.29-5.64 0.01 
rs16840252 T 0.10 0.25 2.06x10-4 4.00x10-3 CCvCT&TT 0.33 0.17-0.65 1.00x10-3 CTLA4 
rs231777 T 0.16 0.29 2.52x10-3 0.01 additive 0.49 0.29-0.81 0.01 
IL-2 rs2069771 T 0.16 0.30 1.75x10-3 0.01 additive 0.48 0.29-0.80 0.01 
rs84460 C 0.25 0.44 1.37x10-4 6.29x10-4 additive 2.36 1.49-3.73 <1.00x10-3 
rs228947 T 0.17 0.31 8.80x10-4 0.01 CCvCT&TT 2.45 1.35-4.43 3.0x10-3 
rs3218315 T 0.18 0.30 3.81x10-3 0.02 TTvCT&CC 2.32 1.28-4.19 0.01 
rs228954 G 0.42 0.57 2.47x10-4 0.01 additive 1.47 1.14-1.89 3.00x10-3 
IL-2RB 
rs2281094 T 0.14 0.26 3.46x10-3 0.02 CCvCT&TT 2.29 1.24-4.23 0.01 
MMP2 rs243832 G 0.40 0.55 3.54x10-3 2.71x10-3 GGvCG&CC 2.97 1.60-5.54 1.00x10-3 
MMP9 rs3918260 C 0.27 0.14 1.37x10-3 3.30x10-3 additive 2.18 1.35-3.54 2.00x10-3 
rs22375851 T 0.45 0.58 0.01 2.70x10-3 TTvCT&CC 0.28 0.12-0.62 2.00x10-3 PON2 
rs2299267 G 0.22 0.12 3.92x10-3 0.01 additive 2.16 1.28-3.65 4.0x10-3 
PTGER3 rs4147115 A 0.39 0.53 4.75x10-3 0.01 additive 0.54 0.35-0.83 4.00x10-3 
Fetal 
TNF-α rs1800683 A 0.35 0.51 6.33x10-4 4.06x10-3 additive 0.49 0.32-0.76 1.00x10-3 
1maternal cases deviated from HWE at rs2075800 (p = 3.60x10-5) and fetal cases deviated at rs4914 (p = 0.02) and rs2237585 (p = 0.01) 
 2maternal controls deviated from HWE at rs6602392 (p = 0.04) 
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Table 4-6.  Genes and markers with strongest associations 
 
a. Maternal 
Gene Name Gene Code Band
1 dbSNP rs# Role 
Amino 
Acid 
Change 
KEGG Pathway 
Heat Shock 70kDa Protein 
1-like 
 
HSPA1L 6p21.33 rs2075800 Coding exon 602 E/K 
MAPK signaling pathway, antigen 
processing and presentation 
Interleukin 15 
 IL-15 4q31.21 rs10833 Exon - 
Cytokine-cytokine receptor interaction, Jak-
STAT signaling 
Interleukin 1 Receptor 
Accessory Protein 
 
IL-1RAP 3q28 rs9290936 Intron - Cytokine-cytokine receptor interaction, apoptosis 
Interleukin 2 Receptor, 
Alpha 
 
IL-2RA 10p15.1 rs6602392 Intron - Cytokine-cytokine receptor interaction, Jak-STAT signaling, hematopoietic cell lineage 
Interleukin 6 Receptor 
 IL-6R 1q21.3 rs4553185 Intron - 
Cytokine-cytokine receptor interaction, 
hematopoietic cell lineage, Jak-STAT 
signaling 
Tumor Necrosis Factor 
Receptor Superfamily, 
Member 1B 
 
sTNF-R2 1p36.22 rs5746053 
Intron, 
Exon/ 
intron 
boundary 
- 
Apoptosis, cytokine-cytokine receptor 
interaction, MAPK signaling pathway, 
adipocytokine signaling pathway 
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b. Fetal 
Gene Name Gene Code Band1 dbSNP rs# Role Amino Acid Change KEGG Pathway 
Monocyte Differentiation antigen CD14 CD14 5q31.3 rs4914 Coding exon 367 L/L 
Regulation of actin cytoskeleton, 
pathogenic Escherichia coli infection - EPEC, 
Hematopoietic cell lineage, 
pathogenic Escherichia coli infection - EHEC, 
MAPK signaling pathway, 
toll-like receptor signaling pathway 
rs16840252 Promoter - 
Cytotoxic T-lymphocyte-Associated Protein 4 CTLA4 2q33.2 
rs231777 Intron - 
T cell receptor signaling pathway, 
cell adhesion molecules (CAMs) 
Interleukin 2 IL-2 4q27 rs2069771 Intron - 
Jak-STAT signaling pathway, 
type I diabetes mellitus, 
T cell receptor signaling pathway, 
cytokine-cytokine receptor interaction 
rs84460 Intron - 
rs228947 Intron - 
rs3218315 Intron - 
rs228954 Intron - 
Interleukin 2 Receptor, beta IL-2RB 22q13.1 
rs2281094 Intron - 
Cytokine-cytokine receptor interaction, 
Jak-STAT signaling pathway 
Matrix Metallopeptidase 2 MMP2 16q12.2 rs243832 Intron (boundary) - GnRH signaling pathway, leukocyte transendothelial migration 
Matrix Metallopeptidase 9 MMP9 20q13.12 rs3918260 Intron (boundary) -  
rs2237585 Intron - Paraoxonase 2 
 PON2 7q21.3 rs2299267 Intron - 
Gamma-Hexachlorocyclohexane degradation, 
bisphenol A degradation 
Prostaglandin E Receptor 3 PTGER3 1p31.1 rs4147115 Intron - Calcium signaling pathway, euroactive ligand-receptor interaction 
Tumor necrosis Facto Alpha TNF-α 6p21.33 rs1800683 Promoter - 
Hematopoietic cell lineage,Fc epsilon RI signaling pathway, 
type II diabetes mellitus, 
cytokine-cytokine receptor interaction, 
natural killer cell mediated cytotoxicity, 
toll-like receptor signaling pathway, 
T cell receptor signaling pathway, 
MAPK signaling pathway, Apoptosis, 
adipocytokine signaling pathway, 
TGF-beta signaling pathway, 
type I diabetes mellitus 
1NCBI build 35.1 
2Gene Ontology and KEGG pathway information obtained from SNPper (http://snpper.chip.org) and KEGG gene ontology browser 
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Haplotype associations 
 One gene for the maternal data met the criterion for haplotype analysis (IL-6R) 
and eight in fetal data (CD14, cytotoxic T-lymphocyte-associate protein 4 (CTLA4), IL-
2, IL-2RB, matrix metalloproteinase 9 (MMP9), paraoxonase 2 isoform 1 (PON2), 
prostaglandin E receptor 3 subtype EP3 isoform (PTGER3), and TNF-α).  Detailed LD 
structure for maternal and fetal genes for cases and controls are available in supplemental 
material (Appendix Figure 4a-r).  Table 4-7 has the results of the significant haplotype 
associations and their ORs.   
 Maternal IL-6R haplotype sliding window analyses (sliding windows were 
performed with windows consisting of 2, 3, and 4 markers and only the strongest (most 
significant p value) window is presented) (Table 4-7; Appendix Figure 4a and b) 
associated intronic markers rs4075015-rs4601580-rs4845618 (p = 0.02) with cases.  
Haplotypes A-T-G (rs4075015-rs4601580-rs4845618; p <10-3) and A-T-T (rs4075015-
rs4601580-rs4845618; OR = 0.17 [CI 0.02-0.71], p = 0.01) were both significantly 
associated haplotypes.  This result does not appear to be main effect driven as despite 
rs4075015 A allele being common to all three, it did not associate at the p 0.05 single 
locus allele or genotype level.   
 Examining the nine genes in fetal data (Table 4-7; Appendix Figure 4c-r), the 
strongest haplotype associations were seen in: CD14 (rs4914-rs2569190), CTLA4 
(rs16840252-rs11571317-rs5742909), IL-2 (rs2069771-rs2069776-rs2069778), IL-2RB 
(rs84460-rs228945-rs228947), MMP9 (rs6104420-rs3918260), and TNF-α (rs1800683-
rs2229094).  Among these associated haplotypes it is unclear whether MMP9 
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(rs6104420-3918260) and TNF-α (rs18006830-rs2229094) are driven by the main effects 
of single markers.  MMP9 (rs6104420-3918260) G-C (OR = 2.27 [CI 1.31-3.91] (p = 
2.0x10-3)) had the strongest associated haplotype and in TNF-α A-C (rs1800683-
rs2229094; OR = 0.37 [CI 0.20-0.68], p 1.0x10-3) had the strongest associated haplotype.  
The haplotype associated in MMP9 included a promoter and an intron and within TNF-α, 
a promoter (rs1800683) and coding marker (rs2229094; nonsynonymous amino acid 
change 13 R/C) are included.  Haplotypes in PON2, PTGER3 and TNF-α haplotype 2 all 
had significance levels no larger than p = 0.02.   
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Table 4-7.  Haplotype frequencies and OR for strongest sliding window 
 
Frequency Population Gene(s) Markers Global P1 Haplotype 
Case Control 
OR 95% CI P 
IL-6R rs4075015-rs4601580-rs4845618  T-T-T 0.30 0.31 1.00 - - 
  0.02 A-T-G 0.07 <10-3 - - <10-3 Maternal 
   A-T-T 0.02 0.08 0.17 0.02-0.71 0.01 
CD14 rs4914-rs2569190 0.01 C-G 0.49 0.60 1.00 - - 
   G-G 0.11 0.03 3.91 1.58-9.71 1.00x10-3 
CTLA4 rs16840252-rs11571317-rs5742909 3.00x10-3 C-T-C 0.88 0.73 1.00 - - 
   T-T-C 0.10 0.22 0.37 0.18-0.71 1.00x10-3 
IL-2 rs2069771-rs2069779-rs2069778 0.01 C-C-C 0.82 0.66 1.00 - - 
   T-C-C 0.15 0.30 0.39 0.22-0.68 <10-3 
IL-2RB rs84460-rs228945-rs228947 4.00x10-4 T-A-C 0.56 0.42 1.00 - - 
   C-G-T 0.16 0.26 0.45 0.25-0.80 4.00x10-3 
   C-G-C 0.09 0.17 0.40 0.18-0.80 0.01 
MMP9 rs6104420-rs3918260 0.02 A-T 0.67 0.76 1.00 - - 
   G-C 0.24 0.12 2.27 1.31-3.91 2.00x10-3 
PON2 rs2237585-rs11976060 2.00x10-3 T-C 0.55 0.42 1.00 - - 
   C-C 0.45 0.58 0.61 0.40-0.93 0.02 
PTGER3 rs2050066-rs6424414-rs2300167-rs6678886 2.00x10-3 T-C-T-A 0.40 0.39 1.00 - - 
   T-T-T-A 0.17 0.29 0.59 0.33-1.06 0.06 
   T-T-T-G 0.11 0.05 2.12 0.92-4.75 0.05 
TNF-α rs1800683-rs2229094 2.00x10-3 G-T 0.59 0.45 1.00 - - 
   A-T 0.21 0.25 0.66 0.38-1.11 0.10 
   A-C 0.13 0.27 0.37 0.20-0.68 1.00x10-3 
TNF-α rs1800683-rs2229094-rs1799964-rs1800629 2.00x10-3 G-T-T-G 0.39 0.33 1.00 - - 
   A-C-C-G 0.11 0.19 0.51 0.25-1.00 0.04 
Fetal 
   A-C-T-G 0.02 0.07 0.27 0.05-0.93 0.03 
1Global P is the p-value for the haplotype sliding window 
*Only haplotypes with frequencies of 5% in at least one status group and with a significant OR are presented. 
*ORs are calculated comparing each haplotype to the highest frequency haplotype. 
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Table 4-8.  Significant results by KEGG pathway  
 
African American KEGG Pathway  
(tags with r2 ≥ 0.60) # Genes MotherA FetalA 
Apoptosis 12   
Arachidonic acid metabolism 5   
Compliment and coagulation cascade 6   
Cytokine-cytokine receptor interactions 31 AG AG 
Focal adhesion 6   
Hematopoietic cell lineage 12  A 
Jak-STAT signaling pathway 14  AG 
MAPK signaling pathway 18   
Neuroactive ligand-receptor interaction 12   
T cell receptor signaling pathway 12  AG 
Toll-like receptor signaling 14   
Type I diabetes mellitus 7   
Other (Genes not in other pathways) 55   
*A indicates statistically significant allelic association 
*G indicates a statistically significant genotypic association 
 
 
Pathway analysis 
All 130 genes were grouped into KEGG biological process pathways (Table 4-8); 
we included in our analyses all pathways with at least 5 genes and allowed for genes to 
be included in more than one pathway.  Globally, across all single locus allelic analyses, 
both maternal and fetal samples had more significant allelic association tests than would 
be expected given the number of tests performed (Table 4-8). In fetal data, the cytokine 
pathway, T cell receptor signaling, and Jak-STAT signaling were significant for both 
allele and genotype tests; the hematopoietic cell lineage was significant for only allelic 
tests.   
There was much overlap between genes across pathways.  Examining the genes in 
the cytokine pathway, there were some genes unique to either maternal data or fetal data.  
For example, chemokine (C-C motif) ligand 2 (CCL2), chemokine (C-C motif) ligand 8 
(CCL8), interleukin 1 beta (IL-1β), interleukin 4 receptor (IL-4R), and interleukin 6 
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receptor (IL-6R) were associated in maternal but not in fetal data; while, interleukin 10 
(IL-10), interleukin 1 receptor type II (IL-1R2), interleukin 2 (IL-2), interleukin 8 (IL-8), 
and tumor necrosis factor alpha (TNF-α) were associated in fetal but not maternal data.  
In the cytokine pathway maternal data had five genes with single locus associations’ ≤ 
10-3 (IL-1RAP, IL-2RA, IL-15, IL-6R and sTNF-R2).  Fetal samples had three (IL-2, IL-
2RB, TNF-α) genes with single locus associations ≤ 10-3 in the cytokine pathway, three 
in the hematopoietic cell lineage pathway (IL-1R2, TNF-α, and CD14), two in the Jak-
STAT signaling pathway (IL-2 and IL-2RB), and three in the T cell receptor signaling 
pathway (IL-2, TNF-α, CTLA4).   
All of the genes within fetal associated pathways, with the exception of the 
neuroactive ligand-receptor binding pathway, overlap with the cytokine pathway 
suggesting that the strongest associated pathway is in the cytokine pathway.  Examining 
each of the non-cytokine pathways in detail did not reveal any clear within pathway 
patterns of association in maternal or fetal data. 
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a. 
# of 
Loci Model 
Testing 
Averaged 
Balanced  
Accuracy (%) 
Cross Validation 
Consistency 
(CVC) 
1 rs1800890 (IL-10) 51.18 4/10 
3 rs3024498 (IL-10) x rs1800683 (TNF-α) 62.46 8/10  
b. 
A/A
A/G
G/G
rs
30
24
49
8
A/A A/G G/G
rs1800683
 
High-Risk 
Low-Risk 
 
Figure 4-3.  MDR T cell receptor two locus model between TNF-α and IL-10 
Each multifactor cell is labeled as “high risk” or “low risk”.  For each multifactor 
combination, hypothetical distributions of cases (left bar in cell) and controls (right bar 
in cell) are shown.  Each multilocus genotype is labeled on the figure.  The testing 
average balanced accuracy is 62.46% (p-value = 0.03) with a cross-validation consistency 
of 8/10.  Logistic regression analyses showed that the interaction for the additive effects 
of these two markers was statistically significant (p = 0.02) and the LR test p value for 
including the interaction in the logistic regression model was 0.02 
 
 
Multi-locus analysis 
 Multilocus analyses examining the full dataset did not reveal any statistically 
significant multilocus associations; however, analyses within pathways with an excess of 
statistically significant associations (based on Z tests from pathway analyses) revealed a 
statistically significant two-locus model in the T cell receptor-signaling pathway in fetal 
data (Figure 4-3a, b).  This model included a marker in TNF-α  (rs1800683) and in IL-10 
(rs3024498) and was confirmed with logistic regression analyses.  The testing average 
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balanced accuracy was 62.46% and the CVC was 8/10 (permutation p = 0.03).  The LR 
test showed that the interaction model (p = 0.02) was statistically significant. 
 
Discussion 
 The present study examined multiple new and previously established PTB 
candidate genes in efforts to elucidate the mechanisms underlying PTB in African 
Americans.  We observed multiple interesting single locus and haplotype associations in 
both maternal and fetal data and confirmed previously established candidates.  In 
addition, pathway analyses demonstrated the strongest associated pathways related to 
infection and inflammation in both maternal and fetal data.  A two-locus interaction was 
found in markers of the T cell receptor-signaling pathway of fetal data.  These findings 
suggest that the documented elevated rates of infection seen in African American PTB 
may have a genetic basis (Goldenberg and Andrews, 1996;Hitti et al., 1997).   
Single locus and haplotype associations revealed several interesting findings.  
Three coding variants associated in single locus and haplotype tests of association. Single 
locus associations identified a nonsynonymous amino acid change (602 E/K) in HSPA1L 
maternal samples, while haplotype associations identified a nonsynonymous amino acid 
change (13 R/C) in TNF-α fetal samples.  Given that these coding variants result in 
nonsynonymous amino acid changes, they are likely to contribute to functional effects.  
One haplotype was associated in maternal data (IL-6R) and nine were associated in fetal 
data (CD14, CTLA4, IL-2, IL-2RB, MMP9, PON2, PTGER3, and two in TNF-α).  Of 
note, one of the associated haplotypes in TNF-α (rs1800683-rs2229094-rs1799964-
rs1800629) included a well established PTB candidate -308 (rs1800629) (Aidoo et al., 
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2001).  TNF-α -308 also had a marginally significant main effect in fetal samples but it 
did not associate in maternal data even at the marginal level.    
Replication of TNF-α -308 associations in maternal data has been inconsistent 
across studies (Kalish et al., 2004).  Despite this, elevated levels of TNF-α have been 
observed in PTB (Macones et al., 2004;Menon et al., 2006a), supporting a role for this 
gene in African Americans.  It may be that fetal tissues rather than maternal tissues are 
contributing to the elevated TNF-α levels.  A large cohort study by Aidoo et al. 2001 
associated TNF-α  -308 with fetal genotype in PTB, malaria, and with increased fetal 
mortality (Aidoo et al., 2001).  Their results suggest that -308 may have a genetic effect 
but with fetal genotype rather than maternal.  Our results are consistent with a fetal -308 
single marker genotype effect as well as a haplotype specific effect. 
 The success of a pregnancy is highly dependent on the suppression of maternal 
immunity and attack by fetal alloantigens.  Present understanding of PTB is limited and it 
is unclear as to what interactions may be occurring between maternal and fetal genetic 
information.  In our study we observed several associations in genes and their receptors 
across maternal and fetal data that suggest interactions may be occurring between 
maternal and fetal genetic information.  We observed that in maternal samples IL-2RA 
and sTNF-R2 associated with PTB and in fetal samples IL-2, IL-2RB, and TNF-α 
associated with PTB.  These results are not necessarily surprising as organ explant studies 
suggest that both IL-2 and TNF-α are released by the amniochorion and not the maternal 
membranes (Aidoo et al., 2001) and other studies support that IL-2RA is regulated by the 
mother (Aidoo et al., 2001;Menon and Fortunato, 2004).  With regard to TNF-α, it is 
regulated by complex interactions with its receptor during pregnancy.  Elevated levels of 
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sTNF-R2 are usually the result of expression by cells of the immune system and are 
elevated in several inflammatory disorders (Zoller et al., 2007), while sTNF-R1 has 
typically been thought to play a role in pregnancy maintenance.  The association with 
sTNF-R2 further supports the contention that infection may contribute to PTB in African 
Americans.  Another gene PTGER3 (associated in fetal data) is expressed in the amnion 
but biological interaction between it and IL-1RA has been previously observed and 
suggests a maternal-fetal interaction may be occurring (Bry et al., 1993;Hirsch et al., 
1999;Waleh et al., 2004).  IL-1RA is associated in maternal data and is known to cause 
reduced prostaglandin production in the amnion/chorions (Bry et al., 1993;Hirsch et al., 
1999;Waleh et al., 2004).   Our results suggest interplay between these receptors and 
cytokines in the maternal-fetal unit may be in response to infection (Hirsch et al., 1999).   
 Several interesting results were observed in fetal data.  The majority of the genes 
identified are known to be expressed in fetal tissue and are related to infection and/or 
inflammation during pregnancy.   Studies examining CD14 (Hartel et al., 2004;Henneke 
et al., 2003;Kalish et al., 2006), CTLA4 (Schaub et al., 2006), IL-2 (Menon and 
Fortunato, 2004), MMP2 (McLaren et al., 2000;Tu et al., 1998), MMP9 (McLaren et al., 
2000;Tu et al., 1998), PON2 (Chen et al., 2004a), PTGER3 (Waleh et al., 2004), and 
TNF-α (Menon and Fortunato, 2004) have observed the expression of these genes in fetal 
tissues (amnion/chorion) and little or no expression in the decidua.  These data and our 
associations together support a genetic basis for the observed alterations in expression 
levels of these genes in fetal tissues in the presence of PTB. 
 Despite basing our candidates on hypothetical PTB pathways, we analyzed genes 
according to biological processes and identified the cytokine/infection/inflammation 
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pathway as the strongest associated pathway.  This is a very promising finding given that 
African Americans are known to have a higher susceptibility to infection during 
pregnancy.  In addition to this we observed the strongest number of associations with 
fetal genotype rather than with maternal genotype, suggesting that the fetal genetic 
contribution to PTB may exceed the maternal contribution.  Sample size is a major 
limitation to our study; however, given the patterns of associations observed within genes 
and by pathway, it is clear that several of the findings are consistent with established 
literature.  
In conclusion, we conducted an association study on PTB in an African American 
population and found several interesting association confirming several established PTB 
candidates.  We observed several cytokines and receptors to associate across maternal 
and fetal data that suggest that a maternal-fetal exchange of genetic information may be 
contributing to the observed PTB.  We also identified the cytokine infection and 
inflammatory response pathway as having the largest number of statistically significant 
associations across maternal and fetal data.  Finally, we found a promising interaction 
between TNF-α and IL-10.  These studies, although not conclusive did identify several 
interesting candidates for follow-up in replicate studies.  Although many of the genes 
identified in Chapter IV part A overlap in the Caucasian population the majority of the 
genes identified here were those that participate in PTB through infection and 
inflammatory response pathways, in contrast to Caucasians were associations were also 
seen in pathways involved in decidual hemorrhage.   These results suggests that many of 
the genetic factors that lead to PTB overlap across ethnic populations but mostly with 
regard the infection and inflammatory response pathways. 
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CHAPTER V 
 
EXAMINING MULTILOCUS INTERACTIONS BETWEEN PRETERM BIRTH 
CANDIDATE GENES 
  
Introduction 
No studies have been performed comprehensively examining multilocus 
interactions in PTB on a large scale.  In the present study we sought to address this 
deficiency by searching for epistatic interactions between PTB candidate genes in 
Caucasian and African American maternal and fetal populations and for maternal-fetal 
data.  Multilocus interactions were analyzed by the use of Multifactor Dimensionality 
Reduction (MDR) (Hahn et al., 2003;Ritchie et al., 2001), a nonparametric approach 
developed to detect epistatic interactions in the absence of main effects that accepts case-
control categorical and binary data (Hahn et al., 2003;Ritchie et al., 2001).  Statistical 
significance of an MDR model was calculated by permutation testing.   
Maternal-fetal interactions were examined by doubling the dimensions of the 
MDR model.  For example, if 27 loci were genotyped 54 dimensions would be assessed 
(27 from mother and 27 from fetus).  We also performed analyses within pathways, as 
previous studies suggest that this is a reasonable approach to reduce noise in an MDR 
analysis (Williams et al., 2004).  We examined pathways individually and all pairwise 
combinations of pathways (defined by KEGG biological pathways).  After performing all 
multilocus analyses, no single analysis produced a result that could be considered a 
strong multilocus model for PTB.   However, promising results were seen in both 
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Caucasian maternal and African American fetal samples that could be followed up in 
future studies. 
 
Materials and Methods 
Study population, DNA sampling and genotyping 
 The study sample and experimental detail are provided in Chapter III part B.   
Demographic variables for the Caucasian and African American populations analyzed in 
the present study are described on Table 3-8. 
Multifactor Dimensionality Reduction (MDR) and analyses performed 
MDR.   In the first step of MDR, the dataset is divided into multiple partitions for 
cross validation (CV) (Ritchie et al., 2001).  Five-fold CV was used in the present 
analyses as studies suggest that this is a powerful and computationally efficient approach 
to find the best model (Motsinger and Ritchie, 2006).  In five-fold CV, the training set is 
comprised of 4/5 of the data, while the testing set is comprised of the remaining 1/5 of the 
data. Second, a set of variables (i.e. SNPs) is selected.  MDR exhaustively searches all 
single locus and all multilocus combinations of the data and collapses data into high and 
low risk categories on the basis of the ratio of cases to controls in each cell.  It ultimately 
selects one genetic model, either single or multilocus, that most successfully predicts 
class or phenotype.   
 The final model is chosen from this set of models based upon maximization of 
testing accuracy and CVC.  When prediction accuracy and CVC indicate different 
models, parsimony is used to choose the simplest model (the model with the fewest loci) 
(Hahn et al., 2003).   
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 The data consisted of an unbalanced ratio of cases to controls, therefore, balanced 
accuracy was used in place of accuracy for the analyses (Velez et al., 2007b).  Balanced 
accuracy is statistically equivalent to accuracy when datasets are completely balanced 
and is calculated from the average of sensitivity (the ability of a test to correctly identify 
those who have the disease) and specificity (the ability of a test to correctly identify those 
who do not have the disease) of the MDR model.   Open-source MDR software is 
available at MDR (available at www.epistasis.org). 
 MDR analyses performed.  Multi-locus analyses were performed examining all 
SNPs within the dataset both within Caucasian and African American maternal and fetal 
data as well as exploratory multilocus analyses of significant pathways.  A 
comprehensive list of the analyses performed is presented on Table 5-1.  Two way 
interactions were examined in African Americans and two and three way interactions 
were examined in Caucasians.  Analyses performed include:  full data, pathways, 
pairwise pathways, and analysis with and without single marker main effects (for either 
allele or genotype tests of association).  These analyses were followed by examination of 
maternal-fetal interactions both within the full data and within pathways.  Finally, for the 
final portion of the analysis (described in Chapter IV part A) we considered only markers 
that had statistically significant single locus effects.  All MDR analyses with statistically 
significant permutation tests were followed up with logistic regression analyses modeling 
the interaction.  This was finally followed up with a likihood ratio (LR) test modeling the 
interaction in logistic regression.  Models were only considered significant if they were 
confirmed with logistic regression analyses.   
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Table. 5-1. List of MDR analyses performed 
Analyses Performed 
Full data in African Americans (both within maternal and within fetal samples) 
Full data in Caucasians (both within maternal and within fetal samples) 
Full data in African Americans with only tag SNPs (both within maternal and within fetal samples) 
Full data in Caucasians with only tag SNPs (both within maternal and within fetal samples) 
SNPs with significant single locus association in African Americans (both within maternal and within fetal samples) 
SNPs with significant single locus association in Caucasians (both within maternal and within fetal samples) 
SNPs with significant single locus association in African Americans with only tag SNPs (both within maternal and within fetal samples) 
SNPs with significant single locus association in Caucasians with only tag SNPs (both within maternal and within fetal samples) 
No SNPs with significant single locus association in African Americans (both within maternal and within fetal samples) 
No SNPs with significant single locus association in Caucasians (both within maternal and within fetal samples) 
No SNPs with significant single locus association in African Americans with only tag SNPs (both within maternal and within fetal samples) 
No SNPs with significant single locus association in Caucasians with only tag SNPs (both within maternal and within fetal samples) 
Pathways in African Americans (both within maternal and within fetal samples) 
Pathways in Caucasians (both within maternal and within fetal samples) 
Pairwise pathways (both within maternal and within fetal samples) in Caucasians considering all markers within a pathway 
Pairwise pathways (both within maternal and within fetal samples) in Caucasians considering all markers with a significant association 
Pairwise pathways (both within maternal and within fetal samples) in African Americans considering all markers within a pathway 
Pairwise pathways (both within maternal and within fetal samples) in African Americans considering all markers with a significant association
Maternal-fetal interactions in African Americans full data and within pathway 
Maternal-fetal interactions in Caucasians full data and within pathway 
Maternal-fetal interactions in African Americans, markers with significant associations in full data and within pathways 
Maternal-fetal interactions in Caucasians, markers with significant associations in full data and within pathway 
Maternal-fetal interactions in African Americans, no markers with significant associations in full data and within pathways 
Maternal-fetal interactions in Caucasians, no markers with significant associations full data and within pathway 
Significant pathways, only significant markers, and doing a systematic removal of markers with strong single locus associations 
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Table 5-2.  Full data MDR analysis 
Population # of Loci 
Best Model 
For Each Interaction 
Average 
Balanced 
Accuracy 
(%) 
CVC 
1 rs879293 (tPA) 59.94 5/5 
2 rs879293 (tPA) x  rs6424776 (PTGFR) 58.73 2/5 Caucasian 
Maternal 
3 rs879293 (tPA) x rs6424776 (PTGFR)x rs380691 (DHFR) 51.24 1/5 
1 rs522796 (KL) 51.31 2/5 
2 rs6424776 (PTGFR) x rs1801133 (MTHFR) 61.78 4/5 Caucasian 
Fetal 
3 rs6424776 (PTGFR) x rs1801133 (MTHFR) x  rs3794808(SLC6A4) 53.05 1/5 
1 rs5744068 (TLR8) 46.51 1/5 African American 
Maternal 2 rs3783950 (MMP2)xrs243836 (TSHR) 40.4 2/5 
1 rs243836 (MMP2) 46.23 1/5 African American 
Fetal 2 rs3788050 (CBS) x rs1061628 (sTNF-R2) 57.3 3/5 
 
 
Results 
 Full data analyses (Table 5-2) identified a one locus model in Caucasian maternal 
samples (tPA rs879293 5/5 = CVC, and p value ~ 0.01) and a two locus model in 
Caucasian fetal samples (PTGFR rs6424776 and MTHFR rs1801133, CVC = 4/5 p ~ 
0.01).  The LR test for interactions in the Caucasian fetal model had a p <10-3; however, 
upon examination of the multilocus model it appears to be driven by the presence of a 
rare genotype in rs6424776.  The models identified in African Americans were not 
statistically significant.  Of note, PTGFR was common to models in Caucasian maternal 
and fetal samples and matrix metalloproteinase 2 (MMP2) was common to African 
American maternal and fetal samples, common associations in maternal and fetal samples 
may be due to maternal fetal sharing. 
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Table 5-3.  Pathway MDR analysis 
Population/ 
Pathway 
# of 
Loci 
Best Model 
For Each Interaction 
Average 
Balanced 
Accuracy 
(%) 
CVC 
1 rs879293 (tPA) 58.90 5/5  
2 rs9332575 (FV) x rs879293 (tPA) 57.43 3/5 
Caucasian Maternal 
(Compliment 
& 
coagulation) 3 rs879293 (tPA) x rs2070682 (SERPINE1) x  rs12131397 (FV) 52.80 1/5 
1 rs3211719 (FVII) 46.31 2/5 
2 rs2070852 (FII) x rs12131397 (FV) 54.02 3/5 
Caucasian Fetal 
(Compliment 
& 
coagulation) 3 rs2070852 (FII) x rs1894697 (FV) x  rs12131397 (FV) 55.14 3/5  
1 rs4848306 (IL-1B) 53.06 3/5  African American 
Maternal 
(Type I diabetes) 2 rs9658742 (FAS) x rs10027390 (IL-2) 49.20 3/5 
1 rs740841 (TNFRSF1A) 58.89 3/5 African American Fetal 
(Apoptosis) 2 rs740841 (sTNF-R1) x  rs1800683 (sTNF-R1) 60.58 4/5  
 
 
Table 5-4.  Pairwise pathway MDR analysis 
Population/ 
Pathway 
# of 
Loci 
Best Model 
For Each Interaction 
Average 
Balanced 
Accuracy 
(%) 
CVC 
1 rs879293 (tPA) 58.90 5/5 
2 rs879293 (tPA) x rs9332575 (FV) 60.60 3/5 
Caucasian Maternal 
(Compliment & 
coagulation & 
Arachidonic acid 
metabolism) 
3 rs879293 (tPA) x rs3820185 (PLA2G4A) x rs2227631 (SERPINE1) 53.83 2/5 
1 rs7674640 (NFKB1) 43.13 2/5 
2 rs2420369 (FV) x  rs2070852 (FII) 50.12 1/5 
Caucasian Fetal 
(Compliment & 
coagulation & 
T cell receptor 
signaling) 
3 rs879293 (tPA)  x rs7674640 (NFKB1)  x rs1800890 (IL-10) 59.95 3/5 
1 rs12885526 (TSHR) 52.28 2/5 African American 
Maternal 
(Neuroactive ligand 
receptor & 
T cell receptor 
signaling) 
2 rs6713532 (POMC)  x rs10027390 (IL-2) 58.85 3/5 
1 rs2069771 (IL-2) 48.83 2/5 African American Fetal 
(Cytokine & Other) 2 rs3789204 (TREM1)  x rs1061628 (sTNF-R2) 61.53 4/5 
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Pathway analyses (Table 5-3) with Caucasians maternal samples again identified 
tPA rs879293 5/5 = CVC.  No other significant models were identified by pathway 
analyses in any other population.  Analyses between pairwise pathways (Table 5-4) also 
identified tPA rs879293 within Caucasian maternal samples.  A three locus model was 
also identified in Caucasian fetal samples (tPA rs879293, PLA2G4A rs7674640, and 
SERPINE1 rs2227631 CVC = 3/5 and p = 0.03).  No significant models were found in 
African American maternal or fetal samples.   
 
Table 5-5.  Best results from MDR analysis of significant single locus associations 
and nonsignificant single locus associations both overall and within pathways 
 
Population/ 
Pathway 
 
# of 
Loci 
 
Best Model 
For Each Interaction 
 
Average 
Balanced 
Accuracy 
(%) 
 
CVC 
1 rs3211719 (FVII) 45.83 1/5 
2 rs6424776 (PTGFR) x rs1801133 (MTHFR) 56.11 4/5 
Caucasian Fetal 
(No significant single locus 
associations 
or genes with 
genes with significant single locus 
associations) Overall data 3 
rs646474 (SERPINH1) x rs6424776 
(PTGFR) x rs3917273 (IL-1R1) 53.06 1/5 
1 rs17007610 (IL-15) 60.64 3/5 African American Maternal 
(Significant single locus associations 
including all 
markers in gene) Other Pathway 
2 rs1700610 (IL-15) x rs10027390 (IL-2) 65.01 3/5 
 
 
 No significant models were found in analyses by removing or including main 
effects from the datasets used in the MDR analysis (Table 5-5).  Further analyses were 
performed examining main effects and systematically removing markers, and are 
presented in Chapter IV part A for Caucasians and part B for African Americans.  
 
  125
Table 5-6.  Best results from MDR analysis of maternal-fetal interactions 
 
Population/ 
Pathway 
 
# of 
Loci 
 
Best Model 
For Each Interaction 
 
Average 
Balanced 
Accuracy 
(%) 
 
CVC 
1 Maternal rs879293 (tPA) 59.21 5/5 
2 Fetal rs17561(IL-1A) x Maternal rs879293 (tPA) 62.15 3/5 
Caucasians 
 
3 Fetal rs7901656 (FAS) x Maternal rs879293 (tPA) x Maternal rs12131397 (FV) 52.34 1/5 
1 Fetal rs84460 (IL-2RB) 46.68 1/5 African 
American 2 Fetal rs7698675 (IL-15) x Maternal rs10027390 (IL-2) 64.95 4/5 
 
 
 Finally, multilocus analyses were performed examining maternal-fetal 
interactions.  No models were found in African American samples; however, in 
Caucasian samples an interaction was found between fetal IL-1A rs17561 and maternal 
tPA rs879293 (CVC = 3/5 and p <10-3).  The LR tests for this model had a p value 
6.0x10-3.  
 
Discussion 
 A comprehensive multilocus analysis was performed in Caucasian and African 
American maternal and fetal samples including analyses of maternal-fetal interaction, in 
efforts to more clearly understand the etiology underlying PTB.  Several marginally 
significant results were found with a few that were significant in logistic regression 
analyses, including a model in Caucasians examining maternal-fetal interaction (tPA 
rs879293 and IL-1A rs17561).  We were underpowered for several of the analyses, in 
particular for African American maternal and fetal analyses and Caucasian and African 
  126
American maternal-fetal analyses.  This may be the reason for weak permutation test p 
values and low CVC.     
A major issue encountered in these analyses was the influence of main effects on 
multilocus analyses; almost all models identified in full data analyses included a strong 
main effect.  For example, the strongest association we identified in single locus analyses, 
tPA rs879293, in Caucasian maternal data was in every model of Caucasian maternal 
analyses.  As a result of this we performed several analyses both with and without main 
effects.  Unfortunately, no models were found with strong CVC in these analyses.  It is 
possible that MDR may not be appropriate for these analyses given that MDR was 
designed to detect interactions in the absence of main effects.  The main effects that we 
identified in the multilocus analyses were the same main effects identified in single locus 
analyses of alleles and genotypes (Chapter IV part A and B). 
Of note, we also performed full data analyses both within Caucasian and African 
American maternal and fetal data by selecting tag SNPs (r2 less than or equal to 0.90).  
Selecting tags reduced the number of SNPs by a negligible amount and produced the 
same models identified in the full data analysis without selecting tags.  We concluded 
that LD does not have great influence over the MDR analyses, this is not surprising given 
that markers were chosen, based on being tags in the representative populations of the 
HapMap. 
We did identify some interesting multilocus associations in Caucasian maternal 
and African American fetal samples that are described in detail in Chapter IV part A and 
B.  However, an issue regarding these analyses is that all of the analyses performed 
(greater than 800) increase the likelihood of finding a false positive which reduces our 
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confidence in these results.  We cannot conclude that these were real multilocus 
interactions, despite the strong statistical evidence.  To determine if these associations are 
not spurious false positive findings, future analyses will be performed in a larger powered 
dataset, with MDR analyses focused on the promising associations found in the present 
study. 
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CHATPER VI 
 
MITOCHONDRIAL DNA VARIANT A4917G, SMOKING AND SPONTANEOUS 
PRETERM BIRTH  
 
 
Overview 
The exact cause of PTB is unknown but oxidative stress may play an important 
role. Genetic studies have recently begun to elucidate the role of genetic variation in PTB 
but these studies have overlooked the mitochondrial genome/gene(s) as a plausible PTB 
candidate.  In the present study we sought to document associations between 
nonsynonymous mitochondrial DNA (mtDNA) variants A4917G, G10398A and T4216C 
and PTB. We performed a case (PTB - less than 36 weeks gestation) - control (normal 
term - ≥ 37 weeks) analysis of these mtDNA markers and examined their potential 
interaction with smoking in PTB.  A sample of 422 pregnant Caucasian women (220 
preterm and 202 terms) was examined for association.  Haplogroup T marker A4917G 
was identified as a possible candidate for association with PTB after adjusting for 
smoking (OR = 1.99 [95% CI 0.93-4.24]) as was T4216C (OR = 1.63 [95% CI 0.93-
2.83]).  No significant multi-locus interactions or interactions with other environmental 
variables were observed.  Our data, although preliminary, support the hypothesis that 
mitochondrial genome polymorphisms may play a significant role in PTB through an 
interaction with smoking.   
(Chapter VI adapted from Velez et. al. “Mitochondrial DNA variant A4917G, smoking 
and spontaneous preterm birth.”  Mitochondrion In press.) 
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Introduction 
Previous studies have found evidence indicating that PTB has a substantial 
genetic component (Romero et al., 2006;Romero et al., 2007;Varner and Esplin, 2005).  
However, genetic studies have focused on genes in a limited number of specific 
pathophysiological pathways proposed to affect risk of PTB (Lockwood and Kuczynski, 
2001) and/or on SNP(s) thought to have functional effects based on in vitro analysis.     
In the previous genetic studies, the mitochondrial genome has been overlooked 
despite the fact that it is a very plausible candidate (Agarwal et al., 2006). The mtDNA is 
of particular interest because oxidative stress is likely to play an important role in the risk 
of PTB. Specifically, previous studies have shown that pregnancy results in increased 
oxidative stress (Myatt and Cui, 2004) and that during labor, in particular, higher levels 
of serum hydroperoxides exist compared to women not in labor (Fainaru et al., 2002).  
Given that both cell apoptosis and oxidative stress during pregnancy may contribute to 
adverse pregnancy outcomes, it is logical to examine mitochondrial DNA (mtDNA) 
variants for association with PTB.  
Other lines of evidence also support the hypothesis that mtDNA variation may 
contribute to PTB.  For example, in the early stages of pregnancy environmental toxins 
can contribute to PTB via oxidative stress, imbalanced production of ROS and reactive 
nitrogen species (RNS) (Mohorovic, 2004).  During the initial stages of pregnancy the 
fetus is unable to defend itself against hypoxia (Jaffe et al., 1997;Jaffe, 1998;Jauniaux et 
al., 2000) and the oxidative stress that increases apoptosis (Jaffe, 1998).  Hypoxia in turn 
leads to disrupted maternal vascular endothelium, accumulation of endothelin, 
thromboxane, superoxides, an increased sensitivity to angiotensin II, and decreased 
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formation of vasodilators (i.e. nitric oxide) (Granger et al., 2002;Roberts, 1998;Roberts, 
2000).  High levels of lipid peroxides have been associated with PTB, suggesting an 
exposure to oxidized nitrogen compounds (Tabacova et al., 1997;Tabacova et al., 1998).   
In the present study we decided to focus on three well established mtDNA 
variants that have been seen to associate with several phenotypes:  A4917G, G10398A, 
and T4216C.  A4917G is a well established marker of the haplogroup T, which has been 
associated with several phenotypes (Ruiz-Pesini et al., 2004;Tanaka et al., 1998).  Both 
A4917G and T4216C (Ruiz-Pesini et al., 2000;Ruiz-Pesini et al., 2004) result in non-
conservative amino acid changes that increase reactive oxygen species (ROS) production 
and electron leakage, directly leading to mtDNA and nuclear DNA mutations and 
dysfunction (Penta et al., 2001;Robinson, 1998;Smeitink and van den, 1999).  These 
markers have been associated with Leber’s Hereditary Optic Neuropathy (LHON) and 
Parkinson’s disease (Fauser et al., 2002;Hofmann et al., 1997;Howell et al., 
1995;Kirchner et al., 2000;Ross et al., 2001;Ross et al., 2003). In addition, G10398A has 
been associated with multiple disease phenotypes potentially related to oxidative damage, 
including Parkinson’s disease, Alzheimer’s disease, Friedreich’s ataxia, and amyotrophic 
lateral sclerosis (Giacchetti et al., 2004;Ivanova et al., 1998;Mancuso et al., 2004;Ross et 
al., 2001;Shoffner et al., 1993;van der Walt et al., 2003;van der Walt et al., 2004). Since 
both apoptosis and oxidative stress are putative risk factors for PTB, we hypothesize that 
these non-conservative mtDNA polymorphisms in the subunits of Complex I of the 
electron transport chain associate with PTB. Given previous observed associations 
between smoking and PTB we decided to examine smoking for interactions with mtDNA 
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variants.  In this study, we examine the association of the above described mitochondrial 
markers with PTB in white maternal DNA samples from preterm and term deliveries.   
 
Materials and Methods 
Study population 
Caucasian subjects were recruited at the Centennial Medical Center, Nashville, 
TN and Magee Women’s Hospital, Pittsburgh, PA.   Please refer to Chapter III part A for 
a description of subject recruitment. 
Demographic and clinical characteristics 
Our study included 220 case and 202 control maternal-fetal paired samples. As 
mtDNA is maternally inherited, fetal genotype should be identical to maternal genotype. 
All maternal-fetal pairs were genotyped as a means of genotyping quality control. 
Smoking status was obtained by questionnaire as described earlier in Chapter IV. 
DNA sampling and genotyping 
DNA was isolated from maternal and cord blood samples, using the Autopure 
automated system (Gentra Systems (Minneapolis, MN).  Genotyping was done using 
5’nuclease allelic discrimination TaqMan assay on an ABI 7900 (Applied Biosystems of 
Foster City, CA).  Three mtDNA single nucleotide polymorphisms (SNPs) were 
examined: A4917G, G10398A, and T4216C.  Genotype data were analyzed using ABI 
Sequence Detection System version 2.1 software and confirmed by visual inspection of 
the plots. Genotypes were classified as undetermined if PCR amplification failed with the 
specified sets of probes and primers.  
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Statistical methods 
 Continuous demographic data were analyzed using Mann-Whitney two sample 
rank sum tests, as data were not normally distributed and categorical demographic data 
were analyzed using a χ2 test.  Both univariate and multivariate analyses were used to 
examine the association between markers and PTB.  For univariate analyses χ2 tests were 
used to compare allele frequencies between cases and controls. Since the mtDNA 
markers are all homoplastic (one allele present for an individual) a single test was 
performed. The major allele was treated as the baseline allele for χ2 tests and calculations 
of OR/effect sizes with 95% confidence intervals.  The major allele was A for A4917G 
and G10398A and T for T4216C.  Multivariate logistic regression analyses were 
performed to assess the relationship between PTB and genetic variation, adjusting for 
smoking, as smoking was significant at the 0.05 level.  Other potential confounders were 
assessed in preliminary analyses, including body mass index (BMI), years of education 
and income, but did not affect results and are not presented. STATA 9.0 statistical 
software (StataCorp, College Station, TX) (StataCorp, 2007) was used for both univariate 
and multivariate analyses.   
 
Results 
The medians and interquartile ranges of demographic and clinical characteristics 
for cases and controls are listed in Table 6-1.  Significant differences between cases and 
controls were observed for birth weight, APGAR 1, APGAR 5, and gestational age at 
delivery (weeks) (as expected) with p-value <0.01.  Smoking was significantly associated 
with PTB (p < 0.01).  
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Table 6-1.  Demographic characteristics 
Caucasian 
Control 
(N=202) 
Case 
(N=220) 
Variable 
Median [IQR] Median [IQR] 
1P-value 
Gestational Age 39 [37-42] 33 [23-36] <0.01 
Gestational Weight (g) 3433 [370-4661] 1879 [370-3790] <0.01 
Maternal Age (yrs) 28 [18-40] 27 [18-40] 0.26 
APGAR 1 8 [4-9] 8 [1-9] <0.01 
APGAR 5 9 [7-10] 9 [1-9] <0.01 
Smoking Status (Count) 15% 29% <0.01 
1P-value-refers to p-value after comparing term to preterm; if continuous data was not normally distributed 
and a Mann-Whitney two-sample rank sum test was used.  A χ2 test was used for comparisons of smoking 
counts. 
*IQR-interquartile range 
 
Single marker analysis of mitochondrial variants did not reveal statistically 
significant associations (Table 6-2). Given the strong association found between cases 
and controls for smoking, we performed logistic regression analyses to examine the 
interaction between smoking and the mtDNA variants (Table 6-3a, b, and c). We 
performed this analysis under the hypothesis that smoking may be interacting with 
genotype, as smoking confers an increased risk for PTB by increasing oxidative stress 
and has been seen to interact with genotype in several disease phenotypes.  Our analyses 
did not reveal any statistically significant interactions with smoking or any of the mtDNA 
polymorphisms.  However, upon adjusting for the effect of genotype x smoking 
interaction the main effects of both A4917G and T4216C trended towards significance, 
with p-values of 0.07 and 0.08, with ORs of 1.91 [95% CI 0.89-4.11] and 1.65 [95% CI 
0.91-2.81], respectively. 
Because of the strong effect of smoking in our sample a secondary analysis on 
non-smokers was performed (Table 6-4).  In cases, both A4917G (Table 6-4a; OR 1.99 
[95% CI 0.93-4.24]; p-value = 0.07) and T4216C (Table 6-4c; OR 1.63 [95% CI 0.93-
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2.83]); p-value = 0.08) became marginally significant in non-smokers.  C10398A (Table 
6-4b) was still non-significant after removing smokers. 
 
Table 6-2. Univariate data analysis A4917G, G10398A, and T4216C  
 
Status 
Case Control Marker Allele 
(N = 220) (N = 202)
OR OR 95% CI P-value 
G 24 18 
A4917G 
A (reference) 193 175 
1.21 0.616-2.45 0.56 
G 43 33 
G10398A 
A (reference) 165 161 
1.27 0.75-2.18 0.35 
Caucasians 49 39 
T4216C 
T (reference) 171 159 
1.17 0.71-1.93 0.52 
 
 
 
Table 6-3.  Multivariate analysis adjusting for confounders and examining smoking 
by genotype interaction 
a.  
Variable OR 95% Confidence Interval P-Value 
Smoking 2.57 1.48-4.48 <0.01 
A4917G 1.91 0.89-4.11 0.07 
Smoking*A4917G 0.33 0.06-1.89 0.21 
b. 
Variable OR 95% Confidence Interval P-Value 
Smoking 2.70 1.48-4.92 <0.01 
G10398A 1.22 0.66-2.54 0.53 
Smoking*G10398A 0.59 0.15-2.37 0.46 
c. 
Variable OR 95% Confidence Interval P-Value 
Smoking 2.73 1.53-4.49 <0.01 
T4216C 1.65 0.91-2.81 0.08 
Smoking*T4216C 0.40 0.10-1.58 0.19 
 
 
 
 
  135
 Table 6-4.  Multivariate analysis adjusting for confounders only using non-smokers 
a. 
Variable OR 95% Confidence Interval P-Value 
A4917G 1.99 0.93-4.24 0.07 
b. 
Variable OR 95% Confidence Interval P-Value 
G10398A 1.19 0.65-2.20 0.57 
c. 
Variable OR 95% Confidence Interval P-Value 
T4216C 1.63 0.93-2.83 0.08 
 
 
Discussion 
A retrospective case-control association study was performed to examine genetic 
variations in several mtDNA related genes of complex I of the electron transport chain in 
an effort to understand their contribution to PTB. In addition, we assessed the interaction 
of these variants with smoking because smoking is a known risk factor for PTB. As 
expected, we observed a strong association between maternal smoking and PTB. 
Approximately 15% of white controls and ~29% white cases smoked (p=0.002), 
supporting a role for environmental sources of oxidative stress that may contribute to 
PTB by interacting with variations in the mtDNA. The strong association of smoking and 
PTB we observed OR 2.3-2.6 exceeds the effect sizes previously published (OR ~ 1.5) 
(Goldenberg and Andrews, 1996;Meis, 2005).  
Both univariate and multivariate analyses adjusting for confounders were 
performed.  Examination of interactions between smoking and mtDNA polymorphisms 
did not reveal any statistically significant associations; however, the main effects of 
A4917G and T4216C became marginally significant upon adjusting for the effect of 
interactions with smoking. Upon stratifying by smoking, non-smokers revealed two 
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marginally significant associations at A4917G and T4216C, further supporting the 
hypothesis that these two markers may influence susceptibility to PTB. Therefore, it is 
still likely that these markers have an effect on PTB when adjusted for smoking, 
especially given the OR of ~2.0. Interactions with smoking need to be considered in any 
analysis of mtDNA because smoking confers such a large increase in risk for PTB from 
oxidative stress that genetic effects related to oxidative damage may not be detected in 
the presence of smoking.  If this is the case, and genetic factors that affect oxidative stress 
are much weaker, but still significant, than the potential environmental factors, then 
statistical association with gene variants will be overwhelmed in the presence of a factor 
such as smoking.  Therefore, it will be important to assess the role of these variants in 
non-smokers only.   
Post-hoc power calculations, using PS statistical software (Goldenberg and 
Andrews, 1996), show that our sample had 80% power to detect an OR of 1.87-2.19 with 
risk allele frequencies of 0.10 and 0.20 (α = 0.05); therefore, a larger sample size may be 
required to detect a statistically more significant effect.  Despite this, marginally 
significant effects for mtDNA polymorphisms were found after stratifying by smoking 
status. Although we cannot draw any strong conclusions as to the role of these markers in 
PTB, our results suggest that in genetic studies of PTB, relating to oxidative stress, 
stratifying by smoking status will be required to detect effects of mtDNA, as smoking is a 
powerful confounder that greatly influences the ability to detect effects. One caveat that 
we have for our study is that we only studied spontaneous preterm birth; other related 
phenotypes such as preterm premature rupture of the membrane (pPROM) and 
preeclampsia may be more related to oxidative stress (Agarwal et al., 2006). However, 
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we would argue that to define genetic risk factors one needs to carefully limit phenotypic 
heterogeneity and we have attempted to do this in our study (Longini et al., 2007). 
Smoking, oxidative stress, and mutations in the mitochondrial respiratory chain 
can lead to PTB by disruption of placental mitochondrial function. Two studies by 
Bouhours-Nouet et al. (2004) and Wiktor et al. (2004) support this contention and found 
that the placenta was susceptible to oxidative damage that can lead to adverse pregnancy 
outcomes (Bouhours-Nouet et al., 2005;Wiktor et al., 2004).   The study by Bouhours-
Nouet et al. (2004), found that maternal smoking, in particular, is associated with 
respiratory chain complex deficiencies in the placenta.  Smoking increases ROS 
production and can have direct effects on both trophoblast formation and amino acid 
uptake in the placenta, affecting amino acid uptake, transfer into the placenta, and 
synthesis (Bouhours-Nouet et al., 2005;Wiktor et al., 2004).  Placental ROS mediated 
damage can either inactivate electron transport chain complexes or inhibit mtDNA 
transcription.  Given that placenta amino acid uptake is carefully regulated by 
mechanisms dependent on the cellular formation of ATP, smoking induced placental 
mitochondrial dysfunction can affect the nutrient transfer by the placenta, resulting in 
fetal stress and PTB.  Our study would suggest that there are variants in the complex I 
mitochondrial electron transport chains that are susceptible to damage by maternal 
smoking and individuals with these variants are susceptible to PTB.  The placental 
mitochondria may be where smoking, induced oxidative stress by smoking, can induce 
adverse effects leading to PTB.   
Based on our data on three markers, we cannot conclude the extent of mtDNA 
contributions to PTB.  However, the strong effect sizes and the trend observed suggest 
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that dismissing the mitochondrial genome’s role in PTB would be premature. Given a 
larger dataset is likely to demonstrate an association with these marker and PTB.  Future 
studies are warranted to confirm the role of mtDNA with PTB. 
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CHAPTER VII 
 
PATTERNS OF CYTOKINE PROFILES DIFFER WITH PREGNANCY 
OUTCOME AND ETHNICITY  
 
 
Overview 
 
PTB is hypothesized to be a disease mediated by a host inflammatory response 
resulting from the release of cytokines. It is likely that no single factor alone adequately 
explains PTB risk; rather, it is more probable that coordinated networks of cytokines 
affect risk. Therefore, we examined the relationships between cytokines/chemokines and 
related biomarkers associated with PTB (cases) and normal term deliveries (controls) in 
African Americans and Caucasians, separately.  Th1 cytokines/chemokines and related 
molecules interleukin (IL)-1, IL-8, and tumor necrosis factor (TNF)-α, TNF soluble 
receptors (sTNF-R1 and sTNF-R2) and Th2 cytokines (IL-6 and IL-10) that were 
previously shown to be associated with PTB were studied.  Correlations between 
biomarkers were calculated; statistical differences between correlations of African 
Americans and Caucasians, and between cases and controls were measured.  Multiple 
differences in correlations were observed between African Americans and Caucasians for 
both cases and controls. Correlation analyses of cytokine/chemokine measurements 
suggest a complex and coordinated interplay between cytokines during pregnancy and 
that significant differences exist in the profiles between African Americans and 
Caucasians, indicating that such analyses may serve as a means of understanding 
differential risk factors in these ethnic groups.   
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Introduction 
 Cytokine and chemokine networks function to maintain homoeostasis during 
pregnancy. Strong inflammatory response mediated by cytokines and chemokines are 
involved in pregnancy complications such as PTB.  In addition, recent in vitro and in vivo 
findings suggest that inflammatory response mediated by cytokines and chemokines may 
not be the same in different geographic populations, and that this may contribute to 
disparity of PTB rates seen between African Americans and Caucasians in the U.S. 
(Demissie et al., 2001;Martin et al., 2003). It is likely that differences in pregnancy 
outcomes are affected by coordinated regulation of cytokines. Differences in such 
coordination between cytokines in African Americans and Caucasians may partially 
explain the disparity in PTB rates. Examining these patterns may therefore be important 
in understanding PTB risk and ethnic disparity.  
Cytokines regulate pregnancy in an autocrine and paracrine way. Pregnancy can 
be seen as maternal immune adaptation to a temporary semi-allogenic graft (fetus) during 
gestation (Shurin et al., 1999;Thellin et al., 2000).  One of the key events of a normal 
pregnancy is a bias towards Th2 immune response that down-regulates several cellular 
immune effector functions, such as cytotoxic response and inflammatory cytokine release 
to maintain pregnancy (Diehl and Rincon, 2002;Ugwumadu, 2002).  In contrast to an 
upregulated Th2 profile, an imbalance of Th1/Th2 production in favor of Th1 can induce 
labor (Ugwumadu, 2002). Th2 cytokines predominate during early stages of pregnancy in 
a positive feedback loop that leads to increased production of progesterone. Progesterone 
in turn increases Th2 cytokine secretion (such as interleukin (IL)-10 and IL-6) and 
decreases Th1 cytokines (such as IL-1β, IL-8 and TNF-α), completing the positive 
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feedback loop that maintains pregnancy (Diehl and Rincon, 2002;Ugwumadu, 2002).  At 
term, this balance is shifted and slowly trends in favor of Th1 cytokines that are 
predominantly proinflammatory. A predisposition to a premature shift in Th1-Th2 
balance may elucidate risk factors and racial disparity in immune response in PTB. Such 
a change can be assessed by understanding the correlation structure of Th1 and Th2 
cytokines in pregnancy.  
Several genetic and functional studies have been performed associating both pro- 
and anti-inflammatory cytokines with PTB, but these studies usually analyzed cytokines 
individually (Dizon-Townson et al., 1997;Dudley, 1997;Menon and Fortunato, 
2007;Rizzo et al., 1998;Roberts et al., 1999;Sadowsky et al., 2006;Simhan et al., 
2003;Speer et al., 2006;Weiyuan and Li, 1998). These data and those indicating PTB is 
predominantly associated with infection (Clark and Croitoru, 2001;Dizon-Townson et al., 
1997;Gardella et al., 2004;Kniss and Iams, 1998) and/or an exaggerated inflammatory 
response (Dudley, 1997;Goldenberg et al., 2000;Gomez et al., 1995;Kniss and Iams, 
1998) that correlate with increased Th1 cytokine concentrations, have led to the 
hypothesis that PTB is a host inflammatory response disease. We further hypothesize that 
differences in patterns of cytokine production contribute to PTB pathophysiology.  
Hence, it is important to understand how cytokines and their receptors are regulated in 
preterm and term deliveries, and whether the patterns of coordination differ between 
African Americans and Caucasians. Differences in coordinated regulation may be 
indicative of different risk profiles that will be important in assessing disparity and the 
role of networks in disease risk.  
  142
In this Chapter we examine the correlations among several cytokines, previously 
associated with PTB, to assess whether there is evidence for differential cytokine 
production patterns between PTB (cases) and normal term deliveries (controls) and also 
between ethnic groups (African Americans and Caucasians) to understand ethnic 
disparity. Specifically, we have examined the correlations between cytokines/chemokines 
(IL-1β, IL-6, IL-8, IL-10, and TNF-α) and biomarkers (soluble sTNF-R1 (sTNF-R1) and 
soluble sTNF-R2 (sTNF-R2)). Correlations were also evaluated with respect to MIAC.  
 
Materials and Methods 
Study population 
  African Americans and Caucasians were used in the present study.  For a 
description of ascertainment and recruitment please refer to Chapter III part A. 
Demographic and clinical characteristics 
Our study included Caucasians (105 cases and 100 controls) and African 
American (41 cases and 91 controls) of non-Hispanic origin. Placental and umbilical cord 
pathology was performed in all cases to document histologic chorioamnionitis and 
funisitis. The demographic and clinical characteristics for African American and 
Caucasian cases and controls are listed in Table 7-1.   
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Table 7-1.  Baseline characteristics 
 
Caucasians African Americans 
Controls (N=100) Cases (N=105) P- Controls (N=91) Cases (N=41) P- Variable 
Median1 Median1 Value2 Median1 Median1 Value2 
Maternal Age (yrs) 28[18-40] 28[18-40] 0.309 24[18-38] 25[18-38] 0.474 
Gestation Age (wks) 39[37-42] 34[24-36] <0.001 39[37-41] 34[23-36] <0.001 
Birth Weight (g) 3352[2134-4252] 2151[370-3790] <0.001 3255[2075-4382] 2267[746-3685] <0.001 
APGAR 1 9 [4-9] 8 [1-9] <0.001 8 [2-9] 8 [1-9] 0.012 
APGAR 5 9 [8-10] 9 [1-9] <0.001 9 [7-10] 9 [6-9] <0.001 
Smoking 
(Count Y=Yes, N=No) 
18Y 80N 25Y 71N 0.198 13Y 77N 10Y 31N 0.165 
1IQR-interquartile range 
2P compares cases to controls 
Non-parametric Mann-Whitney two-sample rank sum tests were used if data was not normally distributed 
 
 
Cytokine and chemokine measurements 
IL-1β, IL-6, IL-8, IL-10, TNF-α and sTNFR1 and sTNFR2 concentrations in the 
AF were measured by multiplex assay (Biosource International, Camarillo, CA), using 
LuminexTM (Austin, TX).  The details of the assay procedure and details about the AF 
sample collection can be found in Chapter III part A.  
Statistical methods 
 Shapiro-Wilks tests of normality were performed on cytokine measurements. All 
measurements deviated significantly from normality; as a result nonparametric tests were 
used for all tests of significance.  Mann-Whitney two-sample rank sum tests (Hollander 
and Wolfe, 1999) were used to test for statistical differences of cytokines between cases 
and controls in each population and in cases stratified by  MIAC status.  STATA 9.0 
statistical software (StataCorp LP, College Station, TX) (StataCorp, 2007) was used for 
all analyses. Correlations between all pairwise combinations of cytokine measurements 
were calculated for cases and controls in African Americans and Caucasians separately.  
Cases were also stratified by MIAC status within each ethnic group. Spearman’s rho, a 
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non-parametric alternative to the correlation coefficient r, was used to calculate 
correlations using JMP statistical software (JMP Start Statistics. SAS Institute Inc., 
Canada) (Sall et al., 2005). Differences or heterogeneity between correlation coefficients 
were tested by z-test of the Fisher’s r to z transformation of the Spearman rho correlation 
coefficient (Sokal and Rohlf, 1987). This approach has been previously published 
(Asselbergs et al., 2007;Reilly et al., 1994).  Briefly, significant correlations are 
represented by lines connecting cytokines, and the strength of the correlation is 
represented by the thickness of each line.  
Analyses were performed separately on African Americans and Caucasians.  This 
was done because prior analyses strongly support the hypothesis that patterns of protein 
concentrations, as well as, the genetic regulation of these concentrations may be different 
between these two groups (Demissie et al., 2001;Martin et al., 2003;Menon et al., 2007). 
 
Results 
Baseline characteristics 
Significant differences between cases and controls were observed in both African 
Americans and Caucasians for gestational age (weeks) (p<0.001 for both), birth weight 
(g) (p<0.001 for both), APGAR 1 (Caucasians p<0.001; African Americans p=0.012) and 
APGAR 5 (at 5 minutes after birth) (p<0.001 for both) (Table 7-1).  
Cytokine measurements 
Median cytokine concentrations and interquartile ranges are reported for African 
American and Caucasian cases and controls (Table 7-2a) and for cases with and without 
MIAC (Table 7-2b).  Within Caucasians, there were significant differences between cases 
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and controls for IL-8 (p=0.002) and a marginally significant result in IL-6 (p = 0.07). 
There were no statistically significant differences between Caucasian cases with and 
without MIAC (Table 7-2b) for any of the biomarkers examined. Multiple significant 
differences in median analyte concentrations between cases and controls were observed 
in African Americans, including IL-1β (p<0.001), TNF-α (p <0.001), sTNF-R1 (p = 
0.012), and sTNF-R2 (p = 0.003) (Table 7-2a). Several differences were also observed 
between African American cases with and without MIAC (for IL-1β, p= 0.015; for TNF-
α p = 0.007; and for sTNF-R2, p = 0.015) (Table 7-2b). No differences between cases 
and controls were observed in either African Americans or Caucasians for IL-10. 
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Table 7-2.  Medians and interquartile ranges and tests of median differences of cytokine concentrations 
a.   
Caucasian 
Controls (N=100) 
Caucasian 
Cases (N=105) 
African American 
Controls (N=91) 
African American 
Cases (N=41) Cytokine concentrations  
(pg/ml) 
Median [IQR]1 Median [IQR]1 
P 
Median [IQR]1 Median [IQR]1 
P 
IL-1β 22.64[0.01-1122.67] 25.64[3.81-1008.72] 0.109 23.74[2.09-432.95] 237.7[7.00-1989.90] <0.001 
IL-8 654.3[36.27-17363.86] 1224.78[28.92- 10529.00] 0.002 729.29[12.07-15847.57] 1617.34[25.3-31302.64] 0.059 
TNF-α 67.62[1.66-2493.49] 138.39[5.36-3508.92] 0.075 67.905[1.66-4476.42] 1009.34[2.09-17807.91] <0.001 
sTNF-R1 2156.89[297.34-16282.3] 2388.42[160.56-15588.60] 0.611 3249.17[297.34-12425.15] 1891.70[54.47-18126.81] 0.012 
sTNF-R2 2681.47[152.5-9227.4] 2581.95[282.31-10946.19] 0.713 3294.08[723.94-10175.73] 2025.97[158.97-9581.80] 0.003 
IL-62 2305.71[108.42-27269.65] 3383.51[118.32-38734.73] 0.070 2396.60[160.76-19611.7] 22103.43[101.46-39712.64] 0.780 
IL-10 22.33[2.16-525.02] 20.30[1.58-817.10] 0.267 12.32[0.99-3043.49] 9.57[1.58-886.21] 0.439 
b.   
Caucasian 
No MIAC  (N=79) 
Caucasian 
MIAC  (N=25) 
African American 
No MIAC (N=31) 
African American 
MIAC  (N=10) Cytokine concentrations 
(pg/ml) 
Median [IQR]1 Median [IQR] 1 
P 
Median [IQR]1 Median [IQR]1 
P 
IL-1β 25.64[2.26-1008.72] 28.88[4.92- 1147.63] 0.538 62.26[7.00- 1989.90] 1179.27[26.70-1760.33] 0.015 
IL-8 1186.07[28.92-9876.35] 1370.23[84.93-10529] 0.697 1266.87[25.30- 31302.64] 1709.37[81.20-7325.40] 0.851 
TNF-α 139.42[5.36-2080.66] 114.83[ 9.86- 3508.92] 0.547 373.68[2.09-8897.65] 6234.50 [209-17807.91] 0.007 
sTNF-R1 2042.15[160.56-14431.83] 2942.96[354.80-15588.60] 0.151 1160.66[54.47-18126.81] 4976.43[66.56-10041.63] 0.057 
sTNF-R2 2473.68[282.31-10946.19] 2955.90[392.06-10094.20] 0.498 1476.82[184.22-8379.87] 4733.60[158.97- 9581.80] 0.015 
IL-6 2648.04[118.32-38734.73] 5211.63[191.49-33087.00] 0.155 3350.75[101.46-39712.64] 1987.60[407.50-  26347.34] 0.816 
IL-10 21.65 [1.58-817.10] 16.56[2.16-282.17] 0.590 7.56[1.58-428.17] 37.50[1.74- 886.21] 0.101 
*Non-parametric Mann-Whitney two-sample rank sum tests were used as data was not normally distributed 
1[IQR]-interquartile range 
2 Of note, in a larger sampled dataset we observed that IL-6 was statistically significant in our Caucasian population but not in our African American population 
and the present analysis shows that it trends toward significance. (Menon et al., 2007). 
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Correlations in African American and Caucasian cases and controls 
Multiple significant correlations between cytokine concentrations were observed 
in both cases and controls (Figure 7-1; Appendix Table 5; Appendix Figure 5a and b). 
Approximately 39% of the Caucasian control correlations were statistically significant.  
In Caucasian controls, IL-6, sTNF-R1, and sTNF-R2 each had five significant positive 
correlations while TNF-α and IL-10 had four and IL-8 had three significant positive 
correlations with other biomarkers (Figure 7-1b). Of note, IL-1β had no significant 
correlation with any other cytokines in Caucasian term pregnancies.  In Caucasian cases, 
approximately 36% of the correlations were statistically significant. Of these, there were 
five significant positive correlations between IL-8 and other cytokines and four positive 
correlations between IL-10 and other cytokines. Both sTNF-R1 and sTNF-R2 had three 
significant correlations with cytokines. Of the significant correlations, 11 were between 
Th1 and Th2 related biomarkers/cytokines, 9 were between Th1 related 
biomarkers/cytokines, and two were between Th2 related biomarkers/cytokines. 
In African American controls, 47% of the correlations were statistically 
significant (Figure 7-1c and d; Appendix Table 5).  Both sTNFR1 and sTNFR2 had four 
positive correlations with other cytokines, while both IL-8 and IL-10 had six, TNF-α had 
five, IL-6 had three and  IL-1β had two (Figure 7-1d).  In African American cases, 39% 
of the correlations were statistically significant. TNF-α, sTNF-R1, sTNF-R2, and IL-1β 
each had four positive correlations with other cytokines, while IL-6 and IL-8 each had 
two, and IL-10 had six.  Of the significant correlations among African Americans 13 
were between Th1 and Th2 related biomarkers/cytokines, 13 were between Th1 related 
biomarkers/cytokines, and two were between Th2 related biomarkers/cytokines. 
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Figure 7-1. Statistically significant correlations between cytokines 
a) Caucasian cases; b) Caucasian controls; c) African American cases; d) African 
American controls.  Lines connect markers that had statistically significant correlations.  
Correlation (r) values are described in the legend above. 
 
 
Significant correlations in cases with and without MIAC 
We next examined correlations in cases with and without MIAC in order to assess 
whether infection affects the correlation structure (Figure 7-2a-d; Appendix Table 6).  In 
Caucasian cases with MIAC IL-10, IL-8, and sTNF-R2 had three positive correlations 
with other cytokines, while sTNF-R1 had two, and IL-6 had one (Figure 7-2b). In cases 
without MIAC, IL-8 and IL-10 had four positive correlations with other cytokines, while 
IL-6 and sTNF-R2 had three, and TNF-α  and sTNF-R1 had two (Figure 7-2a).  Of the 
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significant correlations in Caucasians, three were present in cases without MIAC but not 
in cases with MIAC:  IL-10 and IL-6, TNF-α and IL-6, and TNF-α and IL-8.   
In African American cases with MIAC IL-6, sTNF-R2, IL-1β, and IL-8 had two 
positive correlations with other cytokines, while IL-10 had four.  Of note, TNF-α had no 
positive or negative correlations in MIAC cases (Figure 7-2d).  In African American 
cases without MIAC IL-8, sTNF-R1, and sTNF-R2 each had two positive correlations 
with other cytokines, while IL-6 had one and IL-10 had three (Figure 7-2c).  Of note, IL-
1β had no significant correlations in cases without MIAC as compared to the two in the 
presence of MIAC.  Three significant correlations in African Americans were present 
only in cases without MIAC:  TNF-α and IL-6 (-), sTNF-R1 and IL-10 (+), and sTNF-R2 
and sTNF-R1 (+).  Correlations present only in African American cases with MIAC are: 
IL-10 and IL-1β, IL-10 and IL-6, and sTNF-R2 and IL-1β.   
Of the significant correlations in either Caucasians or African American cases, 
only one was negative regardless of MIAC status. African American cases without MIAC 
had a significant negative correlation for TNF-α and IL-6. 
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Figure 7-2.  Statistically significant correlations between cytokines in cases with and 
without MIAC 
 a)  Caucasians no MIAC; b) Caucasians MIAC; c) African American no MIAC; d) 
African American MIAC.  Lines connect markers that had statistically significant 
correlations.  Correlation (r) values are described in the legend above. 
 
 
Analysis of correlation differences 
Case-control comparisons within each race.  To assess whether correlations 
differed between groups, we tested for differences between correlation coefficients 
(Figure 7-3a and b; Appendix Table 7). In Caucasians three comparisons were 
significantly different between cases and controls, one between Th1 related cytokines 
(TNF-α and IL-8) and two between Th1 and Th2 related analytes (TNF-α and IL-10, and 
IL-6 and sTNF-R1) (Figure 7-3a). In African Americans four comparisons exhibited 
significant correlation differences between cases and controls of which three are between 
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Th1-Th2 related cytokines (TNF-α and IL-6; sTNF-R1 and IL-10; and sTNF-R2 and IL-
10) one between Th1 related cytokines (sTNF-R1 and IL-1β) (Figure 7-3b). Of note, two 
correlations switch direction between cases and controls in African American, IL-6 with 
TNF-α  and IL-1β with sTNF-R1. 
African American and Caucasian comparison within cases and controls.  
Substantial differences were observed for correlations between Caucasians and African 
Americans when comparing cases to cases or controls to controls (Figure 7-3c and d; 
Appendix Table 7). Eight correlations demonstrated significant differences between 
Caucasian and African American cases. Four were between Th1 and Th2 related cytokines 
(IL-10 and IL-1β, TNF-α and IL-6, TNF-α and IL10, sTNF-R2 and IL-10) and four were 
between Th1 related analytes (TNF-α and IL-1β, sTNF-R1 and IL-1β, sTNF-R2 and IL-
1β, sTNF-R2 and TNF-α). Five correlations exhibited differences between Caucasian and 
African American controls:  IL-10 and IL-1β, IL-10 and IL-8, sTNF-R1 and IL-6, sTNF-
R1 and IL-10, sTNF-R2 and IL-10.   
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a. Caucasian cases v controls   b.  African American cases v controls  
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P-Value ≤ 0.05
P-Value ≤ 0.01  
 
Figure 7-3. Significant correlation differences between Caucasians and African 
Americans and between cases and controls within a population 
a) Caucasian cases versus controls ; b) African American cases versus controls; c) 
Caucasian versus African American cases; d) Caucasian versus African American 
controls.  Lines connect markers that had statistically significant differences between 
correlations.  Thick lines indicate a significance p ≤ 0.01 and thinner lines indicate 
correlations with p ≤ 0.05.   
 
 
Significant correlation differences for cases with and without MIAC.  There 
were no statistically significant correlation differences between Caucasian cases with and 
without MIAC (Appendix Table 8). In Caucasians, correlations between cases and 
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controls that showed significant correlation differences demonstrated no such effect 
between cases with and without MIAC. However, in African Americans three 
correlations showed correlation differences between cases with and without MIAC:  IL-
10 with IL-1β (p = 0.004; no MIAC r = 0.35, MIAC r = 0.91); TNF-α with IL-6 (p = 
0.004; no MIAC r = -0.43, MIAC r = 0.64); sTNF-R2 with IL-1β (p = 0.039; no MIAC r 
= 0.11, MIAC r = 0.75).  
 
Discussion  
The role of cytokine production patterns in PTB and in two ethnic groups were 
examined by assessing correlation structures in control vs. case amniotic fluids, in both 
Caucasians and African Americans. The goal of this analysis was to better elucidate the 
role of cytokine networks in PTB. Our data revealed significant differences between 
correlations in African Americans and Caucasians in both cases and controls, revealing 
disparity in immune response. In addition, within an ethnic group we found several 
differences between cases and controls. Our Th1 and Th2 grouping should be tentatively 
considered given that these cytokines were selected for being PTB candidates and not for 
Th1/Th2 grouping.  Nonetheless, interesting patterns were observed that provides some 
indications of Th1 and Th2 effects, and that merit follow-up in future studies with more 
classically accepted Th1/Th2 cytokines. 
Within Caucasians, the strongest evidence of differences in correlation between 
cases and controls was between TNF-α and IL-10. The differential coordination of IL-10 
and TNF-α is of potential significance because IL-10 is a regulator of TNF-α and its 
production is known to be significantly reduced in the placenta of patients at term 
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compared to first and second-trimester tissues (Hanna et al., 2000;Romero et al., 2007). 
Based on previous studies of decidual leukocytes TNF-α and IL-10 concentrations are 
highly correlated during normal labor, with correlations of ~0.6 (Gustafsson et al., 2006), 
indicating a balanced immune status between pro and anti inflammatory cytokines. We 
observed results consistent with these previous reports in controls of both Caucasians and 
African Americans, but this correlation is not observed in cases in either ethnic group. 
These results may indicate a trend towards immune imbalance in cases.   
In African Americans significant differences between correlation coefficients 
were observed between IL-6 and TNF-α (-0.20 in cases and 0.36 in controls). In controls, 
the two cytokine concentrations were positively correlated, suggesting a generalized 
inflammatory status during labor. However, the correlation coefficient is negative in 
cases with the increase in TNF-α  not being coordinated with the IL-6 concentrations, 
indicating an overwhelming TNF-α response.  
Another intriguing result is for IL-1β. In case-case comparisons, correlation 
coefficients indicated that African Americans and Caucasians differed significantly for 
IL-1β/TNF-α and sTNF-R1/sTNF-R2 correlations. These results suggest that the IL-1β is 
coordinately co-regulated with several other cytokines in African American cases; 
however, this co-regulation is absent in Caucasians, again indicating a difference in the 
underlying processes leading to PTB in different ethnic groups. Recent animal model 
studies documented that IL-1β and TNF-α are inducers of preterm labor whereas IL-6 
and IL-8 failed to induce labor even after prolonged administration, although both IL-6 
and IL-8 produced inflammatory changes in the fetal membranes and lungs. Our data 
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support these findings in African Americans where preterm labor may be mediated 
predominantly by TNF-α and IL-1β (Sadowsky et al., 2003).  
 Correlation differences were observed between immune function regulators in 
African Americans. IL-10 was significantly more correlated with sTNFR1 and sTNFR2 
in cases than controls, supporting the existence of immunoinhibitory mechanisms during 
preterm birth. However, a proinflammatory surge, as seen by increases in TNF-α and IL-
1β, may overwhelm the inhibitors further supporting our claim that PTB is a host 
inflammatory disease.  
 The potential role of infection in African American compared to Caucasian 
pregnancies is also illustrated by evidence for differences between correlations in cases 
with and without MIAC in the two groups. We emphasize that the definition of MIAC 
was not based solely on the detection of bacterial DNA in the AF but also clinical 
evidence of MIAC that correlate with PCR data.  However, it is possible that we could 
not detect presence of microbes between membranes or in biofilms in the AF.  We did 
not find strong evidence for correlation differences in Caucasian cases with and without 
MIAC. This suggests the coordinated cytokine activity in Caucasians cases is not 
significantly affected by the presence of infection. Although MIAC may affect individual 
cytokine concentrations in presence of certain genetic predispositions in Caucasians 
(Velez et al., 2007a), infection alone does not appear to explain the observed 
heterogeneity between Caucasians case-control cytokine correlations. In contrast in 
African American cases, there was evidence for heterogeneity between MIAC and no 
MIAC, although these differences were observed in only 14% of our comparisons (3/21).  
We caution, however, that these secondary analyses may not be adequately powered to 
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detect effects of biological importance and that our results with respect to MIAC are 
preliminary.    
  It is important to note that the current analysis is different from previous ones in 
that we are not explicitly comparing changes in protein levels and/or cytokine ratios, but 
the relationships of these within a status group.  Therefore, it is possible to observe 
significant differences in concentrations and/or ratios, but not identify significant 
correlations as we have done here. This can be intimated from the current analysis by 
comparing thickness of lines between cases and controls in each group as well as the 
changes in the overall patterns. Such findings suggest, for example, that even though the 
ratios are different between cases and controls, two factors are both behaving 
monotonically. This may be interpreted as both concentrations increase but that the rate 
of the increase is different. We suggest that the current analyses may add to our overall 
understanding of how a complex set of factors can affect disease risk. 
Our data provide preliminary evidence that Caucasians and African Americans 
have strong differences in patterns of cytokine and cytokine related biomarker 
production. This is especially true in cases, supporting that the observed PTB rate 
differences may in fact be due to differences in the underlying etiology. From the present 
study we cannot conclude whether the mother or fetus is contributing to our AF pool of 
cytokines, given that a response can be initiated by both mother and the fetus and 
measurements of cytokines from the AF are a net affect of the two.  Finally, in assessing 
patterns of coordinated cytokine production it appears that controls in the two populations 
have fewer correlation differences than cases of the two (Figures 7-2 and 7-3).  Based on 
our findings we hypothesize that the pathways leading to PTB operate differently on 
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mediators in each ethnic group, culminating in a comparable terminal events leading to 
labor and delivery.   
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CHATPER VIII 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions and Summaries 
 Studies examining reproductive disorders have been poorly addressed in the 
human genetics literature.  Most of these disorders, including PTB, do not follow a 
simple Mendelian mode of inheritance.  In addition, PTB is unique among genetic 
disorders in that its etiology has both maternal and fetal biological components.   Despite 
this obvious complexity the majority of the genetic studies on PTB performed over the 
last few years only consider relatively simple designs (single gene or single SNP).  The 
studies presented in this dissertation address many of the complexities in the field and 
therefore, provide new insight into the genetic risks underlying PTB.   
 In the studies presented in the previous chapters, several interesting findings 
regarding the genetics of PTB have emerged.  Our initial studies focused on 
understanding the immunological risk of PTB and how genetic variants affect risk.  We 
did this by examining the association of IL-6 AF levels and variants in IL-6 and IL-6R 
genes and by examining the correlation networks between cytokines in the AF of preterm 
and term women.  We did not replicate an association previously found in the IL-6 gene 
at marker C-174G.  However, upon examination of IL-6 AF, we observed an association 
at G-661A with IL-6 AF levels in Caucasians, a marker in tight LD with C-174G.  
Subsequent analyses revealed that IL-6 AF levels were also significantly associated with 
IL-6 and even more strongly associated with IL-6R haplotypes.  The regions associated 
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were consistent across racial populations confirming findings from previous studies that 
found that IL-6 protein expression levels was more strongly associated with IL-6R than 
with IL-6 gene variants and that a haplotype in the IL-6 promoter region has a strong 
regulatory role over IL-6 expression.  AF correlation network analyses assessing 
concentrations of IL-6 and six additional cytokines revealed dramatically different 
correlation networks both between African Americans and Caucasians and between cases 
and controls.  These analyses indicate that at a baseline level (term pregnancy women) 
the relationships between cytokines are drastically different between racial groups and 
these differences may explain some of the observed differences in PTB rates.   
These analyses were followed up by a high-throughput study examining genes 
from all four hypothesized PTB pathways and a study of complex I markers of the 
mitochondrial genome.  To our knowledge this was the first candidate gene association 
study comprehensively examining allelic, genotypic, haplotype, and gene-gene 
associations with candidate genes from all four hypothesized PTB pathways.  We are also 
the first, to our knowledge, to extend the search to the mitochondrial genome.   
Although we did not find a strong association with mtDNA markers, we did find a 
marginally significant association with a marker in complex I haplogroup T after 
stratifying by smoking status.  This marker had a strong OR with borderline levels of 
significance that support it being followed up in a larger powered study. 
The candidate gene screen across hypothesized pathways revealed several 
interesting results with some overlap across African American, Caucasian, maternal, and 
fetal populations (Figure 8-1).  In all four populations pathway analyses revealed an 
excess of significant associations in the pathways involving cytokines.  The strongest 
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overlap across populations (African American, Caucasian, maternal, and fetal; Figure 8-
1, region I) was in genes involved in immune response pathways and decidual 
hemorrhage.  The most promising association in these studies was seen in tPA and 
pathways involving tPA in the maternal Caucasian samples.  
 
 
Figure 8-1. Overview of overlapping associations across populations. 
Gene included in each region: A-COL1A1, DHFR, FVII, HSD11B1, IL-18, PGRMC1, and TLR2; B-COL1A2, CYP19A1, 
CYP2D6, UGT1A1, IL-5, MMP1, NFKB1A, and tPA; C-CBS, CRHR2, GSTP1, HSPA14, IGF1, IL-1A, PGR, PTGS2, and 
SLC23A1; D-CCL2, IL-6-R, PLA2G4A, and TLR7; E-IL-4-R; F-CRHBP, MMP3, and NFKBIB; G-EDN2, NFKBIE, and TREM1; 
H-COL5A1, CTLA4, FV, IL-1R1, sTNF-R1, sTNF-R2, and  VEGF; I-COL3A1, COL5A2, EPHX2, IL-10RA, IL-1RAP, IL-2RA, 
KL, PON2, PTGER3, TIMP3, and TSHR;J-IL-1RN, IL-2-RB, IL-4, and MMP8; K-ACE, ADRB2, CCL8, HSD17B7, HSPA1B, 
HSPA1L, HSPA4, PGRMC2, POMC, and TLR8; L-CARD15, EPHX1, IFNG, IL-10-RB, IL-15, IL-6, IL-8, MMP2, MMP9, NFKB1, 
PGEA1, and SLC6A4. 
 
 
Several associations were found in the compliment and coagulation pathway in 
Caucasian maternal samples.  As described in Chapter IV part A, the compliment and 
coagulation pathway yielded several significant associations, including an excess of 
significant single locus associations within this pathway.  Associations were seen with 
FV, FVII, and tPA at the allele and/or genotype level.  A statistically significant 
interactive effect was also observed between FV and FVII when tPA was excluded, 
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indicating that heterogeneity within the compliment and coagulation pathway may 
contribute to susceptibility to PTB in Caucasians.   
 
Decidual Hemorrhage
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u-PAPAI1
Plasminogen Plasmin
Fibrin degradation ECM degradation
MMPα2-antiplasmin
proMMP
Positive feedback
TIMP
Preterm 
Birth  
Figure 8-2.  Proposed pathway for tPA in spontaneous preterm birth. 
 
 
Figure 8-2 shows a potential mechanism by which mutations in the compliment 
and coagulation pathway may lead to PTB.  A mutation in tPA or other components of 
the compliment and coagulation cascade can activate the conversion of plasminogen to 
plasmin.  Activating tPA production in the process of fibrin degradation leads to small 
fibrin clot formation, depletion of coagulation factors, and finally hemorrhage of the 
decidua.  Excess tPA can also increase the conversion of proMMPs with broad substrate 
specificity to the active secreted (zymogenic) form of MMPs.  Active MMPs lead to the 
degradation of the extra cellular matrix (ECM) by breaking down interstitial collagens 
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that can compromise the structural integrity of the decidua and lead to decidual 
hemorrhage.  Fibrin degradation may also lead to ECM degradation.  Another potential 
mechanism by which tPA may lead to PTB is through maternal-fetal stress response 
pathways, this mechanism is described in the discussion of Chapter IV part A. 
In conclusion, my studies identified several genetic variants in tPA, FV, FVII, 
CRHBP, IL-6, and IL-6R that can influence the risk of a PTB through multiple pathways.  
Most of the genetics studies in the field of PTB have been composed of small sample 
sizes, often of pooled racial grouping, and poorly defined clinical phenotypes.  Our 
dataset was adequately powered and consisted of a clear and clinically well defined case-
control retrospective cohort for all of these analyses.  Unlike many other studies in the 
field, we excluded on several factors for our case and control definitions in efforts to 
avoid phenotypic heterogeneity in our analyses.  This ultimately reduced our power; 
however, despite this we were able to find several interesting associations and are 
confident in our results.  These results support the hypothesis that genetic factors 
influence the susceptibility of delivery preterm.   
 
Future Directions 
 The future goals of this work are to more fully assess the significance of these 
findings by obtaining independent replication datasets.  Given the apparent genetic 
heterogeneity observed in our results and the well established phenotypic heterogeneity 
of PTB, an ideal replication dataset will consist of a larger sample size with a 
homogenous population and a precise clinical definition of PTB.  We anticipate having 
access to several replication datasets. 
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 The compliment and coagulation pathway was found to have several interesting 
associations in Caucasian samples and the cytokine pathway was found to have 
interesting associations in Caucasians and African Americans, as a result we also plan on 
following up these pathways with more saturated analyses.  We will genotype more 
markers within interesting genes, as well as markers in other genes within these 
pathways; this will allow us to assess the degree of heterogeneity occurring in these 
pathways.  We may also follow up the genes with the strongest associations with deep 
resequencing. 
If our findings are found to replicate, biological relevance may be further assessed 
by using transgenic animal models and by pursuing family-based linkage and/or 
association analyses, as these would allow a better understanding of the heritability of 
these variants.  An appropriate transgenic animal model, however, may be difficult to 
find given that pregnancy in humans is very different relative to commonly used animal 
models.   
            In conclusion, we identified several compelling associations with strong and 
diverse genetic effects.  These results both support the hypothesis that PTB has a 
significant genetic basis and highlight that the mechanisms underlying PTB have not 
been fully explained by the literature and are likely to represent a series of heterogeneous 
risks.   
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APPENDIX 
 
 
a. Caucasian maternal cases                          b. Caucasian maternal controls 
  
c. Caucasian fetal cases   d.  Caucasian fetal controls 
  
e. African American maternal cases  f.  African American maternal controls 
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g. African American fetal cases  h.  African American fetal controls 
  
Appendix Figure 1. IL-6 haplotype block structure. 
 a) Caucasians maternal cases; b) Caucasians maternal controls; c)Caucasian fetal cases; 
d) Caucasians fetal controls; e) African American maternal cases; f) African American 
maternal controls; g) African American fetal cases; h) African American fetal controls. 
D’ values are labeled within each square. 
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a. Caucasian maternal cases        b.  Caucasian maternal controls 
    
c. Caucasian fetal cases       d.  Caucasian fetal controls 
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c. African American maternal cases      f.  African American maternal controls 
     
g. African American fetal cases       h.  African American fetal controls 
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Appendix Figure 2. IL-6R haplotype block structure. 
 a) Caucasians maternal PTB; b) Caucasians maternal term; c) Caucasians fetal PTB; d) 
Caucasians fetal term; e) African American maternal PTB; f) African American maternal 
term; g) African American fetal PTB; h) African American fetal term. D’ values are 
labeled within each square. 
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Appendix Table 1.  Genes and number of markers genotyped in Illumina 
genotyping 
Gene # Markers 
 ACE angiotensin I converting enzyme isoform 1 9 
 ADH1B alcohol dehydrogenase 1B (class I), beta 11 
 ADH1C class I alcohol dehydrogenase, gamma subunit 6 
 ADRB2 adrenergic, beta-2-, receptor, surface 4 
 CARD15 NOD2 protein 11 
 CBS cystathionine-beta-synthase 16 
 CCL2 small inducible cytokine A2 precursor 5 
 CCL3 chemokine (C-C motif) ligand 3 4 
 CCL8 small inducible cytokine A8 precursor 7 
 CD14 CD14 antigen precursor 3 
 COL1A1 alpha 1 type I collagen preproprotein 10 
 COL1A2 alpha 2 type I collagen 35 
 COL3A1 procollagen, type III, alpha 1 21 
 COL5A1 alpha 1 type V collagen preproprotein 28 
 COL5A2 alpha 2 type V collagen preproprotein 15 
 CRH corticotropin releasing hormone precursor 6 
 CRHBP corticotropin releasing hormone binding protein 5 
 CRHR1 corticotropin releasing hormone receptor 1 2 
 CRHR2 corticotropin releasing hormone receptor 2 12 
 CRP C-reactive protein, pentraxin-related 3 
 CTLA4 cytotoxic T-lymphocyte-associated protein 4 9 
 CYP19A1 cytochrome P450, family 19 50 
 CYP1A1 cytochrome P450, family 1, subfamily A, 2 
 CYP2D6 cytochrome P450, family 2, subfamily D, 2 
 DHFR dihydrofolate reductase 6 
 EDN2 endothelin 2 10 
 EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) 12 
 EPHX2 epoxide hydrolase 2, cytoplasmic 17 
 FII coagulation factor II precursor 2 
 FV coagulation factor V precursor 26 
 FVII coagulation factor VII precursor, isoform a 4 
 FAS tumor necrosis factor receptor superfamily, 15 
 FASLG fas ligand 6 
 GSTP1 glutathione transferase 1 
 GSTT2 glutathione S-transferase theta 2 1 
 HSD11B1 11-beta-hydroxysteroid dehydrogenase 1 13 
 HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 6 
 HSPA14 heat shock 70kDa protein 14 isoform 2 7 
 HSPA1A heat shock 70kDa protein 1A 3 
HSPA1B heatshock 70kDa protein 1B 2 
 HSPA1L heat shock 70kDa protein 1-like 2 
 HSPA4 heat shock 70kDa protein 4 isoform a 5 
 HSPA6 heat shock 70kDa protein 6 (HSP70B') 6 
 IFNG interferon, gamma 5 
 IGF1 insulin-like growth factor 1 (somatomedin C) 1 
 IGFBP3 insulin-like growth factor binding protein 3 1 
 IL10 interleukin 10 precursor 5 
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 IL-10RA interleukin 10 receptor, alpha precursor 11 
 IL-10RB interleukin 10 receptor, beta precursor 15 
 IL-13 interleukin 13 precursor 6 
 IL-15 interleukin 15 preproprotein 12 
 IL-18 interleukin 18 proprotein 8 
 IL-1A interleukin 1, alpha proprotein 3 
 IL-1B interleukin 1, beta proprotein 7 
 IL-1R1 interleukin 1 receptor, type I precursor 16 
 IL-1R2 interleukin 1 receptor, type II precursor 23 
 IL-1RAP interleukin 1 receptor accessory protein isoform 65 
 IL-1RN interleukin 1 receptor antagonist isoform 3 14 
 IL-2 interleukin 2 precursor 7 
 IL-2RA interleukin 2 receptor, alpha chain precursor 33 
 IL-2RB interleukin 2 receptor beta precursor 25 
 IL-4 interleukin 4 isoform 1 precursor 8 
 IL-4R interleukin 4 receptor alpha chain isoform b 27 
 IL-5 interleukin 5 precursor 5 
 IL-6 interleukin 6 (interferon, beta 2) 8 
 IL-6R interleukin 6 receptor isoform 1 precursor 22 
 IL-8 interleukin 8 precursor 3 
 IL-8RA interleukin 8 receptor alpha 4 
 KL klotho isoform a 19 
 LST1 leukocyte specific transcript 1 isoform 1 1 
 MBL2 soluble mannose-binding lectin precursor 11 
 MMP1 matrix metalloproteinase 1 preproprotein 12 
 MMP2 matrix metalloproteinase 2 preproprotein 21 
 MMP3 matrix metalloproteinase 3 preproprotein 5 
 MMP8 matrix metalloproteinase 8 preproprotein 8 
 MMP9 matrix metalloproteinase 9 preproprotein 4 
 MTHFD1 methylenetetrahydrofolate dehydrogenase 1 13 
 MTHFR 5,10-methylenetetrahydrofolate reductase 15 
 NAT1 N-acetyltransferase 1 10 
 NAT2 arylamide acetylase 2 7 
 NFKB1 nuclear factor kappa-B, subunit 1 19 
 NFKB2 nuclear factor of kappa light polypeptide gene 3 
 NFKBIA nuclear factor of kappa light polypeptide gene 3 
 NFKBIB nuclear factor of kappa light polypeptide gene 8 
 NFKBIE nuclear factor of kappa light polypeptide gene 5 
 NOS3 nitric oxide synthase 3 (endothelial cell) 7 
 NR3C1 nuclear receptor subfamily 3, group C, member 1 18 
 PAFAH1B1 platelet-activating factor acetylhydrolase, 12 
 PAFAH1B2 platelet-activating factor acetylhydrolase, 2 
 PGEA1 PKD2 interactor, golgi and endoplasmic reticulum 4 
 PGR progesterone receptor 21 
 PGRMC1 progesterone receptor membrane component 1 2 
 PGRMC2 progesterone membrane binding protein 5 
 PLA2G4A phospholipase A2, group IVA 30 
 tPA tissue plasminogen activator 8 
 POMC proopiomelanocortin preproprotein 1 
 PON1 paraoxonase 1 25 
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 PON2 paraoxonase 2 isoform 1 14 
 PTCRA pre T-cell antigen receptor alpha 5 
 PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa 7 
 PTGER3 prostaglandin E receptor 3, subtype EP3 isoform 53 
 PTGES prostaglandin E synthase 7 
 PTGFR prostaglandin F receptor isoform a precursor 12 
 PTGS1 prostaglandin-endoperoxide synthase 1 isoform 1 17 
 PTGS2 prostaglandin-endoperoxide synthase 2 precursor 7 
 PTPN22 protein tyrosine phosphatase, non-receptor type 1 
SCNNIA sodium channel, non-voltage gated 1 alpha 1 
 SCGB1A1 secretoglobin, family 1A, member 1 3 
 SERPINE1 plasminogen activator inhibitor-1 7 
 SERPINH1 serine (or cysteine) proteinase inhibitor, clade 3 
 SLC23A1 solute carrier family 23 (nucleobase 3 
 SLC6A4 solute carrier family 6 member 4 14 
 TCN2 transcobalamin II precursor 1 
 TGFB1 transforming growth factor, beta 1 3 
 TIMP3 tissue inhibitor of metalloproteinase 3 32 
 TIMP4 tissue inhibitor of metalloproteinase 4 4 
 TLR2 toll-like receptor 2 4 
 TLR3 toll-like receptor 3 10 
 TLR4 toll-like receptor 4 precursor 13 
 TLR7 toll-like receptor 7 15 
 TLR8 toll-like receptor 8 isoform 1 15 
 TLR9 toll-like receptor 9 isoform B 1 
 TNF tumor necrosis factor alpha 6 
sTNF-R1 soluble tumor necrosis factor receptor 1 9 
sTNF-R2 soluble tumor necrosis factor receptor 2 19 
 TRAF2 TNF receptor-associated factor 2 3 
 TREM1 triggering receptor expressed on myeloid cells 11 
 TSHR thyroid stimulating hormone receptor isoform 2 63 
 UGT1A1 UDP glycosyltransferase 1 family, polypeptide A1 18 
 VEGF vascular endothelial growth factor isoform a 8 
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Appendix Table 2.  Gene list with rs numbers 
Gene SNP rs# 
ACE rs7214530 
ACE rs4295 
ACE rs4305 
ACE rs4311 
ACE rs4362 
ACE rs4461142 
ACE rs4267385 
ACE rs4459610 
ACE rs12451328 
ADH1B rs12507573 
ADH1B rs1042026 
ADH1B rs17033 
ADH1B rs13133908 
ADH1B rs1789882 
ADH1B rs1693457 
ADH1B rs4147536 
ADH1B rs1353621 
ADH1B rs1159918 
ADH1B rs6810842 
ADH1B rs1229982 
ADH1C rs1229980 
ADH1C rs1614972 
ADH1C rs904096 
ADH1C rs3762896 
ADH1C rs17586163 
ADH1C rs1662037 
ADRB2 rs1432622 
ADRB2 rs12654778 
ADRB2 rs1042713 
ADRB2 rs4705271 
CARD15 rs4785224 
CARD15 rs2067085 
CARD15 rs17312836 
CARD15 rs2066843 
CARD15 rs2066844 
CARD15 rs751271 
CARD15 rs2066845 
CARD15 rs5743289 
CARD15 rs5743291 
CARD15 rs7203344 
CARD15 rs8056611 
CBS rs706208 
CBS rs1051319 
CBS rs3788050 
CBS rs2124459 
CBS rs8132811 
CBS rs1005584 
CBS rs6586282 
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CBS rs6586283 
CBS rs11203172 
CBS rs12329764 
CBS rs234705 
CBS rs234709 
CBS rs2851391 
CBS rs234715 
CBS rs11701048 
CBS rs1788484 
CCL2 rs1024611 
CCL2 rs1024610 
CCL2 rs3760396 
CCL2 rs4586 
CCL2 rs991804 
CCL3 rs1634491 
CCL3 rs1851503 
CCL3 rs9972960 
CCL3 rs1634502 
CCL8 rs885691 
CCL8 rs1233650 
CCL8 rs3138034 
CCL8 rs3138035 
CCL8 rs11575060 
CCL8 rs3138039 
CCL8 rs4794999 
CD14 rs4914 
CD14 rs2569190 
CD14 rs2569193 
COL1A1 rs2586482 
COL1A1 rs2586485 
COL1A1 rs1061237 
COL1A1 rs2277632 
COL1A1 rs2586488 
COL1A1 rs2075559 
COL1A1 rs2857396 
COL1A1 rs2696247 
COL1A1 rs2269336 
COL1A1 rs1107946 
COL1A2 rs11765563 
COL1A2 rs388625 
COL1A2 rs3814967 
COL1A2 rs1800222 
COL1A2 rs411717 
COL1A2 rs420257 
COL1A2 rs760043 
COL1A2 rs406226 
COL1A2 rs3763466 
COL1A2 rs17166249 
COL1A2 rs389328 
COL1A2 rs42521 
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COL1A2 rs42523 
COL1A2 rs42524 
COL1A2 rs2621213 
COL1A2 rs2521205 
COL1A2 rs7781954 
COL1A2 rs3736638 
COL1A2 rs42527 
COL1A2 rs369982 
COL1A2 rs42528 
COL1A2 rs4266 
COL1A2 rs2472 
COL1A2 rs42531 
COL1A2 rs441051 
COL1A2 rs400218 
COL1A2 rs7804898 
COL1A2 rs413826 
COL1A2 rs10046552 
COL1A2 rs6465412 
COL1A2 rs12668754 
COL1A2 rs11764718 
COL1A2 rs1062394 
COL1A2 rs11982782 
COL1A2 rs13234022 
COL3A1 rs2138533 
COL3A1 rs11887092 
COL3A1 rs7607614 
COL3A1 rs1878201 
COL3A1 rs1516454 
COL3A1 rs1914037 
COL3A1 rs17358825 
COL3A1 rs16830973 
COL3A1 rs7576108 
COL3A1 rs3736487 
COL3A1 rs3134656 
COL3A1 rs12693525 
COL3A1 rs13306267 
COL3A1 rs7579903 
COL3A1 rs2271682 
COL3A1 rs10191859 
COL3A1 rs10204508 
COL3A1 rs2203602 
COL3A1 rs3134646 
COL3A1 rs4667256 
COL3A1 rs4667258 
COL5A1 rs12002679 
COL5A1 rs4341231 
COL5A1 rs3124291 
COL5A1 rs3128597 
COL5A1 rs3124311 
COL5A1 rs4842151 
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COL5A1 rs11103509 
COL5A1 rs4842157 
COL5A1 rs4842158 
COL5A1 rs4842161 
COL5A1 rs3124932 
COL5A1 rs12005720 
COL5A1 rs3128621 
COL5A1 rs4842167 
COL5A1 rs3811161 
COL5A1 rs11999194 
COL5A1 rs3811153 
COL5A1 rs3811152 
COL5A1 rs3811151 
COL5A1 rs10776908 
COL5A1 rs10745387 
COL5A1 rs3827848 
COL5A1 rs4842172 
COL5A1 rs4841937 
COL5A1 rs4842174 
COL5A1 rs10114036 
COL5A1 rs11103543 
COL5A1 rs13946 
COL5A2 rs6760780 
COL5A2 rs3923384 
COL5A2 rs6434317 
COL5A2 rs6434322 
COL5A2 rs10165260 
COL5A2 rs7420331 
COL5A2 rs13024858 
COL5A2 rs6752781 
COL5A2 rs1515864 
COL5A2 rs9288163 
COL5A2 rs10191420 
COL5A2 rs1399991 
COL5A2 rs10497699 
COL5A2 rs12611950 
COL5A2 rs11691604 
CRH rs10105164 
CRH rs6996265 
CRH rs3176921 
CRH rs6472257 
CRH rs7839698 
CRH rs10098823 
CRHBP rs32897 
CRHBP rs6453267 
CRHBP rs10055255 
CRHBP rs1875999 
CRHBP rs10514082 
CRHR1 rs17689966 
CRHR1 rs878887 
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CRHR2 rs4722999 
CRHR2 rs12701020 
CRHR2 rs7812133 
CRHR2 rs973002 
CRHR2 rs929377 
CRHR2 rs2240404 
CRHR2 rs2190242 
CRHR2 rs2284217 
CRHR2 rs6462219 
CRHR2 rs2284219 
CRHR2 rs2267716 
CRHR2 rs2267717 
CRP rs3093066 
CRP rs1800947 
CRP rs1417938 
CTLA4 rs231770 
CTLA4 rs16840252 
CTLA4 rs11571317 
CTLA4 rs5742909 
CTLA4 rs231777 
CTLA4 rs231779 
CTLA4 rs3087243 
CTLA4 rs231726 
CTLA4 rs231727 
CYP19A1 rs4775932 
CYP19A1 rs4275794 
CYP19A1 rs2899470 
CYP19A1 rs16964201 
CYP19A1 rs2899472 
CYP19A1 rs12439137 
CYP19A1 rs4775934 
CYP19A1 rs2899473 
CYP19A1 rs4775935 
CYP19A1 rs3784308 
CYP19A1 rs700518 
CYP19A1 rs17703883 
CYP19A1 rs726547 
CYP19A1 rs10519295 
CYP19A1 rs727479 
CYP19A1 rs10459592 
CYP19A1 rs12591359 
CYP19A1 rs767199 
CYP19A1 rs12911554 
CYP19A1 rs17703982 
CYP19A1 rs7172156 
CYP19A1 rs11856927 
CYP19A1 rs4545755 
CYP19A1 rs1054984 
CYP19A1 rs4614671 
CYP19A1 rs12050767 
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CYP19A1 rs749292 
CYP19A1 rs17647719 
CYP19A1 rs2305707 
CYP19A1 rs1902586 
CYP19A1 rs16953058 
CYP19A1 rs936306 
CYP19A1 rs936307 
CYP19A1 rs2470176 
CYP19A1 rs3764221 
CYP19A1 rs17523880 
CYP19A1 rs2470152 
CYP19A1 rs17523922 
CYP19A1 rs16964258 
CYP19A1 rs3751592 
CYP19A1 rs3751591 
CYP19A1 rs2470150 
CYP19A1 rs1902584 
CYP19A1 rs1004983 
CYP19A1 rs1004982 
CYP19A1 rs1902585 
CYP19A1 rs10163138 
CYP19A1 rs7174997 
CYP19A1 rs8025191 
CYP19A1 rs1961177 
CYP1A1 rs4646421 
CYP1A1 rs2470893 
CYP2D6 rs5758589 
CYP2D6 rs764481 
DHFR rs12517451 
DHFR rs1650723 
DHFR rs1677693 
DHFR rs10072026 
DHFR rs1650697 
DHFR rs380691 
EDN2 rs12069358 
EDN2 rs1407550 
EDN2 rs6690839 
EDN2 rs734359 
EDN2 rs11572340 
EDN2 rs3754287 
EDN2 rs1077218 
EDN2 rs883304 
EDN2 rs12718439 
EDN2 rs4660541 
EPHX1 rs2854450 
EPHX1 rs3753658 
EPHX1 rs1877724 
EPHX1 rs2671272 
EPHX1 rs1051740 
EPHX1 rs2260863 
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EPHX1 rs2740168 
EPHX1 rs2740170 
EPHX1 rs2234922 
EPHX1 rs1051741 
EPHX1 rs3753663 
EPHX1 rs360063 
EPHX2 rs7837347 
EPHX2 rs4149239 
EPHX2 rs2741334 
EPHX2 rs17057288 
EPHX2 rs7816586 
EPHX2 rs891401 
EPHX2 rs721619 
EPHX2 rs10503812 
EPHX2 rs17057312 
EPHX2 rs4149252 
EPHX2 rs4149253 
EPHX2 rs13269963 
EPHX2 rs1042064 
EPHX2 rs4149259 
EPHX2 rs4149260 
EPHX2 rs7341557 
EPHX2 rs2640726 
FII rs2070852 
FII rs3136485 
FV rs2187952 
FV rs2420369 
FV rs2213865 
FV rs3766103 
FV rs12131397 
FV rs9332624 
FV rs9332618 
FV rs6427197 
FV rs4656687 
FV rs1557572 
FV rs6020 
FV rs6035 
FV rs12120605 
FV rs6427198 
FV rs1894697 
FV rs9332575 
FV rs9332569 
FV rs6022 
FV rs7545236 
FV rs7534848 
FV rs9287095 
FV rs2298908 
FV rs6019 
FV rs12755775 
FV rs10489185 
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FV rs3917854 
FVII rs555212 
FVII rs1475931 
FVII rs488703 
FVII rs3211719 
FAS rs983751 
FAS rs4934434 
FAS rs3758483 
FAS rs4064 
FAS rs6586165 
FAS rs1571011 
FAS rs9658727 
FAS rs9658742 
FAS rs7901656 
FAS rs2031611 
FAS rs9658761 
FAS rs982764 
FAS rs2234978 
FAS rs1051070 
FAS rs7915235 
FASLG rs2859242 
FASLG rs2639614 
FASLG rs6700734 
FASLG rs17370527 
FASLG rs5030772 
FASLG rs12041613 
GSTP1 rs947895 
GSTT2 rs140199 
HSD11B1 rs17389016 
HSD11B1 rs2235543 
HSD11B1 rs4844880 
HSD11B1 rs846910 
HSD11B1 rs3753519 
HSD11B1 rs846911 
HSD11B1 rs11799643 
HSD11B1 rs12040780 
HSD11B1 rs4844488 
HSD11B1 rs846906 
HSD11B1 rs6672256 
HSD11B1 rs9430012 
HSD11B1 rs932335 
HSD17B7 rs1780019 
HSD17B7 rs11589262 
HSD17B7 rs4656381 
HSD17B7 rs1039874 
HSD17B7 rs2805053 
HSD17B7 rs2803865 
HSPA14 rs10906772 
HSPA14 rs11593057 
HSPA14 rs17155992 
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HSPA14 rs7894284 
HSPA14 rs9787671 
HSPA14 rs7905174 
HSPA14 rs10906774 
HSPA1A rs1043618 
HSPA1A rs9469058 
HSPA1A rs13211317 
HSPA1B rs2763979 
HSPA1B rs2471980 
HSPA1L rs2075800 
HSPA1L rs2227956 
HSPA4 rs4574536 
HSPA4 rs4705990 
HSPA4 rs4616886 
HSPA4 rs7730747 
HSPA4 rs10075878 
HSPA6 rs9427401 
HSPA6 rs12129787 
HSPA6 rs4657053 
HSPA6 rs4657054 
HSPA6 rs404508 
HSPA6 rs2099684 
IFNG rs10878763 
IFNG rs2069727 
IFNG rs2069718 
IFNG rs2069716 
IFNG rs2069705 
IGF1 rs1520220 
IGFBP3 rs2471551 
IL10 rs3024498 
IL10 rs3024496 
IL10 rs1800872 
IL10 rs1800896 
IL10 rs1800890 
IL10RA rs4936414 
IL10RA rs2512143 
IL10RA rs4252254 
IL10RA rs4252270 
IL10RA rs2229113 
IL10RA rs9610 
IL10RA rs2508445 
IL10RA rs947889 
IL10RA rs4938467 
IL10RA rs11216666 
IL10RA rs17121510 
IL10RB rs2284552 
IL10RB rs962859 
IL10RB rs2834168 
IL10RB rs2834170 
IL10RB rs2243498 
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IL10RB rs2834172 
IL10RB rs765429 
IL10RB rs2276223 
IL10RB rs735299 
IL10RB rs999261 
IL10RB rs999259 
IL10RB rs1058867 
IL10RB rs8178565 
IL10RB rs6517158 
IL10RB rs2834175 
IL13 rs3091307 
IL13 rs1295686 
IL13 rs848 
IL13 rs1295683 
IL13 rs2243204 
IL13 rs2243209 
IL15 rs12508866 
IL15 rs1519551 
IL15 rs17461269 
IL15 rs1519552 
IL15 rs7698675 
IL15 rs13117878 
IL15 rs12498901 
IL15 rs6850492 
IL15 rs1907949 
IL15 rs17007610 
IL15 rs6537061 
IL15 rs10833 
IL18 rs543810 
IL18 rs5744280 
IL18 rs360722 
IL18 rs4937113 
IL18 rs2043055 
IL18 rs1946519 
IL18 rs5744222 
IL18 rs1293344 
IL1A rs17561 
IL1A rs2856838 
IL1A rs1878321 
IL1B rs2853550 
IL1B rs1143643 
IL1B rs1143634 
IL1B rs1143630 
IL1B rs1143627 
IL1B rs1143623 
IL1B rs4848306 
IL1R1 rs3917225 
IL1R1 rs949963 
IL1R1 rs3771202 
IL1R1 rs2287047 
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IL1R1 rs3917254 
IL1R1 rs3917273 
IL1R1 rs3917292 
IL1R1 rs2160227 
IL1R1 rs3917296 
IL1R1 rs951193 
IL1R1 rs3917304 
IL1R1 rs3917306 
IL1R1 rs3171845 
IL1R1 rs2110726 
IL1R1 rs3732131 
IL1R1 rs3917332 
IL1R2 rs11884283 
IL1R2 rs6543105 
IL1R2 rs12467316 
IL1R2 rs4141134 
IL1R2 rs4851520 
IL1R2 rs4851521 
IL1R2 rs4851522 
IL1R2 rs4321386 
IL1R2 rs1108338 
IL1R2 rs7561191 
IL1R2 rs4851526 
IL1R2 rs4851527 
IL1R2 rs2302589 
IL1R2 rs3218861 
IL1R2 rs2160140 
IL1R2 rs3218883 
IL1R2 rs3218927 
IL1R2 rs2072474 
IL1R2 rs3218979 
IL1R2 rs733498 
IL1R2 rs3218987 
IL1R2 rs7589525 
IL1R2 rs4851531 
IL1RAP rs9817203 
IL1RAP rs6800625 
IL1RAP rs7628333 
IL1RAP rs3821744 
IL1RAP rs7615368 
IL1RAP rs7615533 
IL1RAP rs3773994 
IL1RAP rs9290936 
IL1RAP rs9849030 
IL1RAP rs2059020 
IL1RAP rs2361832 
IL1RAP rs7626071 
IL1RAP rs3773990 
IL1RAP rs2193880 
IL1RAP rs3773989 
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IL1RAP rs1988743 
IL1RAP rs4686554 
IL1RAP rs16865597 
IL1RAP rs2885370 
IL1RAP rs3773983 
IL1RAP rs3773982 
IL1RAP rs3773981 
IL1RAP rs9883249 
IL1RAP rs9845825 
IL1RAP rs2241343 
IL1RAP rs9877268 
IL1RAP rs3773977 
IL1RAP rs3773976 
IL1RAP rs4687151 
IL1RAP rs11929157 
IL1RAP rs10937439 
IL1RAP rs10937442 
IL1RAP rs2161058 
IL1RAP rs1035347 
IL1RAP rs1559018 
IL1RAP rs12053868 
IL1RAP rs6444435 
IL1RAP rs4687154 
IL1RAP rs10513854 
IL1RAP rs7628250 
IL1RAP rs3773958 
IL1RAP rs3773953 
IL1RAP rs1469007 
IL1RAP rs9875362 
IL1RAP rs6781037 
IL1RAP rs6765375 
IL1RAP rs9821002 
IL1RAP rs759783 
IL1RAP rs4140711 
IL1RAP rs9290939 
IL1RAP rs1015704 
IL1RAP rs1015705 
IL1RAP rs4687163 
IL1RAP rs929729 
IL1RAP rs1024941 
IL1RAP rs1024946 
IL1RAP rs1024949 
IL1RAP rs7626795 
IL1RAP rs4624606 
IL1RAP rs9847868 
IL1RAP rs9821122 
IL1RAP rs4320092 
IL1RAP rs9831803 
IL1RAP rs7650510 
IL1RAP rs11915384 
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IL1RN rs17042917 
IL1RN rs315920 
IL1RN rs4251961 
IL1RN rs2637988 
IL1RN rs928940 
IL1RN rs3213448 
IL1RN rs1794066 
IL1RN rs380092 
IL1RN rs579543 
IL1RN rs315951 
IL1RN rs315949 
IL1RN rs315946 
IL1RN rs315943 
IL1RN rs315942 
IL2 rs10027390 
IL2 rs2069772 
IL2 rs2069771 
IL2 rs2069779 
IL2 rs2069778 
IL2 rs2069762 
IL2 rs4833248 
IL2RA rs10795737 
IL2RA rs12359875 
IL2RA rs12722605 
IL2RA rs12244380 
IL2RA rs9663421 
IL2RA rs12722596 
IL2RA rs2386841 
IL2RA rs12722588 
IL2RA rs2076846 
IL2RA rs7093069 
IL2RA rs942200 
IL2RA rs2031229 
IL2RA rs2228150 
IL2RA rs12722563 
IL2RA rs7910961 
IL2RA rs6602392 
IL2RA rs7072398 
IL2RA rs11256457 
IL2RA rs6602398 
IL2RA rs11598648 
IL2RA rs4749926 
IL2RA rs1107345 
IL2RA rs11256497 
IL2RA rs791589 
IL2RA rs791590 
IL2RA rs7089855 
IL2RA rs2476491 
IL2RA rs706779 
IL2RA rs706778 
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IL2RA rs3134883 
IL2RA rs12722486 
IL2RA rs7072793 
IL2RA rs7073236 
IL2RB rs2743827 
IL2RB rs228937 
IL2RB rs3218339 
IL2RB rs3218329 
IL2RB rs84458 
IL2RB rs84460 
IL2RB rs228945 
IL2RB rs228947 
IL2RB rs2072861 
IL2RB rs3218315 
IL2RB rs3218312 
IL2RB rs228953 
IL2RB rs3218297 
IL2RB rs228954 
IL2RB rs3218295 
IL2RB rs3218292 
IL2RB rs228957 
IL2RB rs2281094 
IL2RB rs228968 
IL2RB rs1362904 
IL2RB rs1003694 
IL2RB rs2235330 
IL2RB rs3218264 
IL2RB rs228975 
IL2RB rs3218258 
IL4 rs2243248 
IL4 rs2070874 
IL4 rs2227284 
IL4 rs2243261 
IL4 rs2243263 
IL4 rs2243268 
IL4 rs2243274 
IL4 rs2243290 
IL4R rs2057768 
IL4R rs6498012 
IL4R rs4787948 
IL4R rs3024530 
IL4R rs3024537 
IL4R rs3024547 
IL4R rs3024548 
IL4R rs3024560 
IL4R rs2239349 
IL4R rs2239347 
IL4R rs3024585 
IL4R rs3024623 
IL4R rs4787423 
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IL4R rs3024648 
IL4R rs3024658 
IL4R rs3024668 
IL4R rs3024670 
IL4R rs3024675 
IL4R rs3024676 
IL4R rs2234898 
IL4R rs1805013 
IL4R rs1805015 
IL4R rs1801275 
IL4R rs1805016 
IL4R rs8832 
IL4R rs1029489 
IL4R rs4787956 
IL5 rs743562 
IL5 rs739719 
IL5 rs739718 
IL5 rs2069812 
IL5 rs2069807 
IL6 rs1880243 
IL6 rs12700386 
IL6 rs1800797 
IL6 rs1800795 
IL6 rs2069840 
IL6 rs1554606 
IL6 rs11766273 
IL-6 rs1800796 
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Appendix Table 3.  Genotype model p values after adjusting for smoking and 
gravidity 
 
Population Gene(s) SNP rs# Adjusted  Model P1 
rs1875999 0.02 
rs32897 5.00x10-3 CRHBP 
rs10055255 6.00x10-3 
FV rs9332624 - 
IL-5 rs739718 0.08 
tPA rs879293 <1.00x10-3 
rs977214 0.14 PTGER3 
rs594454 3.00x10-3 
Maternal 
SCNN1A rs3764874 0.03 
CBS rs12329764 0.27 
IL-10RA rs17121510 0.29 
rs9527025 0.14 KL 
rs522796 0.04 
Infant 
TREM1 rs6910730 0.20 
1P value for model in Table 5 adjusted smoking and gravidity 
 
 
 
Appendix Table 4.  Examining cases for allelic and genotypic differences 
between cases with and without MIAC 
 
Cases MIAC v PTB No MIAC 
Population Gene(s) SNP rs# Allele P Genotype P 
rs1875999 0.57 0.39 
rs32897 0.54 0.55 CRHBP 
rs10055255 0.42 0.73 
FV rs9332624 0.33 0.68 
IL-5 rs739718 1.00 1.00 
tPA rs879293 0.19 0.51 
rs977214 0.19 0.47 PTGER3 
rs594454 0.74 0.36 
Maternal 
SCNN1A rs3764874 0.81 0.95 
CBS rs12329764 0.43 0.76 
IL-10RA rs17121510 0.87 0.86 
rs9527025 1.00 0.20 KL 
rs522796 0.17 0.06 
Infant 
TREM1 rs6910730 0.02 0.05 
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a. Maternal CRHBP Cases   b.  Maternal CRHBP Controls 
   
c. Maternal IL-5 Cases    d. Maternal IL-5 Controls 
   
e. Maternal tPA Cases  f.  Maternal tPA controls 
  
 203
g. Maternal FV Cases 
 
h. Maternal FV Controls 
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I. Maternal PTGER3 Cases 
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j. Maternal PTGER3 Controls 
 206
 
k. Fetal CBS Cases 
 
l. Fetal CBS Controls 
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m. Fetal IL-10RA Cases 
 
n. Fetal IL-10RA Controls 
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o. Fetal TREM1 Cases 
 
p. Fetal TREM1 Controls 
 
 
Appendix Figure 3. Haplotype block structure Caucasians. 
 a-j) Caucasian maternal Haploview LD plots for cases and controls; k-p) Caucasian fetal 
Haploview LD plots for cases and controls. D’ values are labeled within each square. 
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a. Maternal IL-6R Cases       b.  Maternal IL-6R Controls 
     
 
     c.  Fetal CD14 Cases       d.  Fetal CD14 Controls 
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e.  Fetal CTLA4 Cases   f.  Fetal CTLA4 Controls 
 
  
g.  Fetal IL-2 Cases       h.  Fetal IL-2 Controls  
  
i.  Fetal MMP9 Cases         j.  Fetal MMP9 Controls 
    
 
 
  211
k.  Fetal IL-2RB Cases 
     
l.  Fetal IL-2RB Controls  
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m.  Fetal PON2 Cases    n.  Fetal PON2 Controls   
  
o.  Fetal PTGER3 Cases            
 
p.  Fetal PTGER3 Controls 
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q.  Fetal TNF-α Cases      r.  Fetal TNF-α  Controls 
  
 Appendix Figure 4. Haplotype block structure African Americans. 
 a-b) African American maternal Haploview LD plots for cases and controls; c-r) African 
American fetal Haploview LD plots for cases and controls. D’ values are labeled within 
each square. 
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Appendix Table 5.  Correlations within cases and within controls 
 
Cases 
Caucasian 
Controls 
 Caucasian 
Cases  
African-American 
Controls  
African-American Cytokine 1 Cytokine 2 
r p r P r p r p 
IL-6 IL-1β 0.046 0.661 0.095 0.398 0.070 0.680 0.110 0.313 
IL-8 IL-1β 0.153 0.136 0.197 0.055 0.281 0.088 0.394 <0.001 
IL-8 IL-6 0.472 <0.001 0.605 <0.001 0.461 0.004 0.624 <0.001 
IL-10 IL-1β 0.080 0.440 -0.029 0.789 0.514 0.001 0.349 0.001 
IL-10 IL-6 0.196 0.054 0.390 <0.001 0.429 0.006 0.466 <0.001 
IL-10 IL-8 0.357 <0.001 0.198 0.070 0.612 <0.001 0.655 <0.001 
TNF-α IL-1β -0.101 0.330 -0.089 0.424 0.428 0.008 0.163 0.141 
TNF-α IL-6 0.311 0.002 0.366 0.001 -0.199 0.245 0.362 0.001 
TNF-α IL-8 0.420 <0.001 0.114 0.308 0.091 0.593 0.374 0.001 
TNF-α IL-10 0.171 0.092 0.611 <0.001 0.503 0.001 0.537 <0.001 
sTNF-R1 IL-1β -0.156 0.142 -0.032 0.771 0.322 0.052 -0.056 0.607 
sTNF-R1 IL-6 0.068 0.517 0.404 <0.001 0.123 0.470 0.049 0.647 
sTNF-R1 IL-8 0.233 0.030 0.343 0.001 0.306 0.061 0.249 0.025 
sTNF-R1 IL-10 0.456 <0.001 0.637 <0.001 0.669 <0.001 0.239 0.022 
sTNF-R1 TNF-α 0.119 0.258 0.260 0.017 0.360 0.031 0.292 0.006 
sTNF-R2 IL-1β -0.055 0.602 -0.101 0.352 0.377 0.020 0.060 0.582 
sTNF-R2 IL-6 0.142 0.166 0.347 0.001 0.094 0.575 0.080 0.451 
sTNF-R2 IL-8 0.295 0.005 0.345 0.001 0.245 0.133 0.231 0.038 
sTNF-R2 IL-10 0.480 <0.001 0.660 <0.001 0.736 <0.001 0.337 0.001 
sTNF-R2 TNF-α 0.071 0.487 0.294 0.006 0.432 0.008 0.302 0.005 
sTNF-R2 sTNF-R1 0.895 <0.001 0.889 <0.001 0.873 <0.001 0.850 <0.001 
*Shaded in grey are the significant correlations 
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Appendix Figure 5.  Positive and negative correlation summary. 
Describes the positive and negative correlations observed in the analysis.  The x and the y 
axis indicate the biomarkers/cytokines being correlated.  The left portion of each cell 
represents the case correlations and the right portion o the control correlations.  Shaded in 
grey are the positive correlations; there are no negative correlations. White boxes indicate 
that the correlation was not statistically significant.  a) Describes the correlations in 
Caucasians; b) describes the correlations in African Americans. 
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Appendix Table 6.  Significant correlations for MIAC 
 
Caucasian Cases African American Cases 
No MIAC MIAC No MIAC MIAC Cytokine 1 Cytokine 2 
r p r p r p r p 
IL-6 IL-1β -0.003 0.978 0.212 0.345 -0.048 0.804 0.429 0.337 
IL-8 IL-1β 0.083 0.480 0.316 0.162 0.170 0.378 0.690 0.058 
IL-8 IL-6 0.449 <0.001 0.425 0.049 0.405 0.029 0.667 0.050 
IL-10 IL-1β 0.022 0.855 0.267 0.229 0.350 0.058 0.905 0.002 
IL-10 IL-6 0.306 0.009 -0.025 0.907 0.328 0.076 0.700 0.036 
IL-10 IL-8 0.339 0.004 0.528 0.012 0.569 0.001 0.709 0.022 
TNF-α IL-1β -0.201 0.090 0.140 0.533 0.168 0.385 0.179 0.702 
TNF-α IL-6 0.387 0.001 0.146 0.496 -0.430 0.020 0.643 0.119 
TNF-α IL-8 0.482 <0.001 0.365 0.095 -0.101 0.604 0.238 0.570 
TNF-α IL-10 0.139 0.242 0.192 0.369 0.276 0.140 0.548 0.160 
sTNF-R1 IL-1β -0.198 0.103 -0.173 0.466 0.109 0.574 0.357 0.432 
sTNF-R1 IL-6 0.071 0.563 0.012 0.958 0.064 0.741 -0.048 0.911 
sTNF-R1 IL-8 0.204 0.101 0.298 0.202 0.294 0.121 -0.117 0.765 
sTNF-R1 IL-10 0.408 <0.001 0.513 0.015 0.619 <0.001 0.333 0.381 
sTNF-R1 TNF 0.069 0.568 0.171 0.446 0.208 0.279 0.214 0.645 
sTNF-R2 IL-1β -0.086 0.470 0.005 0.984 0.105 0.581 0.750 0.052 
sTNF-R2 IL-6 0.147 0.219 0.060 0.779 0.020 0.917 0.333 0.420 
sTNF-R2 IL-8 0.238 0.049 0.503 0.017 0.167 0.378 0.417 0.265 
sTNF-R2 IL-10 0.430 <0.001 0.670 <0.001 0.684 <0.001 0.800 0.010 
sTNF-R2 TNF-α 0.058 0.625 0.084 0.697 0.249 0.185 0.179 0.702 
sTNF-R2 sTNF-R1 0.881 <0.001 0.899 <0.001 0.870 <0.001 0.633 0.067 
  217
Appendix Table 7.  Correlation comparisons 
 
Caucasian v 
African-
American 
Cases 
Caucasian v 
African-
American 
Term 
Caucasian 
Cases v 
Caucasian 
Term 
African-
American Cases 
v African-
American Term 
Cytokine 1 Cytokine 2 
p p p p 
IL-6 IL-1β 0.903 0.920 0.750 0.843 
IL-8 IL-1β 0.504 0.179 0.769 0.532 
IL-8 IL-6 0.941 0.850 0.224 0.254 
IL-10 IL-1β 0.013 0.011 0.469 0.305 
IL-10 IL-6 0.185 0.549 0.160 0.818 
IL-10 IL-8 0.083 <0.001 0.258 0.722 
TNF-α IL-1β 0.005 0.109 0.936 0.153 
TNF-α IL-6 0.010 0.977 0.684 0.005 
TNF-α IL-8 0.077 0.084 0.031 0.144 
TNF-α IL-10 0.054 0.476 <0.001 0.819 
sTNF-R1 IL-1β 0.015 0.878 0.416 0.055 
sTNF-R1 IL-6 0.786 0.014 0.019 0.714 
sTNF-R1 IL-8 0.694 0.513 0.440 0.758 
sTNF-R1 IL-10 0.109 0.001 0.086 0.004 
sTNF-R1 TNF-α 0.205 0.826 0.336 0.712 
sTNF-R2 IL-1β 0.023 0.296 0.756 0.094 
sTNF-R2 IL-6 0.804 0.068 0.150 0.947 
sTNF-R2 IL-8 0.787 0.433 0.715 0.943 
sTNF-R2 IL-10 0.031 0.004 0.071 0.003 
sTNF-R2 TNF-α 0.051 0.954 0.126 0.460 
sTNF-R2 sTNF-R1 0.608 0.298 0.836 0.653 
*Shaded in grey are statistically significant differences between correlations 
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Appendix Table 8.  Correlation comparisons between MIAC and no MIAC 
 
 Caucasian  
MIAC v No MIAC 
African-American 
 MIAC v No MIAC Cytokine 1 Cytokine 2 
P P 
IL-6 IL-1β 0.371 0.229 
IL-8 IL-1β 0.324 0.090 
IL-8 IL-6 0.904 0.325 
IL-10 IL-1β 0.301 0.004 
IL-10 IL-6 0.147 0.166 
IL-10 IL-8 0.339 0.511 
TNF-α IL-1β 0.156 0.978 
TNF-α IL-6 0.267 0.004 
TNF-α IL-8 0.559 0.389 
TNF-α IL-10 0.817 0.405 
sTNF-R1 IL-1β 0.919 0.530 
sTNF-R1 IL-6 0.810 0.780 
sTNF-R1 IL-8 0.693 0.271 
sTNF-R1 IL-10 0.584 0.321 
sTNF-R1 TNF-α 0.672 0.987 
sTNF-R2 IL-1β 0.708 0.039 
sTNF-R2 IL-6 0.711 0.412 
sTNF-R2 IL-8 0.204 0.469 
sTNF-R2 IL-10 0.137 0.490 
sTNF-R2 TNF-α 0.912 0.860 
sTNF-R2 sTNF-R1 0.720 0.124 
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